Compositions and methods for targeted masking autofluorescence
By using a combination of quencher dye and targeted parts in biological samples, the problem of background autofluorescence affecting detection efficiency is solved, and the high signal-to-noise ratio and multi-cycle detection capability is improved.
Patent Information
- Application Number
- CN202380031845.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-01
- Filing Date
- 2023-03-31
- Publication Date
- 2024-11-26
AI Technical Summary
When performing in-situ analysis of biological samples, the determination method based on oligonucleotide probes has problems of sensitivity, specificity and detection efficiency, especially in the presence of background autofluorescence, which affects interest. Fluorescence signal detection of analytes.
Using a quencher dye containing a quencher dye and a targeting moiety, it is contacted into a biological sample, the targeting moiety binds to the endogenous biological moiety, reduces autofluorescence, and binds to detectable probes to improve signal-to-noise ratio and detect the object count density.
It significantly reduces autofluorescence in biological samples, improves signal-to-noise ratio and detects object count density, enhances detection capabilities for molecules of interest, and is suitable for multiple imaging cycles and multi-wavelength analysis.
Smart Images

Figure CN119032271A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 326,698, filed on April 1, 2022, entitled “COMPOSITIONS AND METHODS FORTARGETED MASKING OF AUTOFLUORESCENCE,” which is incorporated herein by reference for all purposes. Technical Field
[0003] The present disclosure generally relates to methods and compositions for analyzing or detecting analytes in biological samples, particularly for in situ analysis of biomolecules in cell or tissue samples. Background Art
[0004] Existing methods can be used to analyze nucleic acids in biological samples (such as cells or tissues) in situ. For example, the advancement of single-molecule fluorescence hybridization (smFISH) has achieved nanoscale resolution imaging of RNA in cells and tissues. However, the assay methods based on oligonucleotide probes for in situ analysis may have problems with low sensitivity, specificity and / or detection efficiency, particularly in the presence of background autofluorescence. Autofluorescence is generally generated by endogenous biological parts of tissue and cell samples. Autofluorescence can also be produced and / or aggravated by standard sample treatment (e.g., formalin fixation). Background autofluorescence may have a significant and continuous impact on the ability to detect and distinguish the fluorescent signals of the analyte of interest from other components also present in the biological sample, particularly when analyzed in multiple imaging cycles or rounds. Improved in situ analysis methods are needed. The present disclosure addresses these and other needs. Summary of the invention
[0005] In some aspects, the present disclosure relates to methods for reducing autofluorescence in tissue samples, methods for analyzing biological samples, and compounds for use in the methods. In some aspects, the methods and compounds of the present disclosure are suitable for use in multiple cycles using fluorescence imaging and analysis methods using multiple wavelengths.
[0006] In one aspect, a method for reducing autofluorescence is provided herein, comprising contacting a tissue sample with a quencher comprising a quencher moiety (e.g., a quencher dye) and a targeting moiety, wherein the targeting moiety binds and / or reacts with an endogenous biological moiety in the tissue sample, thereby targeting the quencher to the endogenous biological moiety; and detecting a signal associated with a detectable probe that is directly or indirectly bound to a molecule of interest in the tissue sample, wherein the quencher reduces autofluorescence in the tissue sample. In some embodiments, the quencher moiety (e.g., a quencher dye) and the targeting moiety are physically coupled to each other, while the quencher moiety and the detectable probe are not physically coupled to each other. For example, the quencher moiety and the targeting moiety can be covalently coupled by a bond or a joint, while the quencher moiety and the detectable probe are physically separated before contacting the tissue sample.
[0007] In some embodiments, the autofluorescence of the tissue sample is reduced compared to the unquenched tissue sample. In some embodiments, the autofluorescence is reduced by at least about 50%, at least about 60%, at least about 70%, or at least about 80% compared to the unquenched tissue sample. In some embodiments, the signal associated with the detectable probe is detected at a position in the tissue sample, and the detected signal has an increased signal-to-noise ratio compared to the unquenched tissue sample. In some embodiments, the signal detected at a certain position in the tissue sample is analyzed to generate an increased signal-to-noise ratio compared to the unquenched tissue sample. In some embodiments, the signal-to-noise ratio is increased by at least about 10%, at least about 20%, or at least about 25% compared to the unquenched tissue sample. In some embodiments, the signal associated with the detectable probe is detected at a position in the tissue sample, and the count density of the detectable object associated with the tissue sample is increased compared to the unquenched tissue sample. In some embodiments, the signal associated with the detectable probe is detected at a position in the tissue sample, and the analysis is performed to generate an increased count density of the detectable object compared to the unquenched tissue sample. In some embodiments, the detectable subject count density is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, or at least about 5-fold compared to an unquenched tissue sample.
[0008] In some embodiments, the tissue sample is contacted with the detectable probe before contacting with the quencher. In some embodiments, the tissue sample is contacted with the detectable probe after contacting with the quencher. In some embodiments, the tissue sample is contacted with the detectable probe and the quencher simultaneously.
[0009] In some embodiments, the method further comprises bleaching the tissue sample with a chemical reagent, an enzyme, light, heat, or any combination thereof, before, simultaneously with, or after contacting the tissue sample with the quencher comprising the quencher dye and the targeting moiety.
[0010] In some embodiments, the method further comprises removing the detectable probe or a portion thereof from the tissue sample, wherein the quencher is retained in the tissue sample. In some embodiments, the removing step comprises treating the tissue sample with a denaturant and / or heat. In some embodiments, the denaturant comprises dimethyl sulfoxide (DMSO), formamide and / or an alkaline solution.
[0011] In some embodiments, the method further comprises contacting the tissue sample with one or more additional detectable probes, wherein each additional detectable probe is directly or indirectly bound to an additional molecule of interest in the tissue sample, and the additional molecule of interest is the same or different from the molecule of interest. In some embodiments, the method further comprises detecting one or more signals associated with one or more additional detectable probes in the tissue sample, wherein the autofluorescence of the tissue sample remains at least partially quenched by the quenching portion of the quencher. In some embodiments, during the detection of one or more signals associated with one or more additional detectable probes, the autofluorescence of the tissue sample remains reduced compared to the unquenched tissue sample. In some embodiments, one or more additional detectable probes are contacted with the tissue sample, and one or more signals associated with one or more additional detectable probes are detected in one or more cycles. In some embodiments, each cycle includes removing the additional detectable probes used for the cycle from the tissue sample before contacting the tissue sample with the additional detectable probes for subsequent cycles. In some embodiments, during the detection of one or more signals associated with the detectable probes in the continuous cycle, the autofluorescence of the tissue sample remains at least partially quenched by the quenching portion of the quencher.
[0012] In some embodiments, the molecule of interest and other molecules of interest are independently selected from the group consisting of nucleic acid (e.g., genomic DNA, RNA or cDNA), protein or peptide, carbohydrate, lipid, small molecule and its complex. In some embodiments, the molecule of interest is a first nucleic acid (e.g., the mRNA transcript of the first gene), and the other molecules of interest are second nucleic acids (e.g., the mRNA transcript of the second different gene, or the different mRNA transcripts of the first gene). In some embodiments, the molecule of interest is a first protein, and the other molecules of interest are second different proteins. In some embodiments, the molecule of interest is a nucleic acid (e.g., the mRNA transcript of a gene), and the other molecules of interest are proteins (e.g., proteins encoded by the gene or different genes), or vice versa. In some embodiments, the molecule of interest is a nucleic acid (e.g., the mRNA transcript of a gene, a probe directly or indirectly combined with an mRNA transcript, or a rolling circle amplification product of an mRNA transcript or a probe), and the other molecules of interest are identical nucleic acids, wherein a detectable probe (which targets the molecule of interest) and a cooled detectable probe (which targets another molecule of interest) are identical or different. Where the detectable probe and the further detectable probe are different, their nucleic acid sequences and / or detectable labels may differ, but the probes still bind directly or indirectly to the same nucleic acid, and the binding may be at the same sequence or at different sequences in the nucleic acid.
[0013] In some embodiments that can be performed after a given cycle, the quencher remains in the tissue sample and the autofluorescence of the tissue sample remains reduced compared to the unquenched tissue sample. In some embodiments, the autofluorescence remains reduced by at least about 50%, at least about 60%, at least about 70%, or at least about 80% for a given cycle compared to the unquenched tissue sample. In some embodiments, the autofluorescence increases by less than about 5%, less than about 10%, or less than about 15% for a given cycle compared to the previous cycle. In some embodiments, after a given cycle, the signal-to-noise ratio remains increased compared to the unquenched tissue sample. In some embodiments, the signal-to-noise ratio remains increased by at least about 10%, at least about 20%, or at least about 25% for a given cycle compared to the unquenched tissue sample. In some embodiments, the signal-to-noise ratio decreases by less than about 5%, less than about 10%, or less than about 15% for a given cycle compared to the previous cycle. In some embodiments, the detectable object count density remains increased for a given cycle compared to the unquenched tissue sample. In some embodiments, the detectable object count density remains increased for a given cycle by at least about 2-fold, at least about 3-fold, at least about 4-fold, or at least about 5-fold compared to an unquenched tissue sample. In some embodiments, the detectable object count density decreases by less than about 5%, less than about 10%, or less than about 15% for a given cycle compared to the previous cycle. In some embodiments, the method comprises at least two, three, four, five, six, or more cycles of contacting the tissue sample with one or more additional detectable probes.
[0014] In some embodiments, the method further comprises bleaching the tissue sample with a chemical reagent, an enzyme, light, heat, or any combination thereof, before, simultaneously with, or after contacting the tissue sample with the quencher.
[0015] In some embodiments, the method further comprises staining the tissue sample. In some embodiments, the method further comprises fixing the tissue sample. In some embodiments, the method further comprises de-crosslinking the tissue sample.
[0016] On the other hand, provided herein is a method for analyzing a biological sample, comprising: contacting the biological sample with a quencher comprising a quencher dye and a targeting portion, wherein the targeting portion directly or indirectly binds to and / or reacts with an endogenous biological portion of the biological sample, thereby targeting the quencher to the biological portion; contacting the biological sample with a detectable probe that directly or indirectly binds to a molecule of interest in the biological sample; and detecting a signal associated with the detectable probe bound to the molecule of interest in the biological sample, wherein the quencher dye reduces the autofluorescence of the biological sample, thereby detecting the molecule of interest in the biological sample.
[0017] In some embodiments, the quencher reduces the autofluorescence of the biological sample without substantially reducing the signal associated with the detectable probe. In some embodiments, the autofluorescence of the biological sample is reduced compared to the unquenched biological sample. In some embodiments, the autofluorescence is reduced by at least about 50%, at least about 60%, at least about 70% or at least about 80% compared to the unquenched biological sample. In some embodiments, the signal associated with the detectable probe is detected at a certain position in the biological sample, and the detected signal has an increased signal-to-noise ratio compared to the unquenched biological sample. In some embodiments, the in situ signal detection in the biological sample generates an increased signal-to-noise ratio compared to the unquenched biological sample. In some embodiments, the signal-to-noise ratio increases by at least about 10%, at least about 20% or at least about 25% compared to the unquenched biological sample. In some embodiments, the count density of detectable objects associated with the biological sample increases compared to the unquenched biological sample. In some embodiments, the in situ signal detection in the biological sample generates an increased count density of detectable objects compared to the unquenched biological sample. In some embodiments, the detectable object count density is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, or at least about 5-fold compared to an unquenched biological sample.
[0018] In some embodiments, the biological sample is contacted with the detectable probe before contacting with the quencher. In other embodiments, the biological sample is contacted with the detectable probe after contacting with the quencher. In other embodiments, the biological sample is contacted with the detectable probe and the quencher simultaneously.
[0019] In some embodiments, the method further comprises bleaching the biological sample with a chemical reagent, an enzyme, light, heat, or any combination thereof before, simultaneously with, or after contacting the biological sample with a detectable probe that binds directly or indirectly to a molecule of interest in the biological sample.
[0020] In some embodiments, the method includes contacting the biological sample with a nucleic acid probe that binds directly or indirectly to a molecule of interest in the biological sample, prior to contacting the biological sample with a detectable probe that binds directly or indirectly to a molecule of interest in the biological sample, and wherein the detectable probe binds directly or indirectly to the nucleic acid probe.
[0021] In some embodiments, the method also includes removing a detectable probe or a portion thereof from the biological sample, wherein the quencher is retained in the biological sample. In some embodiments, the removal step includes treating the biological sample with a denaturant and / or heat. In some embodiments, the denaturant includes dimethyl sulfoxide (DMSO), formamide and / or an alkaline solution. In some embodiments, the method also includes contacting the biological sample with one or more other detectable probes, wherein each other detectable probe is directly or indirectly bound to other molecules of interest in the biological sample, and the other molecules of interest are identical or different from the molecules of interest.
[0022] In some embodiments, the method further comprises detecting one or more signals associated with one or more additional detectable probes in the biological sample, wherein the autofluorescence of the biological sample remains reduced compared to the unquenched biological sample. In some embodiments, one or more additional detectable probes are contacted with the biological sample, and one or more signals associated with one or more additional detectable probes are detected in one or more cycles. In some embodiments, each cycle includes removing the additional detectable probes used for the cycle from the biological sample before contacting the biological sample with the additional detectable probes for subsequent cycles.
[0023] In some embodiments, after a given cycle, the quencher remains in the biological sample, and the autofluorescence of the biological sample remains reduced compared to the unquenched biological sample. In some embodiments, for a given cycle, the autofluorescence remains reduced by at least about 50%, at least about 60%, at least about 70%, or at least about 80% compared to the unquenched biological sample. In some embodiments, for a given cycle, the autofluorescence increases by less than about 5%, less than about 10%, or less than about 15% compared to the previous cycle. In some embodiments, after a given cycle, the signal-to-noise ratio remains increased compared to the unquenched biological sample. In some embodiments, for a given cycle, the signal-to-noise ratio remains increased by at least about 10%, at least about 20%, or at least about 25% compared to the unquenched biological sample. In some embodiments, for a given cycle, the signal-to-noise ratio decreases by less than about 5%, less than about 10%, or less than about 15% compared to the previous cycle. In some embodiments, for a given cycle, the detectable object count density remains increased compared to the unquenched biological sample. In some embodiments, for a given cycle, the detectable object count density remains increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, or at least about 5-fold compared to an unquenched biological sample. In some embodiments, for a given cycle, the detectable object count density decreases by less than about 5%, less than about 10%, or less than about 15% compared to the previous cycle.
[0024] In some embodiments, the method comprises at least two, three, four, five, six, or more cycles comprising contacting the biological sample with one or more additional detectable probes.
[0025] In some embodiments, the method further comprises staining the biological sample. In some embodiments, the method further comprises fixing the biological sample. In some embodiments, the method further comprises decrosslinking the biological sample.
[0026] In some embodiments, the biological sample is a tissue sample.
[0027] In some embodiments of any of the aforementioned aspects, each detectable probe can be independently detectably labeled or hybridized with a detectably labeled probe. In some embodiments, each detectable probe is independently covalently labeled with a fluorophore, or hybridized with a probe covalently labeled with a fluorophore. In some embodiments of any of the aforementioned aspects, the quencher also includes a linker portion connecting the quencher dye and the targeting moiety. In certain embodiments, the linker portion is an alkylene portion, an aminoalkylene portion, an amino(alkyl)alkylene portion, a polyethylene glycol portion, a disulfide portion, or a carbamate portion.
[0028] In some embodiments of any of the foregoing aspects, the quencher dye comprises: (a) at least three aromatic residues, each of which is independently unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, or substituted heteroaryl, wherein at least one aromatic residue is covalently linked to two other aromatic residues via two exocyclic azo bonds; or (b) at least two aromatic residues, each of which is independently unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, or substituted heteroaryl, wherein at least two of the aromatic residues are covalently linked via exocyclic azo bonds, wherein at least one of the aromatic residues is unsubstituted polycyclic aryl, substituted polycyclic aryl, unsubstituted polycyclic heteroaryl, or substituted polycyclic heteroaryl. In some embodiments of any of the foregoing aspects, the quencher dye comprises optionally substituted 1,4-bis((E)-phenyldiazenyl)phenyl Partially or optionally substituted (E)-5-phenyl-3-(phenyldiazenyl)phenazin-5-ium moiety or a salt thereof. In some embodiments of any of the foregoing aspects, the quencher has Figure 1In some embodiments of any of the foregoing aspects, the quencher has a UV-visible absorption curve having at least one absorption peak having a maximum absorption of about 400 nm to 700 nm and a half-maximum full width of at least about 100 nm. In some embodiments of any of the foregoing aspects, the quencher has a UV-visible absorption curve having at least one absorption peak having a maximum absorption of about 500 nm to about 600 nm and a half-maximum full width of at least about 100 nm.
[0029] In some embodiments of any of the preceding aspects, the quencher is a compound of formula (I) as defined herein
[0030]
[0031] or a salt thereof.
[0032] In some embodiments of any of the preceding aspects, the quencher is a compound of formula (II) as defined herein
[0033]
[0034] or a salt thereof.
[0035] On the other hand, provided herein is a method for analyzing a tissue sample, comprising contacting the tissue sample with a nucleic acid probe that directly or indirectly binds to a molecule of interest in the tissue sample; contacting the tissue sample with a quencher comprising a quencher dye and a targeting portion, wherein the targeting portion directly or indirectly binds and / or reacts with an endogenous biological portion in the tissue sample, thereby targeting the quencher to the biological portion, wherein the quencher is a compound of formula (I) or formula (II) as defined herein, or a salt thereof; contacting the tissue sample with a fluorescently labeled detectable probe that directly or indirectly binds to the nucleic acid probe or an amplification product of the nucleic acid probe; and detecting a signal associated with the fluorescently labeled detectable probe in the tissue sample, wherein the quencher dye reduces autofluorescence in the tissue sample, thereby detecting the molecule of interest in the tissue sample.
[0036] In some embodiments, the autofluorescence of the tissue sample is reduced compared to the unquenched tissue sample. In some embodiments, the autofluorescence is reduced by at least about 50%, at least about 60%, at least about 70% or at least about 80% compared to the unquenched tissue sample. In some embodiments, the in situ signal detection generates an increased signal-to-noise ratio compared to the unquenched tissue sample. In some embodiments, the detected signal has a signal-to-noise ratio, wherein the signal-to-noise ratio is increased compared to the unquenched tissue sample. In some embodiments, the signal-to-noise ratio is increased by at least about 10%, at least about 20% or at least about 25% compared to the unquenched tissue sample. In some embodiments, the in situ signal detection generates an increased count density of detectable objects compared to the unquenched tissue sample. In some embodiments, a signal associated with a detectable probe is detected at a certain position in the tissue sample, and the count density of detectable objects associated with the tissue sample is increased compared to the unquenched tissue sample. In some embodiments, the detectable subject count density is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, or at least about 5-fold compared to an unquenched tissue sample.
[0037] In some embodiments, the tissue sample is contacted with the detectable probe before contacting with the quencher. In other embodiments, the tissue sample is contacted with the detectable probe after contacting with the quencher. In other embodiments, the tissue sample is contacted with the detectable probe and the quencher at the same time.
[0038] In some embodiments, the method further comprises bleaching the tissue sample with a chemical reagent, an enzyme, light, heat, or any combination thereof, before, simultaneously with, or after contacting the tissue sample with the quencher.
[0039] In some embodiments, the method further comprises removing the detectable probe or a portion thereof from the tissue sample, wherein the quencher is retained in the tissue sample. In some embodiments, the removing step comprises treating the tissue sample with a denaturant and / or heat. In some embodiments, the denaturant comprises dimethyl sulfoxide (DMSO), formamide and / or an alkaline solution.
[0040] In some embodiments, the method further comprises contacting the tissue sample with one or more additional detectable probes, wherein each additional detectable probe is directly or indirectly bound to an additional molecule of interest in the tissue sample, and the additional molecule of interest is the same or different from the molecule of interest. In some embodiments, the method further comprises detecting one or more signals associated with one or more additional detectable probes in the tissue sample, wherein the autofluorescence of the tissue sample remains reduced compared to the unquenched tissue sample. In some embodiments, one or more additional detectable probes are contacted with the tissue sample, and one or more signals associated with the one or more additional detectable probes are detected in one or more cycles. In some embodiments, each cycle includes removing the additional detectable probes for the cycle from the tissue sample before contacting the tissue sample with the additional detectable probes for the subsequent cycles. In some embodiments, after a given cycle, the quencher remains in the tissue sample, and the autofluorescence of the tissue sample remains reduced compared to the unquenched tissue sample. In some embodiments, compared to the unquenched tissue sample, for a given cycle, the autofluorescence remains reduced by at least about 50%, at least about 60%, at least about 70%, or at least about 80%. In some embodiments, the autofluorescence increases by less than about 5%, less than about 10%, or less than about 15% for a given cycle compared to the previous cycle. In some embodiments, after a given cycle, the signal-to-noise ratio remains increased compared to an unquenched tissue sample. In some embodiments, the signal-to-noise ratio remains increased by at least about 10%, at least about 20%, or at least about 25% for a given cycle compared to an unquenched tissue sample. In some embodiments, the signal-to-noise ratio decreases by less than about 5%, less than about 10%, or less than about 15% for a given cycle compared to the previous cycle. In some embodiments, the detectable object count density remains increased for a given cycle compared to an unquenched tissue sample. In some embodiments, the detectable object count density remains increased by at least about 2 times, at least about 3 times, at least about 4 times, or at least about 5 times for a given cycle compared to an unquenched tissue sample. In some embodiments, the detectable object count density decreases by less than about 5%, less than about 10%, or less than about 15% for a given cycle compared to the previous cycle.
[0041] In some embodiments, the method comprises at least two, three, four, five, six, or more cycles of contacting the tissue sample with one or more additional detectable probes.
[0042] In some embodiments, the method further comprises staining the tissue sample. In some embodiments, the method further comprises fixing the tissue sample. In some embodiments, the method further comprises de-crosslinking the tissue sample.
[0043] In some embodiments where the quencher is a compound of formula (I), m is an integer from 1 to 6 and n is an integer from 1 to 6. In some embodiments where the quencher is a compound of formula (I), At least one, at least two or up to three examples of are substituted phenyl or unsubstituted phenyl.
[0044] In some embodiments where the quencher is a compound of formula (II), m is an integer from 1 to 6 and n is an integer from 1 to 6. In some embodiments where the quencher is a compound of formula (II), At least one, at least two, or at least three examples of are substituted phenyl or unsubstituted phenyl.
[0045] In some embodiments of any of the preceding aspects, the quencher has the structure: or a salt thereof, provided that X a and X c At least one of them is -L-(R 靶 ) w , wherein w is any integer, such as 1 or 2, and wherein L is a bond or linker moiety; and R 靶 It is the targeting part.
[0046] In some embodiments of any of the preceding aspects, the quencher has the structure: or a salt thereof, provided that X a and X c At least one of them is -LR 靶 , wherein L is a bond or a linker moiety; and R 靶 It is the targeting part.
[0047] In some embodiments where the quencher is a compound of Formula (I) or Formula (II), yes Where R b1 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In certain embodiments, yes Where R d is H, C1-C6 alkyl or halo; and s is an integer from 0 to 5.
[0048] In some embodiments of any of the preceding aspects, the quencher has the structure: or a salt thereof.
[0049] In some embodiments of any of the aforementioned aspects that can be combined with any of the aforementioned embodiments, the molecule of interest is a nucleic acid of interest or a protein of interest. In some embodiments, a detectable probe hybridizes with a nucleic acid of interest. In some embodiments, a detectable probe hybridizes with one or more intermediate probes that are directly or indirectly bound to a nucleic acid of interest. In some embodiments, a detectable probe hybridizes with one or more intermediate probes, which are in turn hybridized with a nucleic acid of interest. In some embodiments of any of the aforementioned methods, the method also includes adding a primary probe before adding a detectable probe and one or more intermediate probes, wherein the intermediate probe is bound to the primary probe or its product.
[0050] In some embodiments of any of the foregoing aspects that can be combined with any of the foregoing embodiments, the nucleic acid of interest is a cell or viral DNA or RNA or its product. In some embodiments, the cell or viral DNA or RNA or its product is genomic DNA, coding RNA, non-coding RNA or cDNA. In certain embodiments, the nucleic acid of interest is mRNA.
[0051] In some embodiments, the nucleic acid of interest is a nucleic acid probe that is directly or indirectly bound to a cell or viral DNA or RNA or its product. In some embodiments, the cell or viral DNA or RNA or its product is genomic DNA, coding RNA, non-coding RNA or cDNA. In certain embodiments, the coding RNA is mRNA.
[0052] In some embodiments of any of the preceding aspects that may be combined with any of the preceding embodiments, the nucleic acid probe is linear, cyclizable, circular, or branched. In some embodiments, the nucleic acid probe comprises a 3' overhang and / or a 5' overhang when hybridizing with cellular or viral DNA or RNA or its product. In some embodiments, the nucleic acid probe comprises one or more barcode regions.
[0053] In some embodiments, the nucleic acid of interest is a probe product of one or more nucleic acid probes that are directly or indirectly bound to a cell or viral DNA or RNA or its product. In some embodiments, the cell or viral DNA or RNA or its product is genomic DNA, coding RNA, non-coding RNA or cDNA. In certain embodiments, the coding RNA is mRNA.
[0054] In some embodiments, the probe product is a rolling circle amplification (RCA) product, a hybridization chain reaction (HCR) product, a linear oligonucleotide hybridization chain reaction (LO-HCR) product, a primer exchange reaction (PER) product, an assembly of a branched structure, a hybridization complex of a plurality of fluorescently labeled probes, or any combination thereof. In some embodiments, the probe product and / or one or more nucleic acid probes include one or more barcode regions. In some embodiments, the nucleic acid of interest is a reporter oligonucleotide in a labeling agent, and the labeling agent includes a binding portion that is directly or indirectly bound to a non-nucleic acid analyte. In some embodiments, the reporter oligonucleotide includes one or more barcode regions.
[0055] In some embodiments of any of the preceding aspects that may be combined with any of the preceding embodiments, the detectable probe is linear, circularizable, circular, or branched.
[0056] In some embodiments of any of the foregoing aspects that can be combined with any of the foregoing embodiments, the tissue sample is a formalin-fixed tissue sample or a formalin-fixed paraffin-embedded (FFPE) sample. In some embodiments of any of the foregoing aspects that can be combined with any of the foregoing embodiments, the autofluorescence is fixative-induced autofluorescence. In some embodiments of any of the foregoing aspects that can be combined with any of the foregoing embodiments, the tissue sample is melanoma tissue, brain tissue, lung tissue, tonsil tissue, intestinal tissue, kidney tissue, spleen tissue, liver tissue, breast tissue or liver tissue. In some embodiments, the tissue sample is brain tissue, liver tissue or tonsil tissue.
[0057] In some embodiments of any of the foregoing aspects that may be combined with any of the foregoing embodiments, the endogenous biological moiety is autofluorescent. In some embodiments of any of the foregoing aspects that may be combined with any of the foregoing embodiments, the endogenous biological moiety is selected from the group consisting of lipofuscin, collagen, elastin, erythrocytes, flavin, nicotinamide adenine dinucleotide (NADH), and extracellular matrix. In some embodiments, the targeting moiety comprises a hydrophobic portion for lipophilic insertion into the endogenous biological moiety. In some embodiments, the autofluorescent moiety comprises lipofuscin. In certain embodiments, the hydrophobic portion for lipophilic insertion into the endogenous biological moiety is C6-C 14 Alkyl part, C6-C 14 an alkenyl moiety, a terpenoid moiety, a sterol moiety or a wax moiety.
[0058] In some embodiments of any of the aforementioned aspects that can be combined with any of the aforementioned embodiments, the targeting moiety comprises a first functional group, and the endogenous biological moiety comprises a second functional group that can react with the first functional group to form a covalent bond. In some embodiments, the first functional group is a carboxylic acid moiety or a derivative thereof, an aldehyde or ketone moiety, a sulfonyl halide moiety, a hydroxyl moiety, a thiol moiety, an amino moiety, an alkenyl or diene moiety, an epoxide moiety or a haloalkyl moiety. In some embodiments, the first functional group is a maleimido moiety, an azido moiety, an alkynyl moiety, an N-hydroxysuccinimidyl ester moiety or a carbonyl imidazolyl moiety. In certain embodiments, the first functional group is a maleimido moiety.
[0059] In some embodiments of any of the preceding aspects that may be combined with any of the preceding embodiments, the quencher is selected from the group consisting of:
[0060]
[0061] And any salt thereof. In some embodiments, the quencher is a compound selected from the group consisting of:
[0062] and any salts thereof.
[0063] In some embodiments of any of the foregoing aspects that can be combined with any of the foregoing embodiments, the method also includes processing a biological sample or tissue sample to enrich, produce and / or introduce a second functional group in an endogenous biological part. In some embodiments, the second functional group is a thiol, and the biological sample or tissue sample is treated with a reducing agent to convert a disulfide group into a thiol group. In some embodiments, the reducing agent is dithiothreitol (DTT) or tris (2-carboxyethyl) phosphine (TCEP). In some embodiments, the first functional group is maleimide. In certain other embodiments, the endogenous biological part comprises a third functional group different from the second functional group, and wherein the biological sample or tissue sample is treated with a heterobifunctional cross-linking agent comprising a second functional group and a fourth functional group that can react with the third functional group to form a covalent bond, thereby introducing the second functional group in the endogenous biological part. In some embodiments, the third functional group is an amine and the second functional group is a thiol. In some embodiments, the heterobifunctional cross-linker is succinimidyl 3-(2-pyridyldithio) propionate (SPDP) or 2,5-dioxapyrrolidin-1-yl 3-oxo-1-(pyridin-2-yldisulfonyl)-7,10,13,16-tetraoxa-4-azanonadecan-19-oate (PEG4-SPDP).
[0064] In some embodiments of any of the aforementioned aspects that may be combined with any of the preceding embodiments, the step of detecting a signal associated with a detectable probe bound to a molecule of interest comprises imaging at one or more wavelengths of about 400 nm to about 700 nm. In some embodiments, the one or more wavelengths are selected from the group consisting of 488 nm, 532 nm, 561 nm, 590 nm, 640 nm, and 647 nm. In some embodiments of any of the aforementioned aspects that may be combined with any of the preceding embodiments, the quencher is provided in a DMSO solution at a concentration of about 0.01 mM to about 0.8 mM. BRIEF DESCRIPTION OF THE DRAWINGS
[0065] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0066] The following drawings illustrate certain embodiments of the features and advantages of the present disclosure. These embodiments are not intended to limit the scope of the appended claims in any way.
[0067] Figure 1 Shown with The absorbance spectrum of the quencher dye is compared to the UV-visible absorbance spectrum of the exemplary quenchers of the present disclosure.
[0068] Figure 2 An example of improving the binding of a quencher to a reactive site in a biological sample (eg, a tissue sample) by treating the biological sample with a reducing agent (eg, DTT) and / or a multifunctional linker (eg, PEG4-SPDP) is shown.
[0069] Figure 3A-3D Depicted are in situ imaging of fresh frozen mouse brain tissue before and after targeted quenching using the quencher compound 1A. Figure 3A-3B Depicts fluorescence detected in a mouse brain dentate gyrus (DG) slice. Figure 3C-Figure 3D Depicted is fluorescence detected in a mouse cerebral cortex slice. Figure 3A and Figure 3C Fluorescence in unquenched mouse brain tissue sections is shown; Figure 3B and Figure 3D Describes fluorescence in mouse brain tissue sections that were stripped of fluorescently labeled probes, treated with a quencher containing a targeting moiety, and rehybridized with additional fluorescently labeled probes. The autofluorescence quenching effect was retained after stripping.
[0070] Figure 4A-4CIn situ imaging of FFPE human brain tissue after hybridization of a detectable probe (before quenching), after quenching with compound 1A comprising a targeting moiety, and after stripping of the fluorescently labeled probes and re-hybridization of additional fluorescently labeled probes is described. The autofluorescence quenching effect is retained after stripping.
[0071] Figure 5 Described is the quantification of the local signal-to-noise ratio (average) of the detected object measured from images of FFPE human brain tissue before quenching, after quenching, and after stripping and rehybridization of additional detectable probes using dithiothreitol (DTT) / Compound 1A or a combination of PEG4-SPDP and DTT / Compound 1A.
[0072] Figure 6A-6D Shown is the quantification of local signal-to-noise ratios (average) of the detection objects in the images after 5 cycles of stripping and rehybridization with fluorescently detectable probes. Fig. 6A , Figure 6B , Figure 6C and Fig.6D Described is the quantification of local signal-to-noise ratios for the detection targets using detectable probes labeled with fluorescent dyes ATTO 488, ATTO 532, ATTO 590, and ATTO 647. After a single quenching application, the signal-to-noise ratio remains constant even after five cycles of stripping and rehybridization with the fluorescent probes.
[0073] Figure 7A-7D Depicted are the background signals recorded from tissues quenched with compounds 1A, 2A, 1B, 3B, or a combination of 1A and 3B at four separate wavelengths (detectable probes labeled with ATTO 488, ATTO 532, ATTO 590, and ATTO 647 fluorescent dyes, respectively) compared to unquenched quenchers and commercial quenchers. Fig. 7A , Figure 7B , Figure 7C and Fig.7D Quantification of background signal is described.
[0074] Figure 8A-8C Depicted are the subject local mean signal-to-noise ratios for tissue quenched with compounds 1A, 2A, 1B, 3B, or a combination of 1A and 3B compared to commercial quenchers and unquenched controls. Fig. 8A , Figure 8B and Figure 8C Depicted are the local signal-to-noise ratios (average) of the detection targets for detectable probes labeled with ATTO 532, ATTO 590, and ATTO 647 fluorescent dyes, respectively.
[0075] Figure 9A-9CShown is the background signal of different genes (RPLP0, GAPDH and ACTB) in situ detection in tonsil tissue before and after quenching with compound 1A (0.1mM, 0.5mM and 0.8mM concentration) and imaging using a detectable probe targeting a gene rolling circle amplification (RCA) product. The detectable probe is detected using ATTO 488 labeled detection oligonucleotides. Four tonsil tissue samples are used for staining. Cycles 1, 2 and 3 represent imaging cycles before quenching, and cycles 5, 6 and 7 represent imaging cycles after quenching. Fig. 9A Depicted are the background signals of RPLP0 detection in tonsil tissue after quenching (cycle 5) compared to before quenching (cycle 1). Fig. 9B Depicted is the comparison of the background signal after quenching (cycle 6) to the background signal before quenching (cycle 2) when detecting GAPDH in tonsil tissue. Fig. 9C Depicted is a comparison of the background signal after quenching (cycle 7) with the background signal before quenching (cycle 3) when detecting ACTB in tonsil tissue. A significant reduction in background signal was observed in all quencher concentrations tested and over multiple cycles of stripping and reprobing compared to unquenched tonsil tissue.
[0076] Figure 10A-10C Depicted are the density of detected objects (per μm) in tonsil tissue quenched with Compound 1A (0.1 mM, 0.5 mM, and 0.8 mM concentrations) imaged using ATTO 488-labeled detectable probes. 2 (Counting of RCA products of nuclear area). When treated with compound 1A at all concentrations, an increase in the density of detected objects was observed.
[0077] Figures 11A-11C The subject local signal-to-noise ratio (mean) of tonsil tissue quenched with quencher Compound 1A (0.1 mM, 0.5 mM and 0.8 mM concentrations) is shown. An increase in the signal-to-noise ratio was observed at 488 nm at all concentrations of Compound 1A tested.
[0078] Fig.12 The target signal intensity detected above the local background in tonsil tissue quenched with quencher compound 1A (0.1 mM, 0.5 mM and 0.8 mM concentrations) and imaged at 488 nm is shown. The background intensity of the quenched tissue imaged at 10 milliseconds (10 ms) exposure was compared to the background intensity imaged at 30 milliseconds (30 ms) exposure. Increasing the exposure time from 10 milliseconds to 30 milliseconds significantly increased the detected target signal intensity above the local background. DETAILED DESCRIPTION
[0079] The present disclosure relates to methods for masking or reducing autofluorescence in biological samples. More specifically, the present disclosure relates to methods and compositions for in situ analysis or detection of analytes in samples, and compounds for use in the methods and compositions.
[0080] Analysis of biological samples by fluorescence in situ hybridization relies on the ability to generate and detect fluorescent signals associated with analytes of interest or probes specific for those analytes of interest. Importantly, these analytes or their probes should be distinguished from other non-analytes that may be autofluorescent and contribute to background noise and have brighter fluorescent signals compared to them. Tissue autofluorescence is commonly observed in most tissue types and can be associated with various endogenous biological parts, including but not limited to lipofuscin, collagen, elastin, erythrocytes, flavin, nicotinamide adenine dinucleotide (NADH), and even extracellular matrix. This autofluorescence also exhibits broad color emission, so that the fluorescent signal associated with the analyte of interest may become obscured in the visible light region of the electromagnetic spectrum (the main wavelength band evaluated in in situ fluorescence imaging). Therefore, certain wavelengths cannot be read without auxiliary processing to reduce fluorescence.
[0081] In order to reduce autofluorescence, various commercial quencher compounds and compositions have been developed for use in biological samples. Existing commercially available quenchers for reducing autofluorescence are combined in quenching mixtures that are specifically tailored for certain tissues and / or autofluorescence types. However, the quenching efficiency generally depends on the quencher compound used and the type of tissue analyzed. In fact, there is no universal quencher for all tissue types. Even in the case of a significant reduction in background autofluorescence, even a small amount of unwanted fluorescence may be detrimental to the detection of the actual fluorescent signal. For example, a punctate background fluorescent signal may be similar in size and shape to the fluorescent signal expected from the rolling circle amplification product. Since the size and shape of the background autofluorescence are similar to the actual fluorescent signal, failure to fully reduce the autofluorescence may result in higher false positive readings.
[0082] Another disadvantage of commercially available quenchers is that, when they are applied, they are only weakly physically adsorbed to the tissue sample. Therefore, existing quenchers not only require high concentrations to reduce background fluorescence to provide adequate quenching, but are also easily washed away with standard stripping agents that are commonly used for fluorescence imaging over multiple cycles of hybridization and detection. Therefore, commercially available quenchers are applied and reapplied to individual tissue samples during each cycle of hybridization and imaging. This repeated processing adds a significant burden to the analysis of a given tissue sample—extending analysis time, increasing reagent expenditures, and requiring a degree of complexity in automated sequencing equipment to accommodate the additional step of reapplying the quencher between imaging cycles.
[0083] Therefore, there is a continuing need for improved compounds and methods for reducing autofluorescence and analyzing tissue samples or other biological samples using multiplexed (multicolor) and repetitive (multicycle) fluorescence imaging techniques.
[0084] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0085] The following description sets forth exemplary methods, parameters, etc. However, it should be appreciated that such description is not intended to limit the scope of the present disclosure, but is provided as a description of exemplary embodiments.
[0086] All publications (including patent documents, scientific articles, and databases) mentioned in this application are incorporated herein by reference in their entirety for all purposes to the same extent as if each individual publication were individually incorporated by reference. If definitions set forth herein are contrary to or contradictory to definitions set forth in patents, patent applications, published patent applications, and other publications incorporated herein by reference, the definitions set forth herein take precedence over the definitions incorporated herein by reference.
[0087] I. Overview
[0088] The present disclosure addresses these needs for improved methods for multicolor, multi-cycle fluorescence imaging by providing methods for reducing autofluorescence and analyzing biological and / or tissue samples. The methods of the present disclosure achieve persistent reduction of background autofluorescence over multiple imaging cycles by employing quencher compounds that combine broad visible spectrum absorption with persistent targeting chemistry.
[0089] The absorbing dye portion of the quencher compound used herein is capable of absorbing a broad spectrum of visible light in the range of 400-700 nm, particularly in the range of 500-600 nm, which is the primary region for fluorescence imaging as well as the region of high background autofluorescence. However, the absorption spectrum of the quencher dye can be easily altered and the solubility can be easily adjusted via synthetic modification of the substituents and linkers required for a specific application.
[0090] The targeting portion of the quencher is targeted to the natural functional groups of the tissue sample, particularly those present on endogenous biological moieties or autofluorescent moieties. The targeting portion of the quencher forms a lasting chemical or physical interaction with these autofluorescent endogenous biological moieties through covalent chemical bonds or through energetically favorable intermolecular attraction in close proximity. Since the functional groups present on certain endogenous biological moieties may be different, the targeting portion of the quencher can be selected or combined with other quenchers to provide optimal targeting of the autofluorescent entities in the sample. The use of the quencher can also be combined with a pretreatment step to enrich the presence of functional groups in the biological sample that can be bound to the targeting portion of the quencher.
[0091] The quenching can be performed in a single step on the bench before the first imaging cycle. Once reacted or bound to the endogenous biological moiety via the targeting moiety, the quencher remains intact in the biological sample or tissue sample. Samples treated with the quencher provided in the present disclosure can be subsequently repeatedly treated with washing and stripping buffers to remove and introduce different detectable probes for imaging without significant loss of the quencher and with little increase in background autofluorescence. The combination of a persistent targeting moiety and a broadband quencher dye works in a single application step to reduce autofluorescence over a wide spectral range and in multiple imaging cycles without the need for additional quenching steps.
[0092] Eliminating the need to repeatedly apply a quencher to a given biological sample has important implications for the cost and speed of multiplexed, multi-cycle in situ analysis. For example, when fluorescence imaging is performed on a sample treated with a quencher comprising a quencher dye and a targeting moiety, fluorescence imaging can be performed with less quencher, reduced sample preparation time, and less downtime for each imaging cycle. In addition, since an additional quenching step is no longer required, the device or instrument used to perform the assay may no longer need to include a quenching step as part of each cycle program or be adjusted in its engineering configuration. Where repeated quenching steps may have previously excluded such measurements from being performed on a lower cost, simpler device, the same device can now be used to perform multi-cycle, multiplexed imaging analysis. Therefore, the methods and compounds disclosed herein enable more efficient and cost-effective fluorescence in situ hybridization imaging.
[0093] A. Methods
[0094] (i) Method for reducing autofluorescence
[0095] In one aspect, provided herein is a method for reducing autofluorescence in a biological sample, comprising contacting the biological sample with a quencher comprising a quencher dye and a targeting moiety, wherein the targeting moiety reacts with an endogenous biological moiety of the biological sample, thereby targeting the quencher to the endogenous biological moiety; and detecting a signal associated with a detectable probe that is directly or indirectly bound to a molecule of interest in the biological sample, wherein the quencher reduces autofluorescence in the biological sample. In some embodiments, the biological sample is a tissue sample. In some embodiments, the biological sample is contacted with a plurality of detectable probes, each of which is directly or indirectly bound to a molecule of interest in the biological sample, and signals associated with the plurality of detectable probes are detected at locations in the biological sample.
[0096] In some embodiments, the biological sample is contacted with the detectable probe before contacting with the quencher. In other embodiments, the biological sample is contacted with the detectable probe after contacting with the quencher. In other embodiments, the biological sample is contacted with the detectable probe and the quencher simultaneously.
[0097] In one aspect, provided herein is a method for reducing autofluorescence in a biological sample, comprising: contacting the biological sample with a quencher comprising a quencher dye and a targeting moiety, wherein the targeting moiety reacts with an endogenous biological moiety of the biological sample, thereby targeting the quencher to the endogenous biological moiety; contacting the biological sample with a detectable probe that binds directly or indirectly to a molecule of interest in the biological sample; and detecting a signal associated with the detectable probe that binds directly or indirectly to a molecule of interest in the biological sample, wherein the quencher reduces autofluorescence in the biological sample.
[0098] In one aspect, provided herein is a method for reducing autofluorescence in a biological sample, comprising: contacting the biological sample with a detectable probe that binds directly or indirectly to a molecule of interest in the biological sample; optionally detecting a signal associated with the detectable probe at a location in the biological sample; contacting the biological sample with a quencher comprising a quencher dye and a targeting moiety, wherein the targeting moiety reacts with an endogenous biological moiety of the biological sample, thereby targeting the quencher to the endogenous biological moiety; and detecting a signal associated with the detectable probe that binds directly or indirectly to a molecule of interest in the biological sample, wherein the quencher reduces autofluorescence in the biological sample.
[0099] In one aspect, provided herein is a method for reducing autofluorescence in a biological sample, comprising: contacting the biological sample with a detectable probe that is directly or indirectly bound to a molecule of interest in the biological sample; optionally detecting a signal associated with the detectable probe at a location in the biological sample; contacting the biological sample with a quencher comprising a quencher dye and a targeting moiety, wherein the targeting moiety reacts with an endogenous biological part of the biological sample, thereby targeting the quencher to the endogenous biological part; detecting a signal associated with the detectable probe, which is directly or indirectly bound to a molecule of interest in the biological sample; removing the detectable probe and / or eliminating the signal associated with it; contacting the biological sample with an additional detectable probe that is directly or indirectly bound to another molecule of interest in the biological sample; and detecting a signal associated with an additional detectable probe that is directly or indirectly bound to another molecule of interest in the biological sample, wherein the quencher reduces autofluorescence in the biological sample. The molecule of interest and the additional molecule of interest may be the same or different, and the detectable probe and the additional detectable probe may be the same or different. In some embodiments, after contacting with a quencher comprising a quencher dye and a targeting moiety, a signal associated with an additional detectable probe is detected without contacting the biological sample with the quencher. In some embodiments, removal of the detectable probe from the biological sample is by stripping, e.g., by washing the sample in a solution comprising a denaturing agent and / or under denaturing conditions (e.g., heating).
[0100] In one aspect, the present invention provides a method for reducing the autofluorescence in a biological sample, comprising: contacting the biological sample with a nucleic acid probe or probe group that is directly or indirectly bound to a molecule of interest in the biological sample; contacting the biological sample with a quencher comprising a quencher dye and a targeting moiety, wherein the targeting moiety reacts with an endogenous biological part of the biological sample, thereby targeting the quencher to the endogenous biological part; contacting the biological sample with a labeling agent (e.g., a nucleic acid-labeled binding agent, such as an antibody labeled with a DNA marker for a protein analyte), the labeling agent directly or indirectly binds to other molecules of interest in the biological sample; and detecting a signal associated with the labeling agent and the nucleic acid probe or probe group at one or more positions in the biological sample, wherein the quencher reduces the autofluorescence in the biological sample. In some embodiments, the nucleic acid probe or probe group is a circular probe or a circularizable probe or probe group hybridized with a nucleic acid in the biological sample, and a product (e.g., an RCA product) of the circular probe or the circularizable probe or probe group is generated in the biological sample. In some embodiments, the biological sample is contacted with a detectably labeled nucleic acid probe hybridized to the RCA product before contacting the biological sample with the quencher. In some embodiments, the biological sample is contacted with an intermediate nucleic acid probe hybridized to the RCA product and a detectably labeled nucleic acid probe hybridized to the intermediate nucleic acid probe before contacting the biological sample with a quencher. In some embodiments, detecting a signal associated with a nucleic acid probe or probe set includes detecting a signal associated with a detectably labeled nucleic acid probe; although the biological sample can be contacted with a detectably labeled nucleic acid probe before contacting a quencher and a labeling agent, the detectably labeled nucleic acid probe can be detected after quenching and contacting with a labeling agent (e.g., DNA-labeled antibody staining of the sample).
[0101] On the other hand, provided herein is a method for reducing autofluorescence in a biological sample, comprising: contacting a biological sample with a nucleic acid probe or probe set that is directly or indirectly bound to a molecule of interest in the biological sample; contacting a biological sample with a labeling agent (e.g., a nucleic acid-labeled binding agent, such as a DNA-labeled antibody), the labeling agent being directly or indirectly bound to other molecules of interest in the biological sample; contacting a biological sample with a quencher comprising a quencher dye and a targeting moiety, wherein the targeting moiety reacts with an endogenous biological part of the biological sample, thereby targeting the quencher to the endogenous biological part; and detecting a signal associated with the labeling agent and the nucleic acid probe or probe set at one or more positions in the biological sample, wherein the quencher reduces autofluorescence in the biological sample. In some embodiments, the nucleic acid probe or probe set is a circular probe or a circularizable probe or probe set hybridized with a nucleic acid in the biological sample, and a product (e.g., an RCA product) of the circular probe or the circularizable probe or probe set is generated in the biological sample. In some embodiments, the biological sample is contacted with a detectably labeled nucleic acid probe hybridized to an RCA product before contacting the biological sample with a labeling agent. In some embodiments, the biological sample is contacted with an intermediate nucleic acid probe hybridized to the RCA product and a detectably labeled nucleic acid probe hybridized to the intermediate nucleic acid probe before contacting the biological sample with a labeling agent. In some embodiments, detecting a signal associated with a nucleic acid probe or probe set includes detecting a signal associated with a detectably labeled nucleic acid probe; although the biological sample can be contacted with a detectably labeled nucleic acid probe before contacting a labeling agent and a quencher, a detectably labeled nucleic acid probe can be detected after contacting a labeling agent (e.g., a DNA-labeled antibody staining of the sample) and quenching.
[0102] In another aspect, provided herein is a method for reducing autofluorescence in a biological sample, comprising: contacting the biological sample with a nucleic acid probe or probe set that directly or indirectly binds to a molecule of interest in the biological sample; bleaching the biological sample; contacting the biological sample with a labeling agent (e.g., a nucleic acid-labeled binding agent, such as a DNA-labeled antibody), the labeling agent directly or indirectly binds to other molecules of interest in the biological sample; contacting the biological sample with a quencher comprising a quencher dye and a targeting portion, wherein the targeting portion reacts with an endogenous biological portion of the biological sample, thereby targeting the quencher to the endogenous biological portion; and detecting a signal associated with the labeling agent and the nucleic acid probe or probe set at one or more locations in the biological sample, wherein the quencher reduces autofluorescence in the biological sample. In some embodiments, bleaching the biological sample comprises photochemical bleaching using a chemical reagent and a light source. In some embodiments, bleaching the biological sample comprises contacting the biological sample with a chemical (e.g., 1% hydrogen peroxide) and exposing the biological sample to intense visible light (e.g., light with a wavelength of 455 nm for 5 minutes). Exemplary photochemical bleaching techniques are disclosed in Section IA. In some embodiments, the nucleic acid probe or probe group is a circular probe or a circularizable probe or a probe group hybridized with a nucleic acid in a biological sample, and a product (e.g., RCA product) of the circular probe or circularizable probe or probe group is generated in the biological sample. In some embodiments, the biological sample is contacted with a detectably labeled nucleic acid probe hybridized to the RCA product before bleaching the biological sample (e.g., using photochemical bleaching). In some embodiments, the biological sample is contacted with an intermediate nucleic acid probe hybridized to the RCA product and a detectably labeled nucleic acid probe hybridized to the intermediate nucleic acid probe before bleaching the biological sample (e.g., using photochemical bleaching). In some embodiments, detecting a signal associated with a nucleic acid probe or a probe group includes detecting a signal associated with a detectably labeled nucleic acid probe; although the biological sample can be contacted with a detectably labeled nucleic acid probe before bleaching the biological sample (e.g., using photochemical bleaching), a detectably labeled nucleic acid probe can be detected after bleaching, contacting with a labeling agent (e.g., antibody staining of a DNA marker of a sample) and quenching.
[0103] In some embodiments, before detecting the signal associated with the detectable probe, the method includes contacting the biological sample with a primary probe such as a nucleic acid probe that is directly or indirectly bound to a molecule of interest in the biological sample, and the detectable probe is directly or indirectly bound to the primary probe. In some embodiments, the method also includes removing the detectable probe or a portion thereof from the biological sample, wherein the quencher is retained in the biological sample, and optionally wherein the removal step includes treating the biological sample with a denaturant and / or heat. In some embodiments, the denaturant includes dimethyl sulfoxide (DMSO), formamide and / or an alkaline solution.
[0104] Additional sample processing steps may be included or omitted in the methods as described herein. For example, in some embodiments, the methods of the present disclosure include staining the biological sample. In some embodiments that can be combined with the foregoing embodiments, the method also includes fixing the biological sample. In some embodiments that can be combined with the foregoing embodiments, the method also includes de-crosslinking the biological sample. In some embodiments, the step of contacting the biological sample with a quencher can be performed before or after one or more treatments for fixing, permeabilizing / de-crosslinking and / or staining the biological sample.
[0105] In another aspect, provided herein is a method for reducing autofluorescence comprising contacting a tissue sample with a quencher comprising a quencher dye and a targeting moiety, wherein the targeting moiety reacts with an endogenous biological moiety in the tissue sample, thereby targeting the quencher to the endogenous biological moiety; and detecting a signal associated with a detectable probe that directly or indirectly binds to a molecule of interest in the tissue sample, wherein the quencher reduces autofluorescence in the tissue sample.
[0106] In some embodiments, the tissue sample is contacted with the detectable probe before contacting with the quencher. In other embodiments, the tissue sample is contacted with the detectable probe after contacting with the quencher. In other embodiments, the tissue sample is contacted with the detectable probe and the quencher at the same time.
[0107] In some embodiments, before detecting the signal associated with the detectable probe, the method includes contacting the tissue sample with a primary probe such as a nucleic acid probe that is directly or indirectly bound to a molecule of interest in the tissue sample, and wherein the detectable probe is directly or indirectly bound to the primary probe. In some embodiments, the method also includes removing the detectable probe or a portion thereof from the tissue sample, wherein the quencher is retained in the tissue sample, and optionally wherein the removal step includes treating the tissue sample with a denaturant and / or heat. In some embodiments, the denaturant includes dimethyl sulfoxide (DMSO), formamide and / or an alkaline solution.
[0108] It should be appreciated that the contact order of biological or tissue samples with quenchers and detectable probes can be adjusted to adapt to one or more additional sample processing steps as required. Depending on the type of analyte to be evaluated, certain sample processing steps may be included or omitted, and the order in which reagents are applied may change. For example, in the analysis of proteins as molecules of interest and protein-related sample processing steps, preferably after fixation, permeabilization / solution cross-linking and staining, but before any detectable probe is introduced into the sample, quenchers are added to obtain better protein stability and downstream signals. In the analysis of nucleic acids only as molecules of interest and nucleic acid-related processing steps, such as in RNA workflows, preferably quenchers are added after primary probes are applied to the sample, but can be added before or after any amplification step (such as rolling circle amplification).
[0109] In some embodiments, the method for reducing autofluorescence comprises bleaching (e.g., chemical bleaching, photobleaching, photochemical bleaching, exposure to heat) the sample before, simultaneously with, or after contact with a quencher disclosed herein. In some embodiments, the combination of bleaching and quenching prior to signal detection increases the signal-to-noise ratio and detectable object count density compared to an unbleached and / or unquenched tissue sample.
[0110] As used herein, an unbleached biological sample or an unbleached tissue sample is understood to be a biological sample or tissue sample of the same type that has undergone the same treatment as the bleached sample, except for being treated with a bleaching agent (e.g., a chemical agent in chemical bleaching, light in photobleaching, chemical and light in photochemical bleaching, heat and / or enzymes).
[0111] In some embodiments, methods for reducing autofluorescence include chemical bleaching. In some embodiments, samples are treated with chemicals (e.g., hydrogen peroxide, sodium borohydride, trypan blue, chrome black T, ammonium chloride, copper sulfate, Sudan black, or similar chromophores). Any suitable chemicals or dyes can be used to chemically bleach tissue samples.
[0112] Some tissues may have high endogenous enzymes (e.g., high endogenous peroxidases, phosphatases), resulting in high background. In some embodiments, the sample is treated with a chemical to block enzyme activity (e.g., hydrogen peroxide, acetic acid, potassium borohydride). Any suitable chemical can be used to block the background generated by high endogenous enzyme activity.
[0113] In some embodiments, the method for reducing autofluorescence includes enzymatic bleaching. In one aspect, the enzymatic bleaching can include a hydrolase. In one aspect, the enzymatic bleaching can include an enzyme targeting an endogenous biological part, such as those described in Section 1C.
[0114] In some embodiments, the method for reducing autofluorescence includes photobleaching. In some embodiments, the sample is exposed to a strong visible light source. In some aspects, the strong visible light source can be a fluorescent lamp, an incandescent ultraviolet bulb, a light emitting diode (LED) lamp with a broad spectrum emission of a white phosphor, an LED lamp or an LED array with blue and red emission peaks. Any suitable light source can be used for photobleaching tissue samples.
[0115] In some embodiments, the method for reducing autofluorescence comprises exposing the sample to heat. In some embodiments, the sample is exposed to heat.
[0116] In some embodiments, the method for reducing autofluorescence includes photochemical bleaching. In some embodiments, the sample is treated with chemicals and exposed to a strong visible light source simultaneously or in any order. For example, the tissue sample is bleached by exposure to a solution containing methanol, ethanol or octanol and DMSO and reagents such as potassium hydroxide, bleach or hydrogen peroxide. In one embodiment, 1% hydrogen peroxide is used. In another embodiment, a mixture of methanol and DMSO and 30% hydrogen peroxide is used. In some embodiments, the tissue sample is photobleached with 1% hydrogen peroxide and exposed to light of wavelength 455nm for 5 minutes. In some embodiments, the strong visible light source is a fluorescent lamp, an incandescent ultraviolet bulb, a light emitting diode (LED) lamp with a broad spectrum emission of a white phosphor, an LED lamp with blue and red emission peaks, an LED array, sunlight or any suitable light source. In some embodiments, the tissue sample is exposed to light of about 400nm to 700nm. In some embodiments, photobleaching is carried out in the presence of a quencher (e.g., a quencher dye of about 0.1nM to about 0.1mM). In some embodiments, the sample is exposed to light, such as light of 365nm to 525nm wavelength. In some embodiments, the sample is exposed to light of about 365nm, about 375nm, about 385nm, about 395nm, about 405nm, about 415nm, about 425nm, about 430nm, about 435nm, about 445nm, about 455nm, about 465nm, about 475nm, about 485nm, about 495nm, about 505nm, about 515nm, about 525nm or any wavelength between the foregoing. In some embodiments, the sample is exposed to light such as 100 watts to 200 watts. In some embodiments, the sample is exposed to light of about 100 watts, 110 watts, 120 watts, 130 watts, 140 watts, 150 watts, 160 watts, 170 watts, 180 watts, 200 watts or between any of the foregoing. In some embodiments, the sample is photobleached for about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, about 8 minutes, or between any of the above times. In some embodiments, the sample is photobleached for about 2 minutes, about 5 minutes, or about 8 minutes. In some embodiments, the concentration of hydrogen peroxide used is about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, or between any of the above concentrations. In some embodiments, the tissue sample is treated with a combination of 0.1 mM quencher, 1% hydrogen peroxide, and exposed to light of a wavelength of 455 nm (high power) for 5 minutes in any order thereof. In some embodiments, for photochemical bleaching, the tissue sample is treated with about 1% to about 4% hydrogen peroxide and exposed to light of a wavelength of about 365 nm to about 525 nm for about 2, about 5, and about 8 minutes at a power of about 100 W to about 200 W.In some embodiments, for photochemical bleaching, the tissue sample is treated with about 1% hydrogen peroxide and exposed to light having a wavelength of about 455 nm for about 5 minutes at high power, such as about 150 W to about 200 W. Photochemical bleaching can be performed before, during, and / or after contacting the sample with a quencher disclosed herein.
[0117] In some embodiments, the method for reducing autofluorescence comprises any combination of the foregoing methods. In some embodiments, the method further comprises bleaching the biological or tissue sample with a chemical reagent, enzyme, light, heat, or any combination thereof before, simultaneously with, or after contacting the biological or tissue sample with the quencher.
[0118] In some embodiments, bleaching is performed for at least 1, at least 2, at least 3, at least 4, at least 5, at least 6 bleaching cycles (e.g., photochemical bleaching). In some embodiments, each cycle is performed for about 1 minute, about 2 minutes, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 60 minutes, or any time between the foregoing. In some embodiments, the sample is treated with a reagent (e.g., hydrogen peroxide), and photochemical bleaching is performed for about no more than 1 minute, no more than 2 minutes, no more than 5 minutes, no more than 8 minutes, or no more than 10 minutes. In certain embodiments, compared with unquenched and / or unbleached tissue samples, autofluorescence is reduced by at least about 50%, at least about 60%, at least about 70%, or at least about 80%. In any embodiment herein, the photochemical bleaching method is compatible with the method for analyzing biological samples (e.g., tissue samples) described herein. Other methods and aspects of bleaching tissue samples are described, for example, in Du et al., Nature Protocols 14(10):2900-2930, 2019, US 6,232,092, Meeker AK, Photochemical pre-bleaching of formalin-fixed archival prostate tissues significantly reduces autofluorescence to facilitate multiplex immunofluorescence staining, bioRxiv doi:10.1101 / 2021.11.09.467916, all of which are incorporated herein by reference in their entirety. In any of the foregoing embodiments, the method for reducing autofluorescence can be performed using a buffer comprising a crowding agent. In some embodiments, the crowding agent is selected from poly(ethylene glycol) (PEG), glycerol, and dextran sulfate. In any of the foregoing embodiments, the crowding agent can be poly(ethylene glycol) (PEG). In some embodiments, the crowding agent includes PEG having an average molecular weight of about 200 Da to about 35,000 Da. In some embodiments, the PEG has an average molecular weight of about 2000 Da to about 16,000 Da. In some embodiments, the PEG is PEG 200, PEG 2000, PEG 3000, PEG 4000, PEG 5000, PEG 6000, PEG 7000, PEG 8000, PEG 9000, PEG 10000, PEG 11000, PEG 12000, PEG 13000, PEG 14000, PEG 15000, PEG 16000, PEG 30000, PEG 35000, or PEG 40000. In any of the preceding embodiments, PEG may be selected from the group consisting of PEG200, PEG8000, and PEG35000.
[0119] In some embodiments, PEG is present at a concentration of about 2% to 25%, about 4% to about 23%, about 6% to about 21%, or about 8% to about 20% (v / v). In any of the foregoing embodiments, the buffer may comprise about 5% to about 15% PEG (v / v), optionally wherein the buffer comprises about 10% PEG (v / v).
[0120] (ii) Methods for analyzing biological samples
[0121] In another aspect, provided herein is a method for analyzing a biological sample, comprising: contacting the biological sample with a quencher comprising a quencher dye and a targeting moiety, wherein the targeting moiety directly or indirectly binds to and / or reacts with an endogenous biological moiety of the biological sample, thereby targeting the quencher to the biological moiety; contacting the biological sample with a detectable probe that directly or indirectly binds to a molecule of interest in the biological sample; and detecting a signal associated with the detectable probe bound to the molecule of interest in the biological sample, wherein the quencher dye reduces autofluorescence of the biological sample, thereby detecting the molecule of interest in the biological sample.
[0122] In some embodiments, the biological sample is contacted with the detectable probe before contacting with the quencher. In other embodiments, the biological sample is contacted with the detectable probe after contacting with the quencher. In other embodiments, the biological sample is contacted with the detectable probe and the quencher simultaneously.
[0123] In some embodiments, before contacting the biological sample with a detectable probe that directly or indirectly binds to a molecule of interest in the biological sample, the method includes contacting the biological sample with a nucleic acid probe that directly or indirectly binds to a molecule of interest in the biological sample, and wherein the detectable probe directly or indirectly binds to the nucleic acid probe. In some embodiments, the method also includes removing the detectable probe or a portion thereof from the biological sample, wherein the quencher remains in the biological sample, optionally wherein the removing step includes treating the biological sample with a denaturing agent and / or heating.
[0124] Additional sample processing steps may be included or omitted in the methods as described herein. For example, in some embodiments, the methods of the present disclosure include staining the biological sample. In some embodiments that can be combined with the foregoing embodiments, the method also includes fixing the biological sample. In some embodiments that can be combined with the foregoing embodiments, the method also includes de-crosslinking the biological sample. In some embodiments, the step of contacting the biological sample with a quencher can be performed before or after one or more treatments of staining, permeabilization, fixing and / or de-crosslinking the biological sample.
[0125] In some embodiments in which the biological sample is a tissue sample, a similar process and order of applying a quencher and a detectable probe may be employed. For example, in some embodiments, the method of the present disclosure includes staining the tissue sample. In some embodiments that may be combined with the foregoing embodiments, the method further includes fixing the tissue sample. In some embodiments that may be combined with the foregoing embodiments, the method further includes de-crosslinking the tissue sample.
[0126] As described herein, it should be appreciated that the contact order of biological or tissue samples with quenchers and detectable probes can be adjusted to adapt to one or more additional sample processing steps as required. Depending on the type of analyte to be evaluated, certain sample processing steps may be included or omitted, and the order of reagent application may change. For example, in the analysis of proteins as molecules of interest and protein-related sample processing steps, preferably after fixation, permeabilization / solution cross-linking and staining, but before any detectable probe is introduced into the sample, quenchers are added to obtain better protein stability and downstream signals. In the analysis of nucleic acids only as molecules of interest and nucleic acid-related processing steps, such as in RNA workflows, preferably quenchers are added after primary probes are applied to the sample, but can be added before or after any amplification step (such as rolling circle amplification).
[0127] In some embodiments, the method for analyzing a biological sample comprises bleaching (e.g., chemical bleaching, photobleaching, photochemical bleaching, and / or exposure to heat) the sample prior to, simultaneously with, or after contact with a quencher. In some embodiments, the combination of bleaching and quenching prior to signal detection increases the signal-to-noise ratio and detectable object count density of the quenched biological sample compared to an unbleached and / or unquenched biological sample.
[0128] (iii) Methods for analyzing tissue samples
[0129] In one aspect, provided herein is a method for analyzing a tissue sample, comprising contacting the tissue sample with a nucleic acid probe that binds directly or indirectly to a molecule of interest in the tissue sample; contacting the tissue sample with a quencher comprising a quencher dye and a targeting portion, wherein the targeting portion binds directly or indirectly to and / or reacts with an endogenous biological moiety in the tissue sample, thereby targeting the quencher to the biological moiety; contacting the tissue sample with a fluorescently labeled detectable probe that binds directly or indirectly to the nucleic acid probe or an amplification product of the nucleic acid probe; and detecting a signal associated with the fluorescently labeled detectable probe in the tissue sample, wherein the quencher dye reduces autofluorescence in the tissue sample, thereby detecting the molecule of interest in the tissue sample.
[0130] In another aspect, provided herein is a method for analyzing a tissue sample, comprising contacting the tissue sample with a nucleic acid probe that binds directly or indirectly to a molecule of interest in the tissue sample; contacting the tissue sample with a quencher comprising a quencher dye and a targeting moiety, wherein the targeting moiety binds and / or reacts directly or indirectly with an endogenous biological moiety in the tissue sample, thereby targeting the quencher to the biological moiety, wherein the quencher is a compound of formula (I)
[0131]
[0132] or a salt thereof, wherein
[0133] Each are independently selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;
[0134] X a is H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkyl, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO, -cyano or -L-(R 靶 ) w, where w is any integer such as 1 or 2;
[0135] X c is H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkyl, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO, -cyano or -L-(R 靶 ) w , where w is any integer such as 1 or 2;
[0136] Where R 1 and R 2 are independently H, C1-C6 alkyl or substituted C1-C6 alkyl; and
[0137] Each R a and R c are independently H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkyl, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO or -cyano;
[0138] Each R b is H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkyl, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO, -cyano, R b1 or -L-(R 靶 ) w , where w is any integer such as 1 or 2;
[0139] R b1 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
[0140] L is a bond or linker moiety;
[0141] R 靶is the targeting portion;
[0142] m is an integer from 0 to 6;
[0143] n is an integer from 0 to 6; and
[0144] Each of x, y and z is independently an integer from 0 to 5;
[0145] The condition is that at least one of m and n is non-zero; and the condition is that X a , X c or R b At least one of them is -L-(R 靶 ) w , where w is any integer such as 1 or 2;
[0146] contacting the tissue sample with a fluorescently labeled detectable probe that is directly or indirectly bound to the nucleic acid probe or an amplification product of the nucleic acid probe; and detecting a signal associated with the fluorescently labeled detectable probe in the tissue sample, wherein the quencher dye reduces autofluorescence in the tissue sample, thereby detecting a molecule of interest in the tissue sample.
[0147] In another aspect, provided herein is a method for analyzing a tissue sample, comprising contacting the tissue sample with a nucleic acid probe that binds directly or indirectly to a molecule of interest in the tissue sample; contacting the tissue sample with a quencher comprising a quencher dye and a targeting moiety, wherein the targeting moiety binds and / or reacts directly or indirectly with an endogenous biological moiety in the tissue sample, thereby targeting the quencher to the biological moiety, wherein the quencher is a compound of formula (II)
[0148]
[0149] or a salt thereof, wherein
[0150] Each are independently selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;
[0151] X a is H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkyl, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO, -cyano or -LR 靶 ;
[0152] X cis H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkyl, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO, -cyano or -LR 靶 ;
[0153] Where R 1 and R 2 are independently H, C1-C6 alkyl or substituted C1-C6 alkyl; and
[0154] Each R a and R c are independently H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkyl, hydroxy-C1-C6 alkylene, -NR 1 R 2 , -NO2, -SO3H, -SO3-, -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO or -cyano;
[0155] Each R b is H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkyl, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO, -cyano, R b1 or -LR 靶 ;
[0156] R b1 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
[0157] L is a bond or linker moiety;
[0158] R 靶 is the targeting portion;
[0159] m is an integer from 0 to 6;
[0160] n is an integer from 0 to 6; and
[0161] Each of x, y and z is independently an integer from 0 to 5;
[0162] The condition is that at least one of m and n is non-zero; and the condition is that X a , X c or R b At least one of them is -LR 靶 ;
[0163] contacting the tissue sample with a fluorescently labeled detectable probe that is directly or indirectly bound to the nucleic acid probe or an amplification product of the nucleic acid probe; and detecting a signal associated with the fluorescently labeled detectable probe in the tissue sample, wherein the quencher dye reduces autofluorescence in the tissue sample, thereby detecting a molecule of interest in the tissue sample.
[0164] In some embodiments, the tissue sample is contacted with the detectable probe before contacting with the quencher. In other embodiments, the tissue sample is contacted with the detectable probe after contacting with the quencher. In other embodiments, the tissue sample is contacted with the detectable probe and the quencher at the same time.
[0165] In some embodiments, the step of contacting the tissue sample with the quencher can be performed before or after one or more treatments for fixing, permeabilizing / decrosslinking and / or staining the biological sample. For example, in some embodiments, the method of the present disclosure includes staining the tissue sample. In some embodiments that can be combined with the foregoing embodiments, the method also includes fixing the tissue sample. In some embodiments that can be combined with the foregoing embodiments, the method also includes decrosslinking the tissue sample.
[0166] It should be appreciated that the contact order of tissue sample with quencher and detectable probe can be adjusted to adapt to one or more additional sample processing steps as required. Depending on the type of analyte to be evaluated, some sample processing steps can be included or omitted, and the order of reagent application can be changed. For example, in the analysis and protein-related sample processing steps related to the protein as a molecule of interest, preferably after fixation, permeabilization / solution cross-linking and staining, but before any detectable probe is introduced into the sample, quencher is added to obtain better protein stability and downstream signals. In the analysis and nucleic acid-related processing steps only related to the nucleic acid as a molecule of interest, such as in the RNA workflow, preferably a quencher is added after the primary probe is applied to the sample, but can be added before or after any amplification step (such as rolling circle amplification).
[0167] In some embodiments, the method for analyzing a tissue sample comprises bleaching (e.g., chemical bleaching, photobleaching, photochemical bleaching, exposure to heat) the sample prior to, simultaneously with, or after contacting with a quencher. In some embodiments, the combination of bleaching and quenching prior to signal detection increases the signal-to-noise ratio and detectable object count density in the quenched tissue sample compared to an unbleached and / or unquenched tissue sample.
[0168] (iv) Additional detectable probes and multiple imaging cycles
[0169] The method of any of the foregoing aspects may also include multiple imaging cycles and concomitant treatments for adding and / or removing detectable probes. As described in detail herein, the quenchers of the present disclosure combine broadband absorption with durable targeted chemistry, such that the quenchers persist in the biological or tissue sample being evaluated during multiple rounds of washing and stripping to exchange detectable probes.
[0170] In some embodiments of any of the foregoing aspects, the method further comprises removing a detectable probe or a portion thereof from a biological sample, wherein the quencher is retained in the biological sample, and optionally wherein the removal step comprises treating the biological sample with a denaturant and / or heat. In some embodiments of any of the foregoing aspects, the method further comprises removing a detectable probe or a portion thereof from a tissue sample, wherein the quencher is retained in the tissue sample, and optionally wherein the removal step comprises treating the tissue sample with a denaturant and / or heat. In certain embodiments, the denaturant comprises dimethyl sulfoxide (DMSO), formamide and / or an alkaline solution. In some embodiments, the method comprises a signal removal step. For example, the method provided herein may comprise photobleaching, chemical inactivation, chemical cleavage (e.g., disulfide bond cleavage) of a fluorophore, enzymatic cleavage (using, for example, an exonuclease, an endonuclease, a protease or a USER TM (uracil specific excision reagent) cutting system), DNA / RNA strand displacement, chemical or thermal denaturation of intermediate fluorescent oligonucleotides and / or any suitable signal removal step. In some embodiments, the removal step includes stringent cleaning. Exemplary detectable methods are described in US 6,828,109, US2019 / 0376956, US2019 / 0376956, US2022 / 0026433, US2022 / 0128565 and US2021 / 0222234, all of which are incorporated herein by reference in their entirety. The signal removal step can be performed before, after and / or simultaneously with the quenching of the autofluorescence in the biological sample with a quencher, and can be repeated one or more times while the quencher remains in the biological sample and at least partially quenches the autofluorescence in the biological sample.
[0171] In some embodiments of any of the foregoing aspects, the method further comprises contacting the biological sample with one or more additional detectable probes, wherein each additional detectable probe directly or indirectly binds to additional molecules of interest in the biological sample, and the additional molecules of interest are the same or different from the molecules of interest in the detection step (b). In certain embodiments of any of the foregoing aspects, the method further comprises contacting the tissue sample with one or more additional detectable probes, wherein each additional detectable probe directly or indirectly binds to additional molecules of interest in the tissue sample, and the additional molecules of interest are the same or different from the molecules of interest in the detection step (b).
[0172] In some embodiments, the method further comprises detecting one or more signals associated with one or more additional detectable probes in the biological sample, wherein the autofluorescence of the biological sample remains reduced compared to the unquenched biological sample. In certain embodiments, the method further comprises detecting one or more signals associated with one or more additional detectable probes in the tissue sample, wherein the autofluorescence of the tissue sample remains reduced compared to the unquenched tissue sample.
[0173] In other embodiments, one or more additional detectable probes are contacted with a biological sample, and signals associated with the one or more additional detectable probes are detected in one or more cycles, optionally wherein each cycle includes removing the additional detectable probes used in that cycle from the biological sample before contacting the biological sample with the additional detectable probes for subsequent cycles. In other embodiments, one or more additional detectable probes are contacted with a tissue sample, and signals associated with the one or more additional detectable probes are detected in one or more cycles, optionally wherein each cycle includes removing the additional detectable probes used in that cycle from the tissue sample before contacting the tissue sample with the additional detectable probes for subsequent cycles.
[0174] In some embodiments of any of the foregoing aspects wherein one or more additional detectable probes are contacted with a biological sample and one or more signals associated with the one or more additional detectable probes are detected in one or more cycles, the method comprises at least two, three, four, five, six or more cycles of contacting the biological sample with the one or more additional detectable probes. In some embodiments of any of the foregoing aspects wherein one or more additional detectable probes are contacted with a tissue sample and one or more signals associated with the one or more additional detectable probes are detected in one or more cycles, the method comprises at least two, three, four, five, six or more cycles of contacting the tissue sample with the one or more additional detectable probes.
[0175] B. Quencher
[0176] As provided herein, methods for reducing autofluorescence and analyzing biological samples, optionally wherein the biological sample is a tissue sample, employ a quencher compound comprising a quencher dye moiety having a broad visible light absorption spectrum and a targeting moiety that reacts or binds to endogenous biological moieties present in the biological sample over multiple imaging cycles. The quenchers provided herein can be described in terms of their constituent chemical moieties, their overall chemical structure, or even their optical properties.
[0177] Quencher dye can absorb energy from fluorophore (such as fluorescent dye), and re-emit energy in the form of heat (in the case of dark quencher) or visible light (in the case of fluorescent quencher). In some embodiments, quencher dye disclosed herein is dark quencher, such as quencher comprising dabcyl moiety. In some embodiments, quencher dye disclosed herein is not fluorescent quencher. In some embodiments, quencher dye disclosed herein is targeted near the autofluorescence source in the sample, and quencher dye absorbs energy emitted from the autofluorescence source, thereby suppressing autofluorescence emission. In some embodiments, quencher dye is a masking part, wherein quencher dye masks energy emitted from the autofluorescence source. In some embodiments, quencher disclosed herein comprises quencher dye coupled with targeting part, and the size of quencher is such that when targeting part is combined with autofluorescence source in sample and / or reacts, quencher dye is close enough to autofluorescence source to quench autofluorescence source. In some embodiments, the distance between quencher dye and autofluorescence source is less than 15nm. In some embodiments, the distance between the quencher dye and the autofluorescence source is less than 10 nm. In some embodiments, the distance between the quencher dye and the autofluorescence source is less than 5 nm. In some embodiments, the quencher dye is preferentially targeted to the autofluorescence source in the sample by the targeting moiety compared to a detectable probe (e.g., a fluorescently labeled probe) that is directly or indirectly bound to a molecule of interest in the sample.
[0178] (i) Quencher dye
[0179] Quencher dyes as described herein include a chemical portion of a quencher that reduces autofluorescence emitted by an endogenous biological moiety by absorbing the emitted light. Quencher dyes and therefore quenchers containing a quencher dye portion have broadband absorption in the visible region of the electromagnetic spectrum. Quencher dyes are represented by several monocyclic, bicyclic or polycyclic aromatic or heteroaromatic rings. The absorption spectrum of the quencher can be altered or adjusted by adjusting the substitution pattern of various (hetero)aromatic residues or rings.
[0180] In some embodiments, the quencher dye comprises (a) at least three aromatic residues, each of which is independently an unsubstituted aryl, substituted aryl, unsubstituted heteroaryl or substituted heteroaryl, wherein at least one aromatic residue is covalently linked to two other aromatic residues via two exocyclic azo bonds; or (b) at least two aromatic residues, each of which is independently an unsubstituted aryl, substituted aryl, unsubstituted heteroaryl or substituted heteroaryl, wherein at least two of the aromatic residues are covalently linked via exocyclic azo bonds, wherein at least one of the aromatic residues is an unsubstituted polycyclic aryl, a substituted polycyclic aryl, an unsubstituted polycyclic heteroaryl or a substituted polycyclic heteroaryl. In any embodiment herein, "polycyclic" comprises an aromatic ring system or heteroaromatic ring system having multiple rings (e.g., more than one ring). In any embodiment herein, "azo" comprises a diazenyl functional group having the structure -N=N-.
[0181] In some embodiments, the quencher dye comprises an optionally substituted 1,4-bis((E)-phenyldiazenyl)benzene Partially or optionally substituted (E)-5-phenyl-3-(phenyldiazenyl)phenazin-5-ium moiety or a salt thereof.
[0182] In some embodiments, the quencher dye comprises at least three aromatic moieties or residues, wherein each aromatic moiety or residue is independently unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, or substituted heteroaryl, wherein at least one aromatic moiety or residue is covalently linked to two other aromatic moieties or residues via two exocyclic azo bonds. In certain embodiments, the quencher dye comprises an optionally substituted 1,4-bis((E)-phenyldiazenyl)benzene moiety or a salt thereof. In other embodiments, the quencher dye comprises at least two aromatic moieties or residues, wherein each aromatic moiety or residue is independently unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, or substituted heteroaryl, wherein at least two of the aromatic moieties or residues are covalently linked via an exocyclic azo bond, wherein at least one of the aromatic moieties or residues is an unsubstituted polycyclic aryl, substituted polycyclic aryl, unsubstituted polycyclic heteroaryl, or substituted polycyclic heteroaryl. In certain other embodiments, the quencher dye comprises an optionally substituted (E)-5-phenyl-3-(phenyldiazenyl)phenazine-5-ium moiety or a salt thereof.
[0183] Those skilled in the art will recognize that the effective quenching of any fluorescent entity is highly dependent on the distance between the quencher dye and the fluorescence or autofluorescence source. Although the quencher dyes provided herein have broadband absorption, the quenchers of the present disclosure achieve high quenching efficiency of background autofluorescence while also not significantly reducing the desired fluorescence signal emitted by or associated with the detectable probe. The quenchers of the present disclosure achieve specific quenching of background autofluorescence by using a targeting moiety to react the quencher dye with or near the autofluorescence source in a biological sample or tissue sample.
[0184] (ii) Targeting moiety
[0185] In some embodiments, the quencher dye can be modified with a functional group targeting an endogenous biological part (such as lipofuscin, collagen, elastin, etc.). For example, lipofuscin is a brownish yellow, electron-dense autofluorescent substance that gradually accumulates in the lysosomes of post-mitotic cells (such as neurons and cardiomyocytes) over time. In some embodiments, the quencher dye can be a dark quencher, such as a dark dye that absorbs energy from a fluorophore and re-emits most of the energy in the form of heat. In some embodiments, the quencher dye is chemically modified with one, two or more functional groups to target the quencher dye to one or more autofluorescence sources in the sample. In some embodiments, two or more quencher dye molecules can be modified with the same one or more functional groups. In some embodiments, two or more quencher dye molecules can be modified with one or more different functional groups. In some embodiments, two or more functional groups on the same modified quencher dye molecule can be the same or different. In some embodiments, one or more hydrophobic tails can be attached (directly or indirectly and / or covalently or non-covalently) to the quencher dye to bind lipofuscin or other molecules or complexes containing lipids. For example, the hydrophobic tail can be inserted into the lipid layer, thereby targeting the quencher dye to the complex containing the lipid layer. In some embodiments, the NHS moiety can be bound to a polypeptide such as a protein, thereby targeting the quencher dye to the polypeptide.
[0186] In some embodiments, the quencher comprising the targeting moiety disclosed herein can provide selectivity and persistence for targeting and masking the autofluorescence in the sample, for example, via the lipophilicity and / or covalent anchoring of the quencher dye in the sample. In some embodiments, the quencher comprising the targeting moiety disclosed herein can be used for targeted quenching, for example, the quencher dye is targeted to one or more autofluorescence sources in the sample, and substantially does not interfere with the detectable signal associated with the detectable probe of the molecule of interest directly or indirectly bound to the tissue sample. In some embodiments, the quencher dye targeted to one or more autofluorescence sources in the sample does not substantially interfere with the detectable signal associated with the rolling circle amplification product in the sample. In some embodiments, the quencher dye targeted to one or more autofluorescence sources in the sample is retained in the sample, for example, by covalent bonds and / or non-covalent interactions, such as lipophilic insertion. In some embodiments, the quencher dye coupled to the targeting moiety disclosed herein is retained in the sample (e.g., tissue sample) for a longer time than the quencher dye not coupled to the targeting moiety. In some embodiments, the quencher dye coupled to the targeting moiety disclosed herein requires a lower frequency of quenching than the quencher dye not coupled to the targeting moiety. In some embodiments, the quencher dye coupled to the targeting moiety can be contacted with the sample once. In some embodiments, the quencher dye coupled to the targeting moiety allows the detection of signals associated with molecules of interest in the sample with a high signal-to-noise ratio and / or a high detectable object count density through sequential probe hybridization, stripping and rehybridization cycles.
[0187] Targeting moieties as provided herein include quencher moieties that react or bind to endogenous biological moieties in a biological sample. In some embodiments, the targeting moiety binds directly or indirectly to an endogenous biological moiety present in a biological or tissue sample.
[0188] In some embodiments, the interaction between the targeting moiety and the endogenous biological moiety can take the form of a covalent chemical bond, such that the quencher remains intact in the biological or tissue sample. In some embodiments, the targeting moiety comprises a first functional group, and the endogenous biological moiety comprises a second functional group capable of reacting with the first functional group to form a covalent bond.
[0189] The first functional group of the targeting moiety may include, but is not limited to, carboxylic acid or a derivative thereof, such as various acyl halides or esters, hydroxyl groups, thiol groups, amino groups, alkenyl or dienyl groups, epoxy groups, haloalkyl groups, or phosphoramidites. In certain embodiments, the first functional group is a carboxylic acid moiety or a derivative thereof, an aldehyde or ketone moiety, a sulfonyl halide moiety, a hydroxyl moiety, a thiol moiety, an amino moiety, an alkenyl or dienyl moiety, an epoxide moiety, or a haloalkyl moiety.
[0190] In certain embodiments, the first functional group is a maleimido moiety, an azido moiety, an alkynyl moiety, an N-hydroxysuccinimidyl ester moiety, or a carbonyl imidazolyl moiety. In certain other embodiments, the first functional group is a maleimido moiety.
[0191] It should be appreciated that, according to the first functional group selected, the first functional group of the targeting moiety can react with the second functional group of the endogenous biological part with many different chemical reaction mechanisms. For example, some first functional groups can contain a chemical moiety suitable as a leaving group or a nucleophilic reagent for nucleophilic or electrophilic substitution, or other chemical moieties that can be contained can carry out cycloaddition. In other embodiments, some first functional groups can be converted into other functional groups that can form covalent bonds with the endogenous biological part.
[0192] Alternatively, in other embodiments, the endogenous biological part may not have any functional group, and another functional group can easily form a covalent bond with it. In this case, the interaction between the targeting part and the endogenous biological part can take the form of intermolecular attraction between similar polar or similar non-polar parts. For example, lipofuscin, an endogenous biological part, includes spontaneous fluorescent particles composed of lipid residues produced by lysosomal digestion. The hydrocarbons and lipid residues of lipofuscin are not easy to react with other functional groups to form covalent bonds. On the contrary, the targeting part of lipofuscin can include hydrophobic, lipophilic parts, which form favorable intermolecular interactions with lipid residues by inserting between adjacent lipid residues, so that the targeting part is effectively wedged in lipofuscin. In some cases, the targeting part of lipofuscin can include protein targeting parts (e.g., thiol or amine targeting chemicals).
[0193] In some embodiments, the targeting moiety comprises a hydrophobic moiety for lipophilic insertion into an endogenous biological moiety, optionally wherein the autofluorescent moiety comprises lipofuscin. In some embodiments, the hydrophobic moiety for lipophilic insertion into an endogenous biological moiety is C6-C 14 Alkyl part, C6-C 14 an alkenyl moiety, a terpenoid moiety, a sterol moiety or a wax moiety.
[0194] The targeting part that makes quencher dye react or combine with the endogenous biological part of biological sample limits the distance of quencher dye to the certain range of autofluorescence source (such as endogenous biological part described in detail herein). The targeting of quencher dye to endogenous biological part is contrasted with the existing use of commercially available quenchers. For example, the commercially available quenchers measured for fluorescence in situ hybridization are randomly physically adsorbed on biological samples without targeting the autofluorescence background source. Therefore, these commercially available quenchers can also quench the fluorescence signal related to the analyte of interest. In addition, the use of quenchers provided herein is different from other technologies, such as Foster resonance energy transfer, in which quenchers are targeted to the analyte of interest and are actively used to quench the fluorescence signal related to the analyte of interest.
[0195] (iii) Linker moiety
[0196] In some embodiments, the quencher further comprises a linker moiety that connects the quencher dye and the targeting moiety, which is not a bond. In other embodiments, the linker moiety is an alkylene moiety, an aminoalkylene moiety, an amino(alkyl)alkylene moiety, a polyethylene glycol moiety, a disulfide moiety, or a carbamate moiety.
[0197] The linker moiety of the quencher can be selected based on the need to synthesize the complete quencher compound, taking into account the availability of starting reagents, but also provides additional means to adjust the overall chemical properties of the quencher and control the distance between the quencher dye and the endogenous biological activity. For example, in some embodiments, certain linkers, such as polyethylene glycol moieties or alkylene moieties, can be selected to change the solubility of the quencher in polar or non-polar solvents. Other linkers can be selected for easy enzymatic cleavage, such as carbamate linkers, or chemical removal, such as disulfide bonds, as required by other technical analyses.
[0198] In some embodiments, the linker is cleavable or comprises a hydrophilic group or a stimulus-driven cleavable functional group (such as intelligent spontaneous fluorescence masking) to promote higher solubility. In certain embodiments, the linker comprises a stimulus-driven cleavable functional group, and when exposed to stimulation, the functional group releases the entire quencher or at least a portion of the quencher, such as a quencher dye. Removing the quencher from the quenched biological sample can be used for downstream processing, such as hematoxylin and eosin (H&E) staining after fluorescence imaging. For example, in some embodiments in which the linker is cleavable, the method provided herein may include contacting the biological sample of the quencher or the tissue sample of the quencher with a reducing agent, thereby cracking the quencher dye. In certain embodiments, the reducing agent is sodium dithionite (Na2S2O4). In some embodiments, the method includes contacting the biological sample of the quencher or the tissue sample of the quencher with sodium dithionite, optionally wherein the sample is contacted with a 10mM sodium dithionite aqueous solution at room temperature.
[0199] (iv) UV-Visible Absorption
[0200] The visible region of the electromagnetic spectrum is the primary region evaluated in fluorescence measurements for in situ analysis. However, many autofluorescent endogenous biological moieties also fluoresce in this wavelength range. As described above, the quenchers of the present disclosure combine broadband visible light absorption with targeted chemistry to remain intact in biological samples and maintain high levels of autofluorescence quenching over multiple imaging cycles.
[0201] In some embodiments, the quencher has a UV-visible absorption curve, the UV-visible absorption curve has at least one absorption peak, the at least one absorption peak has a maximum absorption of about 400nm to 700nm, about 400nm to 600nm, about 400nm to 500nm, about 500nm to 700nm, about 500nm to 600nm, or about 600nm to 700nm, and a half-height full width of at least about 50nm, at least about 75nm, or at least about 100nm. In certain embodiments, the quencher has a UV-visible absorption curve, the UV-visible absorption curve has at least one absorption peak, the at least one absorption peak has a maximum absorption of about 400nm to 700nm and a half-height full width of at least about 100nm. In some embodiments, the quencher has a UV-visible absorption curve, the UV-visible absorption curve has at least one absorption peak, the at least one absorption peak has a maximum absorption of about 500nm to about 600nm and a half-height full width of at least about 100nm.
[0202] In some embodiments, the quencher has Figure 1 UV-Visible absorption spectrum shown.
[0203] (v) Compounds of formula (I) and formula (II)
[0204] In some embodiments of the foregoing methods, the quencher is a compound of formula (I),
[0205]
[0206] (I)
[0207] or a salt thereof, wherein
[0208] Each are independently selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;
[0209] X a is H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 , -NO2, -SO3H, -SO3-, -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO or -L-(R 靶 ) w , where w is any integer such as 1 or 2;
[0210] X c is H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO or -L-(R 靶 ) w , where w is any integer such as 1 or 2;
[0211] Where R 1 and R 2 are independently H, unsubstituted C1-C6 alkyl or substituted C1-C6 alkyl; and
[0212] Each R a and R c are independently H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2, -NO2, -SO3H, -SO3-, -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN or -NCO;
[0213] Each R b are independently H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3-、-OSO2-C1-C6 alkyl、-OSO2-C1-C6 haloalkyl、-CN、-SCN、-NCO、R b1 or -L-(R 靶 ) w , where w is any integer such as 1 or 2;
[0214] R b1 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
[0215] L is a bond or linker moiety;
[0216] R 靶 is the targeting portion;
[0217] m is an integer from 0 to 6;
[0218] n is an integer from 0 to 6; and
[0219] Each of x, y and z is independently an integer from 0 to 5;
[0220] The condition is that at least one of m and n is non-zero; and the condition is that X a , X c or R b At least one of them is -L-(R 靶 ) w , where w is any integer such as 1 or 2.
[0221] In some embodiments of the foregoing methods, the quencher is a compound of formula (II),
[0222]
[0223] or a salt thereof, wherein
[0224] Each are independently selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;
[0225] X ais H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 , -NO2, -SO3H, -SO3-, -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO or -LR 靶 ;
[0226] X c is H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 , -NO2, -SO3H, -SO3-, -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO or -LR 靶 ;
[0227] Where R 1 and R 2 are independently H, unsubstituted C1-C6 alkyl or substituted C1-C6 alkyl; and
[0228] Each R a and R c are independently H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 , -NO2, -SO3H, -SO3-, -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN or -NCO;
[0229] Each R b are independently H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3-、-OSO2-C1-C6 alkyl、-OSO2-C1-C6 haloalkyl、-CN、-SCN、-NCO、R b1 or -LR 靶 ;
[0230] R b1 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
[0231] L is a bond or linker moiety;
[0232] R 靶 is the targeting portion;
[0233] m is an integer from 0 to 6;
[0234] n is an integer from 0 to 6; and
[0235] Each of x, y and z is independently an integer from 0 to 5;
[0236] The condition is that at least one of m and n is non-zero; and the condition is that X a , X c or R b At least one of them is -LR 靶 .
[0237] In some embodiments, m is an integer from 0 to 6, provided that at least one of m and n is non-zero. In certain embodiments, m is an integer from 0, 1, 2, 3, 4, 5 or 6, provided that at least one of m and n is non-zero. In other embodiments, m is an integer from 1 to 6, 2 to 6, 3 to 6, 4 to 6 or 5 to 6. In some embodiments, n is an integer from 0 to 6, provided that at least one of m and n is non-zero. In certain embodiments, n is an integer from 0, 1, 2, 3, 4, 5 or 6, provided that at least one of m and n is non-zero. In other embodiments, n is an integer from 1 to 6, 2 to 6, 3 to 6, 4 to 6 or 5 to 6.
[0238] In some embodiments, m is an integer from 1 to 6 and n is an integer from 0 to 6. In other embodiments, m is an integer from 0 to 6 and n is an integer from 1 to 6. In certain embodiments, m is an integer from 1 to 6 and n is an integer from 1 to 6. In some embodiments, m is 0 and n is 1. In other embodiments, m is 1 and n is 0. In other embodiments, m is 1 and n is 1.
[0239] In some embodiments, each is independently selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. is independently substituted or unsubstituted aryl. In certain embodiments, each is independently substituted or unsubstituted phenyl. In other embodiments, each is independently substituted or unsubstituted heteroaryl. In certain other embodiments, each is independently substituted or unsubstituted pyridinyl.
[0240] In some embodiments, is selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. In some embodiments, is a substituted or unsubstituted aryl. In certain embodiments, is a substituted or unsubstituted phenyl. In other embodiments, is a substituted or unsubstituted heteroaryl. In certain other embodiments, is a substituted or unsubstituted pyridyl group or a substituted or unsubstituted phenazinyl group.
[0241] In some embodiments, each is independently selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. is independently substituted or unsubstituted aryl. In certain embodiments, each is independently substituted or unsubstituted phenyl. In other embodiments, each is independently substituted or unsubstituted heteroaryl. In certain other embodiments, is a substituted or unsubstituted pyridyl group.
[0242] In some embodiments of the compound of Formula (I) or Formula (II), At least one, at least two or at least three examples of are substituted phenyl or unsubstituted phenyl. In some embodiments of the compound of formula (I), the quencher has the following structure:
[0243] or a salt thereof,
[0244] The condition is X a and X c At least one of them is -L-(R 靶 ) w , wherein w is any integer, such as 1 or 2, and wherein L is a bond or linker moiety; and R 靶 It is the targeting part.
[0245] In some embodiments of the compound of Formula (II), the quencher has the following structure:
[0246] or a salt thereof,
[0247] The condition is X a and X c At least one of them is -LR 靶 , wherein L is a bond or a linker moiety; and R 靶 It is the targeting part.
[0248] In other embodiments, yes: Where R b1 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In certain embodiments, yes Where R d is H, C1-C6 alkyl or halo; and s is an integer from 0 to 5. In some embodiments, the quencher has the following structure: or a salt thereof.
[0249] In some embodiments, X a is H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 , -NO2, -SO3H, -SO3-, -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO or -L-(R 靶 ) w , where w is any integer, such as 1 or 2. In some embodiments, X a H, halo, -OH, C1-C6 alkyl, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -CN or -L-(R 靶 ) w , where w is any integer such as 1 or 2.
[0250] In some embodiments, X a is H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO or -LR 靶 In some embodiments, X a H, halo, -OH, C1-C6 alkyl, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -CN or -LR 靶 .
[0251] In some embodiments, X cis H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO or -L-(R 靶 ) w , where w is any integer, such as 1 or 2. In some embodiments, X c H, halo, -OH, C1-C6 alkyl, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -CN or -L-(R 靶 ) w , where w is any integer such as 1 or 2.
[0252] In some embodiments, X c is H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO or -LR 靶 In some embodiments, X c H, halo, -OH, C1-C6 alkyl, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -CN or –LR 靶 .
[0253] In some embodiments, R 1 and R 2 R is independently H, unsubstituted C1-C6 alkyl or substituted C1-C6 alkyl. 1 is H and R 2 is H. In other embodiments, R 1 is H and R 2 is unsubstituted C1-C6 alkyl or substituted C1-C6 alkyl. In other embodiments, R 1 is a substituted C1-C6 alkyl group or a substituted C1-C6 alkyl group and R 2 is H. In other embodiments, R1 is an unsubstituted C1-C6 alkyl group or a substituted C1-C6 alkyl group and R 2 It is an unsubstituted C1-C6 alkyl group or a substituted C1-C6 alkyl group.
[0254] In some embodiments, each R a and R c are independently H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN or -NCO. In some embodiments, R a H, halo, -OH, C1-C6 alkyl, -NR 1 R 2 、-NO2、-SO3H、-SO3 - Or -CN. In other embodiments, R c H, halo, -OH, C1-C6 alkyl, -NR 1 R 2 、-NO2、-SO3H、-SO3 - 、-CN.
[0255] In some embodiments, each R b are independently H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO, R b1 or -L-(R 靶 ) w , where w is an integer, such as 1 or 2. In some embodiments, each R b Independently -NR 1 R 2 , R b1 or -L-(R 靶 ) w , where w is any integer such as 1 or 2.
[0256] In some embodiments, each R bare independently H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3-、-OSO2-C1-C6 alkyl、-OSO2-C1-C6 haloalkyl、-CN、-SCN、-NCO、R b1 or -LR 靶 In some embodiments, each R b Independently -NR 1 R 2 , R b1 or -LR target .
[0257] In some embodiments, R 1 and R 2 R is independently H, unsubstituted C1-C6 alkyl or substituted C1-C6 alkyl. 1 is H and R 2 is H. In other embodiments, R 1 is H and R 2 is unsubstituted C1-C6 alkyl or substituted C1-C6 alkyl. In other embodiments, R 1 is a substituted C1-C6 alkyl group or a substituted C1-C6 alkyl group and R 2 is H. In other embodiments, R 1 is an unsubstituted C1-C6 alkyl group or a substituted C1-C6 alkyl group and R 2 It is an unsubstituted C1-C6 alkyl group or a substituted C1-C6 alkyl group.
[0258] In some embodiments, R b1 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. b1 is a substituted or unsubstituted alkyl group. In other embodiments, R b1 is a substituted or unsubstituted aryl group. In certain embodiments, R b1 is substituted or unsubstituted phenyl. In other embodiments, R b1 is a substituted or unsubstituted heteroaryl. In certain other embodiments, R b1 is a substituted or unsubstituted pyridyl group.
[0259] In some embodiments, L is a bond or a linker moiety. In certain embodiments, L is a linker moiety. In certain other embodiments, L is an alkylene moiety, an aminoalkylene moiety, an amino(alkyl)alkylene moiety, a polyethylene glycol moiety, a disulfide moiety, or a carbamate moiety. In some embodiments, L is a linker moiety comprising one or more of an alkylene moiety, an aminoalkylene moiety, an amino(alkyl)alkylene moiety, a oligoethylene glycol moiety, a polyethylene glycol moiety, a disulfide moiety, or a carbamate moiety. In some embodiments, L is a linker moiety comprising a carbamate and a polyethylene glycol moiety.
[0260] In some embodiments, R 靶 is a targeting moiety. In some embodiments, R 靶 It is C6-C 14 Alkyl part, C6-C 14 In other embodiments, R 靶 is a carboxylic acid moiety or a derivative thereof, an aldehyde or ketone moiety, a sulfonyl halide moiety, a hydroxyl moiety, a thiol moiety, an amino moiety, an alkenyl or dienyl moiety, an epoxide moiety, or a haloalkyl moiety. In certain embodiments, R 靶 is a maleimido moiety, an azido moiety, an alkynyl moiety, an N-hydroxysuccinimidyl ester moiety, or a carbonyl imidazolyl moiety. 靶 is the maleimido moiety.
[0261] In some embodiments, the quencher is selected from the group consisting of:
[0262]
[0263]
[0264] and any salts thereof.
[0265] In certain embodiments, the quencher is a compound selected from the group consisting of:
[0266]
[0267]
[0268] and any salts thereof.
[0269] In another aspect, the present disclosure also provides compounds of formula (I) or formula (II) or salts thereof, compositions, combinations and kits thereof, as well as methods for preparing such compounds and any intermediates used in these compounds.
[0270] In any embodiment herein, unless otherwise stated, "alkyl" itself or as part of another substituent, includes a straight or branched hydrocarbon group (e.g., C1-C6 represents one to six carbons) with a specified number of carbon atoms. Examples of alkyls include methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, etc. In some embodiments, the term "alkyl" can include C1-C6 alkyl, C2-C6 alkyl, C3-C6 alkyl, C4-C6 alkyl, C5-C6 alkyl, C1-C5 alkyl, C2-C5 alkyl, C3-C5 alkyl, C4-C5 alkyl, C1-C4 alkyl, C2-C4 alkyl, C3-C4 alkyl, C1-C3 alkyl, C2-C3 alkyl, or C1-C2 alkyl.
[0271] In any embodiment herein, "alkoxy" and "alkylamino" are used in their conventional sense and include those alkyl groups attached to the remainder of the molecule via an oxygen atom or an amino group, respectively.
[0272] In any embodiment herein, unless otherwise indicated, the term "halo" or "halogen" by itself or as part of another substituent includes fluorine, chlorine, bromine or iodine atoms or ions. In some embodiments, terms such as "haloalkyl" include monohaloalkyl or polyhaloalkyl. For example, the term "C1-C4 haloalkyl" can include trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, difluoromethyl, etc.
[0273] In any embodiment herein, the term "hydroxy-alkylene" or "alkyl-OH" includes an alkyl group substituted with one or more hydroxy groups. The term can include an alkyl group substituted with one hydroxy group, or an alkyl group substituted with multiple hydroxy groups. For example, the input "alkyl-OH" can include -CH2OH, -CH(OH)CH3, -CH2CH2OH, etc.
[0274] In any embodiment herein, unless otherwise specified, the term "aryl" includes polyunsaturated aromatic hydrocarbon groups, which can be single rings or polycyclic rings (up to three rings) fused together. In some embodiments, "aryl" includes C6-C 14 Aryl, C8-C 14 Aryl, C 10 -C 14 Aryl, C 12 -C 14 Aryl, C6-C 12 Aryl, C8-C 12 Aryl, C 10 -C 12 Aryl, C6-C 10 Aryl, C8-C10 In some embodiments, typical aryl groups include C6-C 20 Aryl. Non-limiting examples of aryl groups include phenyl, naphthyl, and biphenyl.
[0275] In any embodiment herein, "heteroaryl" comprises an aromatic ring containing a specified number of atoms (e.g., 5 to 20 or 5 to 10 membered heteroaryl) consisting of one or more heteroatoms (e.g., 1, 2, 3, or 4 heteroatoms) selected from N, O, and S, and the remaining ring atoms are carbon. The heteroaryl does not contain adjacent S and O atoms. In some embodiments, the total number of S and O atoms in the heteroaryl does not exceed 2. In some embodiments, the total number of S and O atoms in the heteroaryl does not exceed 1. Unless otherwise stated, the heteroaryl can be bound to the parent structure through a carbon or nitrogen atom where valence permits. In some embodiments, the term "heteroaryl" can include 5-10 membered heteroaryl, 6-10 membered heteroaryl, 7-10 membered heteroaryl, 8-10 membered heteroaryl, 9-10 membered heteroaryl, 5-9 membered heteroaryl, 6-9 membered heteroaryl, 7-9 membered heteroaryl, 8-9 membered heteroaryl, 5-8 membered heteroaryl, 6-8 membered heteroaryl, 7-8 membered heteroaryl, 5-7 membered heteroaryl, 6-7 membered heteroaryl, or 5-6 membered heteroaryl. In some embodiments, heteroaryl is a monocyclic ring. In some embodiments, heteroaryl is a bicyclic fused ring. In some embodiments, heteroaryl is a tricyclic fused ring. Non-limiting examples of heteroaryl groups include pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, quinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, benzotriazinyl, purinyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl, benzisoxazolyl, isobenzofuranyl, isoindolyl, cinnolinyl, benzotriazinyl, thienopyridinyl, thienopyrimidinyl, pyrazolopyrimidinyl, imidazopyridine, benzothiaxolyl, benzofuranyl, benzothiophenyl, indolyl, quinolyl, isoquinolyl, isothiazolyl, pyrazolyl, indazolyl, pteridinyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiadiazolyl, pyrrolyl, thiazolyl, furanyl, thienyl, and the like.
[0276] In some embodiments, the above terms (e.g., "alkyl", "aryl" and "heteroaryl") will include substituted and unsubstituted forms of the groups shown. In any embodiment herein, the term "substituted" includes that a particular group or part carries one or more substituents, including but not limited to substituents such as alkoxy, acyl, acyloxy, alkoxycarbonyl, carbonylalkoxy, acylamino, amino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, cycloalkyl, cycloalkenyl, aryl, heteroaryl, aryloxy, cyano, azido, halo, hydroxyl, nitro, carboxyl, thiol, thioalkyl, alkyl, alkenyl, alkynyl, heterocycloalkyl, heterocycloalkenyl, aralkyl, aminosulfonyl, sulfonylamino, sulfonyl, oxo, etc. In any embodiment herein, the term "unsubstituted" includes that a particular group does not carry a substituent. When the term "substituted" is used to describe a structural system, substitution means occurring at any valence-allowed position on the system. When a group or part carries more than one substituent, it should be understood that these substituents can be the same or different from each other. In some embodiments, the substituted group or part carries one to five substituents. In some embodiments, the substituted group or part carries one substituent. In some embodiments, the substituted group or part carries two substituents. In some embodiments, the substituted group or part carries three substituents. In some embodiments, the substituted group or part carries four substituents. In some embodiments, the substituted group or part carries five substituents.
[0277] In any embodiment herein, "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and the description includes instances where the event or circumstance occurs and instances where it does not occur. For example, "optionally substituted alkyl" includes "alkyl" and "substituted alkyl" as defined herein. It will be understood by those skilled in the art that for any group containing one or more substituents, such groups are not intended to introduce any sterically impractical, synthetically infeasible and / or inherently unstable substitutions or substitution patterns. It will also be understood that when a group or moiety is optionally substituted, the present disclosure includes embodiments in which the group or moiety is substituted and embodiments in which the group or moiety is not substituted.
[0278] In any embodiment herein, salts include salts of compounds prepared with relatively nontoxic acids or bases, depending on the specific substituents found on the compounds described herein. When the compounds of the present disclosure contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base (neat or in a suitable inert solvent). Examples of salts derived from pharmaceutically acceptable inorganic bases include aluminum, ammonium, calcium, copper, iron, ferrous, lithium, magnesium, manganese, manganous, potassium, sodium, zinc, etc. Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary, and tertiary amines, including substituted amines, cyclic amines, naturally occurring amines, and the like, such as arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like. When compounds of the present disclosure contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include salts derived from inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, monohydrogencarbonic acid, phosphoric acid, monohydrogenphosphoric acid, dihydrogenphosphoric acid, sulfuric acid, monohydrogensulfuric acid, hydroiodic acid or phosphorous acid, and salts derived from relatively nontoxic organic acids such as acetic acid, propionic acid, isobutyric acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, methanesulfonic acid, etc. Also included are salts of amino acids such as arginine, and salts of organic acids such as glucuronic acid or galacturonic acid (see, e.g., Berge, SM et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66, 1-19, the contents of which are incorporated herein by reference in their entirety). In any of the embodiments herein, certain specific compounds of the present disclosure contain both basic and acidic functionalities, which allow the compounds to be converted into either base or acid addition salts.
[0279] In any embodiment herein, the neutral form of the compound can be regenerated by contacting the salt with a base or acid and isolating the parent compound in a conventional manner. In any embodiment herein, the parent form of the compound may differ from the various salt forms in certain physical properties, such as solubility in polar solvents, but in other respects, for purposes of this disclosure, the salt is equivalent to the parent form of the compound.
[0280] (vi) Concentration
[0281] In some embodiments of the present disclosure, the biological sample or tissue sample to be analyzed can be treated with a specific concentration of a quencher. The concentration of the quencher applied to the sample can be optimized to achieve the desired reduction in background autofluorescence without significantly reducing the fluorescent signal associated with the molecule or analyte of interest.
[0282] In some embodiments, the methods of the present disclosure include contacting a biological sample with a quencher, wherein the quencher is provided at a concentration of at least about 0.01 mM, at least about 0.02 mM, at least about 0.05 mM, at least about 0.07 mM, at least about 0.1 mM, at least about 0.2 mM, at least about 0.3 mM, at least about 0.4 mM, or at least about 0.5 mM in a DMSO solution. In some embodiments, the methods of the present disclosure include contacting a biological sample with a quencher, wherein the quencher is provided at a concentration of less than or equal to about 2 mM, less than or equal to about 1.7 mM, less than or equal to about 1.5 mM, less than or equal to about 1.2 mM, less than or equal to about 1.1 mM, or less than or equal to about 1 mM in a DMSO solution. In other embodiments, the methods of the present disclosure comprise contacting a biological sample with a quencher, wherein the quencher is provided in a DMSO solution at a concentration of less than or equal to about 0.8 mM, less than or equal to about 0.7 mM, less than or equal to about 0.6 mM, less than or equal to about 0.5 mM, or less than or equal to about 0.4 mM. In certain embodiments, the methods of the present disclosure comprise contacting a biological sample with a quencher, wherein the quencher is provided in a DMSO solution at a concentration of about 0.01 mM to 0.8 mM, about 0.05 mM to 0.8 mM, about 0.1 mM to 0.8 mM, about 0.1 mM to 0.7 mM, about 0.1 mM to 0.6 mM, about 0.1 mM to 0.5 mM, about 0.1 mM to 0.4 mM, about 0.2 mM to 0.8 mM, about 0.2 mM to 0.7 mM In some embodiments, the quencher may be selected from the group consisting of about 0.4 mM to 0.5 mM, about 0.2 mM to 0.6 mM, about 0.2 mM to 0.5 mM, about 0.2 mM to 0.4 mM, about 0.3 mM to 0.8 mM, about 0.3 mM to 0.7 mM, about 0.3 mM to 0.6 mM, about 0.3 mM to 0.5 mM, about 0.3 mM to 0.4 mM, about 0.4 mM to 0.8 mM, about 0.4 mM to 0.7 mM, about 0.4 mM to 0.6 mM, or about 0.4 mM to 0.5 mM of the quencher.
[0283] It can also be observed that certain concentrations of quenchers result in certain reductions in autofluorescence background, increases in signal-to-noise ratios, or increases in detectable object density. In some embodiments, when the concentration of the quencher is at least about 0.05 mM, the autofluorescence background is reduced by at least about 20%, at least about 30%, at least about 40%, or at least about 50%. In certain embodiments, when the quencher is compound 1A and the concentration of the quencher is at least about 0.05 mM, the autofluorescence background is reduced by at least 20%, at least about 30%, at least about 40%, or at least about 50%. In other embodiments, when the concentration of the quencher is at least about 0.05 mM, the signal-to-noise ratio is increased by at least about 5%, at least about 7%, at least about 10%, at least about 12%, or at least about 15%. In certain other embodiments, when the quencher is compound 1A and the concentration of the quencher is at least about 0.05 mM, the signal-to-noise ratio increases by at least about 5%, at least about 7%, at least about 10%, at least about 12%, or at least about 15%. In some embodiments, when the concentration of the quencher is about 0.8 mM, the detectable object density increases by at least 2-fold, at least 3-fold, at least 4-fold, or at least 5-fold. In certain embodiments, when the quencher is compound 1A and the concentration of the quencher is about 0.8 mM, the detectable object density increases by at least 2-fold, at least 3-fold, at least 4-fold, or at least 5-fold.
[0284] C. Endogenous biological part
[0285] In some embodiments, an endogenous biological moiety present in an organism or tissue sample as described herein is autofluorescent, or is associated with or in proximity to another endogenous biological moiety that is autofluorescent. In some embodiments, an endogenous biological moiety is autofluorescent. An endogenous biological moiety that is autofluorescent may also be referred to herein as an "autofluorescent moiety."
[0286] In some embodiments, the endogenous biological part is selected from the group consisting of lipofuscin, collagen, elastin, erythrocytes, flavin, nicotinamide adenine dinucleotide (NADH), and extracellular matrix. In some embodiments, the endogenous biological part is lipofuscin. In other embodiments, the endogenous biological part is collagen. In some embodiments, the endogenous biological part is elastin. In other embodiments, the endogenous biological part is erythrocytes. In other embodiments, the endogenous biological part is flavin. In other embodiments, the endogenous biological part is nicotinamide adenine dinucleotide. In other embodiments, the endogenous biological part is extracellular matrix. It should be recognized that various biological samples and tissue samples can contain one or more of the above-mentioned endogenous biological parts. It should also be recognized that certain tissue types can include a combination of certain endogenous biological parts that distinguish the tissue type from other tissue types.
[0287] As described herein, methods for reducing autofluorescence and for analyzing biological samples or tissue samples employ quenchers with targeting moieties that react or bind to endogenous biological moieties present in the biological sample or tissue sample. The interaction produced between the targeting moiety and the endogenous biological moiety provides a persistent connection between the quencher and the endogenous biological moiety, even after several cycles of washing, stripping, and dehybridization. In some embodiments in which the quencher is retained in the biological sample or tissue sample after the detectable probe is removed, the quencher remains targeted to the endogenous biological moiety. In some embodiments, the presence of the quencher can be visually observed and confirmed. In other embodiments, the presence of the quencher is observed by the continued reduction of the autofluorescence background in multiple cycles of washing, stripping, dehybridization, and imaging, the continued increase of the signal-to-noise ratio, and / or the continued increase of the density of the detected objects.
[0288] (i) Interaction between the targeting moiety and the endogenous biological moiety via the second functional group
[0289] The targeting moieties of the quenchers as described herein may interact via formation of covalent bonds or via intermolecular attraction.
[0290] In some embodiments, the targeting moiety comprises a first functional group, and the endogenous biological part comprises a second functional group that can react with the first functional group to form a covalent bond. As described above for the targeting moiety, the targeting moiety can include a first functional group, and the first functional group can form a covalent bond with the endogenous biological part via the second functional group on the endogenous biological part. Suitable second functional groups can include but are not limited to amine, thiol, hydroxyl, alkene, alkyne or azide. It should be appreciated that the second functional group present in the endogenous biological part can change with the type of the targeted endogenous biological part, and the first functional group on the targeting moiety will be selected to supplement the reactivity of the second functional group, so as to be able to form a covalent bond. The mechanism of covalent bond formation can include but is not limited to such reaction types, such as nucleophilic or electrophilic substitution or cycloaddition. For example, in some embodiments where the second functional group is an amine, the first functional group of the targeting moiety is a carboxylic acid or a derivative thereof. In other embodiments where the second functional group is a thiol, the first functional group is a maleimide. In other embodiments where the second functional group is an alkyne, the first functional group is an azide.
[0291] (ii) Enrichment of the second functional group
[0292] In some embodiments, the second functional group may be native to an endogenous biological moiety in a protected or precursor form, but may require enrichment to increase the concentration or introduction of the second functional group in the sample. In some embodiments, the methods of the present disclosure include a step of treating a biological sample or tissue sample to enrich, generate and / or introduce a second functional group in an endogenous biological moiety.
[0293] For example, a biological sample or tissue sample can include a precursor of a second functional group, and the precursor can not form a covalent bond with the first functional group before exposure, such as a disulfide bond, which can be reduced by any suitable reducing agent to enrich the concentration of the free sulfhydryl group as the second functional group. In some embodiments, the second functional group is a thiol, and the biological sample or tissue sample is treated with a reducing agent to convert a disulfide group into a thiol group. In certain embodiments, the reducing agent is dithiothreitol (DTT) or tris (2-carboxyethyl) phosphine (TCEP). In some other embodiments in which the second functional group is a thiol, and the biological sample or tissue sample is treated with a reducing agent to convert a disulfide group into a thiol group, the first functional group is maleimide.
[0294] Endogenous biological parts can contain two or more independent second functional groups, such as amines and thiols, or it may be desirable to target two endogenous biological parts with different available functional groups, such as collagen and erythrocytes. In such cases, additional treatment converts the functional groups present on the endogenous biological parts into the same second functional groups. Suitable treatment can include the introduction of heterobifunctional crosslinking agents. For example, in some embodiments, the endogenous biological part contains a third functional group different from the second functional group, and wherein the biological sample or tissue sample is treated with a heterobifunctional crosslinking agent comprising a second functional group and a fourth functional group capable of reacting with the third functional group to form a covalent bond, thereby introducing the second functional group in the endogenous biological part. In certain embodiments, the third functional group is an amine and the second functional group is a thiol. In certain other embodiments in which the third functional group is an amine and the second functional group is a thiol, the heterobifunctional crosslinking agent is 3-(2-pyridyldithio) propionic acid succinimidyl ester (SPDP) or a derivative thereof. In certain embodiments, the heterobifunctional cross-linker is 2,5-dioxopyrrolidin-1-yl 3-oxo-1-(pyridin-2-ylsulfonyl)-7,10,13,16-tetraoxa-4-azanonadecane-19-carboxylate (PEG4-SPDP).
[0295] D. Detection
[0296] As described in detail herein, the methods of the present disclosure include one or more steps of detecting a signal associated with a detectable probe or one or more signals associated with one or more detectable probes. The signal associated with the detectable probe is a fluorescent signal, which becomes observable or becomes more easily observable after quenching to reduce autofluorescence according to the methods described herein.
[0297] (i) Detectable probe
[0298] Detectable probes (e.g., fluorescently labeled detectable probes) can themselves contain fluorescent moieties, or can be combined with or hybridized to additional probes containing fluorescent moieties. In some embodiments of any of the aforementioned aspects, each detectable probe can be independently detectably labeled or hybridized to a detectably labeled probe. In certain embodiments, each detectable probe is independently covalently labeled with a fluorophore, or hybridized to a covalently labeled probe with a fluorophore.
[0299] In some embodiments, the molecule of interest is an interested nucleic acid or an interested protein. In certain embodiments in which the molecule of interest is an interested nucleic acid, the detectable probe hybridizes with the nucleic acid of interest. In certain other embodiments, the detectable probe hybridizes with one or more intermediate probes that are directly or indirectly bound to the nucleic acid of interest. In other embodiments, the detectable probe hybridizes with one or more intermediate probes, which in turn hybridize with the nucleic acid of interest.
[0300] In other embodiments, the method further comprises adding a primary probe before adding a detectable probe and one or more intermediate probes, wherein the intermediate probe is bound to the primary probe or its product. In some embodiments, the primary probe is a nucleic acid probe that is directly or indirectly bound to a cell or virus DNA or RNA or its product. In other embodiments, the intermediate probe is a nucleic acid probe that hybridizes with the primary probe or its product, wherein the primary probe is a nucleic acid probe.
[0301] In some embodiments, the signal associated with one or more detectable probes is associated with a probe in a branched complex of a linear, cyclizable, circular probe or hybridization probe (e.g., various probes and amplification methods are described in Sections III-V). In some embodiments, a probe that is directly or indirectly bound to a target analyte or directly or indirectly bound to a primary nucleic acid probe or its product (e.g., an amplification product) includes a detectable label that can be detected and associated with an analyte of interest. In some embodiments, a barcode sequence (e.g., in a probe or its product) is used to combine and encode a variety of analytes of interest. Therefore, a signal associated with a detectably labeled probe at a specific location in a biological sample can be used to generate different signal characteristics through multiple hybridization cycles, each hybridization cycle corresponding to an analyte in the sample, thereby identifying the analyte at a specific location.
[0302] (ii) Imaging and detection wavelengths
[0303] In some embodiments, the method includes the step of detecting a signal associated with a detectable probe bound to a molecule of interest, the step comprising imaging at one or more wavelengths of about 400 nm to about 700 nm. In some embodiments, the one or more wavelengths are selected from the group consisting of 488 nm, 532 nm, 561 nm, 590 nm, 640 nm, and 647 nm.
[0304] (iii) Improvement of background autofluorescence, signal-to-noise ratio, and / or detectable object density
[0305] As described herein, the methods of the present disclosure reduce background autofluorescence in a single-step application of a quencher to provide improved fluorescence imaging compared to unquenched samples. The improvement in imaging can be observed as a persistent reduction in background autofluorescence levels, an increase in signal-to-noise ratio, and even an increase in detectable object count density compared to unquenched tissue samples.
[0306] An unquenched biological sample or unquenched tissue sample is understood to be a biological sample or tissue sample of the same type that has undergone the same treatment as a quenched sample, except that the treatment is performed with a quencher comprising a quencher dye and a targeting moiety, as described herein. It should also be recognized that comparisons of autofluorescence background intensity, signal-to-noise ratio, detectable object count density, and / or fluorescence intensity of a detectable probe refer to comparisons of characteristic metrics at the same wavelength.
[0307] The methods of the present disclosure can also achieve these improvements in detection without significantly reducing the fluorescence signal associated with the detectable probe due to targeted quenching of the autofluorescent moiety. The preservation of the fluorescence signal associated with the detectable probe distinguishes the methods of the present disclosure from other techniques such as FRET, in which the quenching of fluorescence associated with the analyte of interest is the signal to be measured.
[0308] In any embodiment herein, the term "autofluorescence" is used to distinguish background fluorescence (which can be caused by a variety of sources, including aldehyde fixation, extracellular matrix components, erythrocytes, lipofuscin, etc.) from the desired immunofluorescence of fluorescently labeled antibodies or probes. The reduction of autofluorescence can be represented or characterized by the reduction of the average detected light intensity of the biological sample or the detector photoelectron count. In some embodiments, the autofluorescence of the biological sample is reduced compared to the unquenched biological sample. In certain embodiments, the autofluorescence is reduced by at least about 50%, at least about 60%, at least about 70%, or at least about 80% compared to the unquenched biological sample. In some embodiments, the autofluorescence of the tissue sample is reduced compared to the unquenched tissue sample. In certain embodiments, the autofluorescence is reduced by at least about 50%, at least about 60%, at least about 70%, or at least about 80% compared to the unquenched tissue sample.
[0309] In some embodiments, the quencher reduces autofluorescence of a biological sample without substantially reducing the signal associated with the detectable probe. In certain embodiments, the quencher reduces autofluorescence of a tissue sample without substantially reducing the signal associated with the detectable probe.
[0310] In some embodiments, the combination of the reduction of background autofluorescence and the retention of the signal intensity associated with the detectable probe produced by the targeted quenching herein can lead to an increase in the signal-to-noise ratio. In any embodiment herein, the phrase "signal-to-noise ratio" (or SNR or S / N) is a comparison of the level of the desired signal (e.g., the fluorescent signal associated with the detectable probe) to the level of the background noise. In other embodiments, the signal-to-noise ratio is increased compared to an unquenched biological sample. In certain embodiments, the signal-to-noise ratio is increased by at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35% or at least about 40% compared to an unquenched biological sample. In other embodiments, the signal-to-noise ratio is increased compared to an unquenched tissue sample. In certain embodiments, the signal-to-noise ratio is increased by at least about 10%, at least about 20% or at least about 25% compared to an unquenched tissue sample.
[0311] In other embodiments, the reduction in background autofluorescence can also allow for the observation of low-intensity signals that might otherwise have been masked by autofluorescence. This improvement in imaging is characterized by an increase in detectable object count density. In any embodiment herein, the phrase "detectable object count density," "detectable object density," or "detected object density" is a measure of the number of objects (e.g., fluorescent objects) detectable for a given area of a biological sample. In some embodiments, the given area of a biological sample is, for example, a cell nuclear area measured by DAPI staining, and the detectable object count density is the count of detected objects per unit cell nuclear area in the cells of the biological sample (e.g., object counts / μm2 In some embodiments, the detectable count density is increased compared to an unquenched biological sample. In certain embodiments, the detectable count density is increased by at least about 2 times, at least about 3 times, at least about 4 times, or at least about 5 times compared to an unquenched biological sample. In some embodiments, the detectable count density is increased compared to an unquenched tissue sample. In certain embodiments, the detectable count density is increased by at least about 2 times, at least about 3 times, at least about 4 times, or at least about 5 times compared to an unquenched tissue sample.
[0312] Similar to the above-described improvements observed in the detection of a signal associated with a detectable probe in one imaging cycle, improvements in imaging as determined by a reduction in autofluorescence, an increase in signal-to-noise ratio, and / or an increase in detectable object count density can also be measured when one or more additional probes are detected in one or more cycles. Any reduction in autofluorescence, increase in signal-to-noise ratio, and / or increase in detectable object count density can be characterized relative to an unquenched tissue sample that has undergone the same number of imaging cycles, or relative to the previous value of the previous cycle of a quenched sample.
[0313] In some embodiments, after a given cycle, the quencher remains in the biological sample and the autofluorescence of the biological sample remains reduced compared to the unquenched biological sample. In certain embodiments, after a given cycle, the quencher remains in the tissue sample and the autofluorescence of the tissue sample remains reduced compared to the unquenched tissue sample.
[0314] In some embodiments, after a given cycle, the quencher remains in the biological sample, and the autofluorescence of the biological sample remains reduced compared to the unquenched biological sample. In some embodiments, compared to the unquenched biological sample, for a given cycle, the autofluorescence remains reduced by at least about 50%, at least about 60%, at least about 70%, or at least about 80%. In other embodiments, compared to the previous cycle, for a given cycle, the autofluorescence increases by less than about 5%, less than about 10%, or less than about 15%. In some embodiments, after a given cycle, the quencher remains in the tissue sample, and the autofluorescence of the tissue sample remains reduced compared to the unquenched tissue sample. In some embodiments, compared to the unquenched tissue sample, for a given cycle, the autofluorescence remains reduced by at least about 50%, at least about 60%, at least about 70%, or at least about 80%. In other embodiments, compared to the previous cycle, for a given cycle, the autofluorescence increases by less than about 5%, less than about 10%, or less than about 15%.
[0315] In some embodiments, after a given cycle, the signal-to-noise ratio remains increased compared to an unquenched biological sample. In some embodiments, the signal-to-noise ratio remains increased by at least about 10%, at least about 20%, or at least about 25% for a given cycle compared to an unquenched biological sample. In some embodiments, the signal-to-noise ratio decreases by less than about 5%, less than about 10%, or less than about 15% for a given cycle compared to the previous cycle. In some embodiments, after a given cycle, the signal-to-noise ratio remains increased compared to an unquenched tissue sample. In some embodiments, the signal-to-noise ratio remains increased by at least about 10%, at least about 20%, or at least about 25% for a given cycle compared to an unquenched tissue sample. In some embodiments, the signal-to-noise ratio decreases by less than about 5%, less than about 10%, or less than about 15% for a given cycle compared to the previous cycle.
[0316] In some embodiments, the detectable object count density remains increased for a given cycle compared to an unquenched biological sample. In certain embodiments, the detectable object count density remains increased for a given cycle compared to an unquenched biological sample by at least about 2 times, at least about 3 times, at least about 4 times, or at least about 5 times. In certain other embodiments, the detectable object count density decreases by less than about 5%, less than about 10%, or less than about 15% for a given cycle compared to the previous cycle. In some embodiments, the detectable object count density remains increased for a given cycle compared to an unquenched tissue sample. In certain embodiments, the detectable object count density remains increased for a given cycle compared to an unquenched tissue sample by at least about 2 times, at least about 3 times, at least about 4 times, or at least about 5 times. In certain other embodiments, the detectable object count density decreases by less than about 5%, less than about 10%, or less than about 15% for a given cycle compared to the previous cycle.
[0317] II. Samples, Analytes, and Target Sequences
[0318] A. Samples and Sample Processing
[0319] Samples disclosed herein can be or are derived from any biological sample. In some embodiments, the sample herein is a sample in which it is desired to analyze a target molecule and its position in two-dimensional or three-dimensional space. Methods and compositions disclosed herein can be used to analyze biological samples, which can be obtained from a subject using any of a variety of techniques (including but not limited to biopsy, surgery, and laser capture microscopy (LCM)), and generally include cells and / or other biological materials from a subject. Biological samples can also be obtained from non-mammalian organisms (e.g., plants, insects, arthropods, nematodes, fungi, or amphibians). Biological samples can also be obtained from eukaryotic organisms, such as tissue samples, patient-derived organoids (PDO) or patient-derived xenografts (PDX). Biological samples from organisms can include one or more other organisms or components thereof. For example, in addition to mammalian cells and non-cellular tissue components, mammalian tissue sections can include prions, viroids, viruses, bacteria, fungi, or components from other organisms. The subject from whom a biological sample can be obtained can be a healthy or asymptomatic individual, an individual having or suspected of having a disease (e.g., a patient having a disease such as cancer) or susceptible to a disease, and / or an individual in need of therapy or suspected of being in need of therapy.
[0320] Biological sample can include any number of macromolecules, for example, cellular macromolecules and organelles (for example, mitochondria and nucleus). Biological sample can be obtained as tissue sample (such as tissue section, biopsy sample, core needle biopsy sample, needle aspirate or fine needle aspirate). Biological sample can be obtained as cell group (for example, dissociated cells obtained from tissue sample or cell culture). Dissociated cells can be deposited and / or fixed on substrate, for example, for analyzing using the platform of one or more analytes in the original situ detection cell. Sample can be a fluid sample, such as a blood sample, a urine sample or a saliva sample, and cells and cell components therein can be analyzed after cells or cell components are placed on substrate. Sample can be skin sample, colon sample, cheek swab, histological sample, histopathological sample, plasma or serum sample, tumor sample, living cell, cultured cell, clinical sample (for example, whole blood or blood-derived products, hemocytes or cultured tissue or cells, including cell suspension). In some embodiments, the biological sample may comprise cells deposited on a surface, and the cells may be isolated from a bodily sample such as blood, plasma, serum, urine, saliva, mucosal secretions, sputum, feces, and tears.
[0321] The biological sample may be derived from a homogenous culture or population of the subjects or organisms mentioned herein, or alternatively from a collection of several different organisms, for example, in a community or ecosystem.
[0322] Biological samples can include one or more diseased cells. Diseased cells may have altered metabolic properties, gene expression, protein expression and / or morphological characteristics. Examples of diseases include inflammatory disorders, metabolic disorders, nervous system disorders and cancer. Cancer cells can be derived from solid tumors, hematological malignancies, cell lines, or obtained as circulating tumor cells. Biological samples can also include fetal cells and immune cells.
[0323] Biological samples can include target molecules (e.g., proteins, RNA and / or DNA) in 3D matrix. In some embodiments, amplicons (e.g., rolling circle amplification products) derived from analytes (e.g., proteins, RNA and / or DNA) or related thereto can be embedded in 3D matrix. In some embodiments, 3D matrix can include natural molecules and / or synthetic molecular networks chemically and / or enzymatically connected (e.g., by cross-linking). In some embodiments, 3D matrix can include synthetic polymers. In some embodiments, 3D matrix includes hydrogel.
[0324] The biological sample within the 3D matrix can be cleared of proteins and / or lipids that are not targets of interest. For example, the biological sample can be cleared of proteins by enzymatic proteolysis (also known as "deproteinization"). The clearing step can be performed before or after covalently immobilizing any target molecule or derivative thereof.
[0325] In some cases, a removal step is performed after the target molecule (e.g., RNA or DNA), primer, derivative of the target molecule (e.g., cDNA or amplicon), or probe is covalently fixed to the synthetic 3D matrix. Performing a removal step after fixation can enable any subsequent nucleic acid hybridization reaction to be performed under conditions where the sample has been substantially deproteinized, such as by enzymatic protein hydrolysis ("protein removal"). This method can have the advantage of removing ribosomes and other RNA target binding proteins or nucleic acid target binding proteins from the target molecule (while maintaining spatial location), where protein components may hinder or inhibit probe binding.
[0326] The clearing step may include removing non-targets from the 3D matrix. The clearing step may include degrading non-targets. The clearing step may include exposing the sample to an enzyme (e.g., a protease) capable of degrading proteins. The clearing step may include exposing the sample to a detergent.
[0327] Protein can be removed from sample using enzymes, denaturants, chelating agents, chemicals, etc., which can decompose protein into smaller components and / or amino acids. These smaller components may be more easily physically removed, and / or may be small enough or inert enough so that they do not significantly affect background. Similarly, surfactants, etc. can be used to remove lipids from sample. In some cases, for example, one or more of these reagents are used simultaneously or sequentially. The non-limiting examples of suitable enzymes include proteases, such as proteinase K, proteases or peptidases, or digestive enzymes, such as trypsin, pepsin or chymotrypsin. The non-limiting examples of suitable denaturants include guanidine hydrochloride, acetone, acetic acid, urea or lithium perchlorate. The non-limiting examples of chemical agents that can denature proteins include solvents, such as phenol, chloroform, guanidine isocyanate, urea, formamide, etc. Non-limiting examples of surfactants include Triton X-100 (polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-phenyl ether), SDS (sodium dodecyl sulfate), Igepal CA-630, or poloxamer. Non-limiting examples of chelating agents include ethylenediaminetetraacetic acid (EDTA), citrate, or polyaspartic acid. In some embodiments, compounds such as these can be applied to the sample to remove proteins, lipids, and / or other components. For example, a buffer solution (e.g., containing Tris or tris(hydroxymethyl)aminomethane) can be applied to the sample and then removed.
[0328] In some cases, it is also possible to remove nucleic acids that are not target molecules of interest. These non-target nucleic acids can be removed with enzymes to degrade nucleic acid molecules. These non-target nucleic acids can be removed with enzymes to degrade nucleic acid molecules. The non-limiting examples of DNA enzymes that can be used to remove DNA include DNA enzyme I, dsDNA enzymes, multiple restriction enzymes, etc. The non-limiting examples of the technology of removing RNA include RNA enzymes, such as RNA enzyme A, RNA enzyme T or RNA enzyme H, or chemical agents, for example, by alkaline hydrolysis (for example, by raising pH to greater than 10). The non-limiting examples of the system of removing sugar or extracellular matrix include enzymes, such as chitinase, heparinase or other glycosylases. The non-limiting examples of the system of removing lipids include enzymes such as lipases, chemical reagents such as alcohols (for example, methanol or ethanol), or detergents such as Triton X-100 or sodium lauryl sulfate. In this way, the background of the sample can be removed, so that the analysis of nucleic acid probes or other targets (for example, using fluorescence microscopy or other technologies described herein) can be promoted.
[0329] In some embodiments, sample disclosed herein can be provided on substrate.In some embodiments, substrate herein can be any support that is insoluble in aqueous liquid, and allows to locate biological sample, analyte, feature and / or reagent (for example, probe) on the support.In some embodiments, biological sample can be attached to substrate.The attachment of biological sample can be irreversible or reversible, depending on the subsequent steps in the properties of sample and analytical method.In certain embodiments, by applying suitable polymer coating to substrate and contacting sample with the polymer coating, sample can be reversibly attached to substrate.Then, for example, using an organic solvent that at least partially dissolves the polymer coating, sample can be separated from substrate.Hydrogel is an example of a polymer suitable for this purpose.
[0330] In some embodiments, the substrate can be coated or functionalized with one or more substances to facilitate attachment of the sample to the substrate. Suitable substances that can be used to coat or functionalize the substrate include, but are not limited to, lectins, polylysine, antibodies, and polysaccharides.
[0331] Various steps may be performed to prepare or process biological samples for and / or during an assay. Unless otherwise indicated, the preparation or processing steps described below may generally be combined in any manner and in any order to appropriately prepare or process a particular sample for and / or analysis.
[0332] In some embodiments of the methods provided herein, the biological sample is a tissue sample. The methods for reducing autofluorescence and analyzing biological samples as detailed herein are particularly applicable to tissue samples that contain many endogenous biological parts that may contribute to background autofluorescence.
[0333] In some embodiments, the tissue sample is melanoma tissue, brain tissue, lung tissue, tonsil tissue, intestinal tissue, kidney tissue, spleen tissue, liver tissue, mammary tissue or liver tissue. Some tissue types, including but not limited to brain, liver and tonsil tissue samples, tend to show high levels of background fluorescence, and can benefit from the methods for reducing autofluorescence and analyzing tissue samples described in detail herein. In certain embodiments, the tissue sample is brain tissue, liver tissue or tonsil tissue.
[0334] (i) Tissue sections
[0335] Biological samples can be obtained from subjects (e.g., by surgical biopsy, whole subject sectioning) or grown in vitro as cell populations on growth substrates or culture dishes and prepared for analysis as tissue slices or tissue sections. The grown samples can be thin enough to be analyzed without further processing steps. Alternatively, the grown samples and samples obtained via biopsy or sectioning can be prepared into thin tissue sections using mechanical cutting devices such as vibrating blade microtomes. As another alternative, in some embodiments, thin tissue sections can be prepared by applying a touch impression of the biological sample to a suitable substrate material.
[0336] The thickness of the tissue section can be a fraction of the maximum cross-sectional dimension of the cells (e.g., less than 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, or 0.1). However, tissue sections having a thickness greater than the maximum cross-sectional cell dimension can also be used. For example, cryostat sections can be used, which can be, for example, 10-20 μm thick.
[0337] More generally, the thickness of the tissue section usually depends on the method for preparing the section and the physical properties of the tissue, so sections with various thicknesses can be prepared and used. For example, the thickness of the tissue section can be at least 0.1, 0.2, 0.3, 0.4, 0.5, 0.7, 1.0, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14, 15, 20, 30, 40 or 50 μm. If necessary or convenient, thicker sections can also be used, such as at least 70, 80, 90 or 100 μm or thicker. Typically, the thickness of the tissue section is between 1-100 μm, 1-50 μm, 1-30 μm, 1-25 μm, 1-20 μm, 1-15 μm, 1-10 μm, 2-8 μm, 3-7 μm or 4-6 μm, but as mentioned above, sections with thickness greater than or less than these ranges can also be analyzed.
[0338] Multiple slices can also be obtained from a single biological sample. For example, multiple tissue slices can be obtained from a surgical biopsy sample by serially slicing the biopsy sample using a microtome blade. Spatial information between serial slices can be preserved in this way, and the slices can be analyzed continuously to obtain three-dimensional information about the biological sample.
[0339] (ii) Freezing
[0340] In some embodiments, biological samples (e.g., tissue sections as described above) can be prepared by deep freezing at a temperature suitable for maintaining or preserving the integrity (e.g., physical properties) of the tissue structure. Any number of suitable methods can be used to slice (e.g., thin slices) frozen tissue samples onto the substrate surface. For example, a freezing microtome (e.g., a cryostat) can be used to prepare tissue samples at a temperature suitable for maintaining the structural integrity of the tissue sample and the chemical properties of the nucleic acid in the sample. Such a temperature can be, for example, below -15 ° C, below -20 ° C, or below -25 ° C.
[0341] (iii) Fixation and post-fixation
[0342] In some embodiments, established method formalin fixation and paraffin embedding (FFPE) can be used to prepare biological samples. In some embodiments, formalin fixation and paraffin embedding can be used to prepare cell suspensions and other non-tissue samples. After fixing the sample and being embedded in paraffin or resin blocks, the sample can be sliced as described above. Before analysis, it is possible to remove paraffin embedded materials (e.g., dewaxing) from tissue sections by incubating tissue sections in appropriate solvents (e.g., xylene), then rinsing (e.g., 99.5% ethanol for 2 minutes, 96% ethanol for 2 minutes, and 70% ethanol for 2 minutes).
[0343] As an alternative to formalin fixation described above, biological samples can be fixed in any of a variety of other fixatives to preserve the biological structure of the sample prior to analysis. For example, the sample can be fixed by immersion in ethanol, methanol, acetone, paraformaldehyde (PFA)-Triton, and combinations thereof.
[0344] In some embodiments, acetone fixation is used for fresh frozen samples, which may include, but are not limited to, cortical tissue, mouse olfactory bulbs, human brain tumors, human postmortem brains, and breast cancer samples. When acetone fixation is performed, a pre-permeabilization step (described below) may not be performed. Alternatively, acetone fixation may be performed in conjunction with a permeabilization step.
[0345] In some embodiments, the method provided herein includes one or more post-fixing (post-fixing, also referred to as postfixation) steps. In some embodiments, one or more post-fixing steps are performed after contacting the sample with polynucleotides disclosed herein, such as one or more probes. In some embodiments, one or more post-fixing steps are performed after the hybridization complex comprising the probe and the target is formed in the sample.
[0346] In some embodiments, one or more post-fixation steps are performed after contacting the sample with a binding agent or a labeling agent (e.g., an antibody or its antigen binding fragment) for a non-nucleic acid analyte such as a protein analyte. The labeling agent may include a nucleic acid molecule (e.g., a reporter oligonucleotide) comprising a sequence corresponding to the labeling agent and therefore corresponding to the analyte (e.g., uniquely identified). In some embodiments, the labeling agent may include a reporter oligonucleotide containing one or more barcode sequences.
[0347] The post-fixation step can be performed using any suitable fixation reagent disclosed herein (eg, 3% (w / v) paraformaldehyde in DEPC-PBS).
[0348] Fixing agents may induce or exacerbate autofluorescence in tissue samples. Therefore, the disclosed methods for reducing autofluorescence and analyzing biological samples (such as tissue samples) as provided herein are also applicable to samples that have undergone a fixation step. In some embodiments, the tissue sample is a formalin-fixed tissue sample or a formalin-fixed paraffin-embedded (FFPE) sample. In some embodiments, the autofluorescence is fixative-induced autofluorescence.
[0349] (iv) Embedding
[0350] As an alternative to the above-mentioned paraffin embedding, the biological sample can be embedded in any of a variety of other embedding materials to provide a structural substrate for the sample before sectioning and other processing steps. In some cases, the embedding material can be removed, for example, before analyzing the tissue sections obtained from the sample. Suitable embedding materials include, but are not limited to, wax, resins (e.g., methacrylic resins), epoxy resins, and agar.
[0351] In some embodiments, biological samples can be embedded in a matrix (e.g., a hydrogel matrix). In some aspects, an embedding material can be applied to the sample once or multiple times. Embedding samples in this way generally involve contacting the biological sample with a hydrogel so that the biological sample becomes surrounded by the hydrogel. For example, the sample can be embedded by contacting the sample with a suitable polymer material and activating the polymer material to form a hydrogel. In some embodiments, forming a hydrogel internalizes the hydrogel in the biological sample.
[0352] In some embodiments, the biological sample is immobilized in the hydrogel by cross-linking of the polymeric material forming the hydrogel. The cross-linking may be performed chemically and / or photochemically, or alternatively by any other suitable hydrogel-forming method.
[0353] The composition of the hydrogel-matrix and the application to the biological sample generally depend on the nature and preparation (e.g., sliced, non-sliced, fixed type) of the biological sample. As an example, when the biological sample is a tissue slice, the hydrogel-matrix may include a monomer solution and an ammonium persulfate (APS) initiator / tetramethylethylenediamine (TEMED) accelerator solution. As another example, when the biological sample is composed of cells (e.g., cultured cells or cells dissociated from a tissue sample), the cells may be incubated with a monomer solution and an APS / TEMED solution. For cells, the hydrogel-matrix gel is formed in a compartment, which includes, but is not limited to, a device for culturing, maintaining or transporting cells. For example, a hydrogel-matrix may be formed to a depth range of about 0.1 μm to about 2 mm with a monomer solution added to the compartment plus APS / TEMED.
[0354] Additional methods and aspects of hydrogel embedding of biological samples are described, for example, in Chen et al., Science 347(6221):543–548, 2015, US2016 / 0024555, US2019 / 0276881, US2020 / 0071751, WO2020 / 0076976, WO2020 / 0076979, and WO2020 / 0096687, the entire contents of which are incorporated herein by reference. Tissue or cell samples can be embedded in conductive hydrogels. U.S. Patent Publication No. 2011 / 0256183 (Frank et al.), U.S. Patent No. 10,138,509 (Church et al.), U.S. Patent No. 10,545,075 (Deisseroth et al.), and U.S. Patent Publication No. 2019 / 0233878 (Delaney et al.), which are incorporated herein by reference, describe hydrogels and their use for embedding tissues and cells.
[0355] (v) Staining and immunohistochemistry (IHC)
[0356] In order to promote visualization, various staining agents and staining techniques can be used to dye biological samples. For example, in some embodiments, any number of staining agents and / or immunohistochemical reagents can be used to dye samples. One or more staining steps can be performed to prepare or process biological samples for determinations described herein, or can be performed during and / or after determination. In some embodiments, samples can be contacted with one or more nucleic acid stains, membrane stains (for example, cell membrane or nuclear membrane), cytological stains, or a combination thereof. In some instances, staining can be specific to the compartment of proteins, phospholipids, DNA (for example, dsDNA, ssDNA), RNA, organelles, or cells. Samples can be contacted with one or more labeled antibodies (for example, a first antibody specific to an analyte of interest and a second antibody specific to a label of the first antibody). In some embodiments, one or more images taken of the stained sample can be used to segment the cells in the sample.
[0357] In some embodiments, lipophilic dye is used for dyeing. In some instances, lipophilic carbocyanine or aminostyrene dye or their analog (for example, DiI, DiO, DiR, DiD) are used for dyeing. Other cell membrane stains can include FM and RH dye or immunohistochemical reagents specific to cell membrane proteins. In some instances, staining agent can include but is not limited to acridine orange, acid fuchsin, Bismarck brown, carmine, Coomassie blue, cresyl violet, DAPI, eosin, ethidium bromide, acid fuchsin, hematoxylin, Hoechst stain, iodine, methyl green, methylene blue, neutral red, Nile blue, Nile red, osmium tetroxide, ruthenium red, propidium iodide, rhodamine (for example, rhodamine B) or safranin or their derivatives. In some embodiments, sample can be dyed with hematoxylin and eosin (H&E).
[0358] Samples can be stained using hematoxylin and eosin (H&E) staining techniques, using Papanicolaou staining techniques, Masson's trichrome staining techniques, silver staining techniques, Sudan staining techniques, and / or using periodic acid Schiff (PAS) staining techniques. PAS staining is usually performed after formalin or acetone fixation. In some embodiments, Romanovsky stains (including Wright's stain, Jenner's stain, Can-Grunwaldstain, Leishman stain, and Giemsa stain) can be used to stain samples.
[0359] In some embodiments, any suitable method for decolorizing or fading a biological sample can be used to decolorize a biological sample, and generally depends on the properties of the stain applied to the sample. For example, in some embodiments, one or more immunofluorescence stains are applied to the sample by antibody coupling. Such stains can be removed using techniques such as cleaving disulfide bonds, chaotropic salt treatment, antigen repair solution treatment, and acidic glycine buffer treatment. Methods for multiple staining and destaining are described in, for example, Bolognesi et al., J. Histochem. Cytochem. 2017; 65 (8): 431-444; Lin et al., Nat Commun. 2015; 6: 8390; Pirici et al., J. Histochem. Cytochem. 2009; 57: 567–75; and Glass et al., J. Histochem. Cytochem. 2009; 57: 899–905, the entire contents of each document are incorporated herein by reference.
[0360] (vi) Isometric Expansion
[0361] In some embodiments, biological samples embedded in a matrix (e.g., a hydrogel) can be isovolumetrically expanded. Useful isovolumetric expansion methods include hydration, which is a preparatory step in expansion microscopy, as described in Chen et al., Science 347(6221):543–548, 2015, the contents of which are incorporated herein by reference in their entirety.
[0362] Isovolumetric expansion can be performed by anchoring one or more components of the biological sample to the gel, followed by gel formation, proteolysis and swelling. In some embodiments, the analyte in the sample, the product of the analyte and / or the probe associated with the analyte in the sample can be anchored to a matrix (e.g., a hydrogel). Isovolumetric expansion of the biological sample can occur before the biological sample is fixed to the substrate or after the biological sample is fixed to the substrate. In some embodiments, the isochoric expanded biological sample can be removed from the substrate before contacting the substrate with the probe disclosed herein.
[0363] In general, the steps used to perform isochoric expansion of a biological sample may depend on the characteristics of the sample (e.g., thickness of tissue sections, fixation, cross-linking) and / or the analytes of interest (e.g., different conditions for anchoring RNA, DNA, and proteins to a gel).
[0364] In some embodiments, the protein in the biological sample is anchored to a swellable gel (such as a polyelectrolyte gel). Antibodies can be directed to proteins before, after, or in conjunction with anchoring to a swellable gel. DNA and / or RNA in a biological sample can also be anchored to a swellable gel through a suitable joint. Examples of such joints include, but are not limited to, 6-((acryloyl)amino)hexanoic acid (acryloyl-X SE) (available from ThermoFisher, Waltham, MA), Label-IT amine (available from MirusBio, Madison, WI) and Label X (e.g., described in Chen et al., Nat. Methods 13: 679-684, 2016, the entire contents of which are incorporated herein by reference).
[0365] In some embodiments, the biological sample is isovolumetrically expanded to a size of at least 2x, 2.1x, 2.2x, 2.3x, 2.4x, 2.5x, 2.6x, 2.7x, 2.8x, 2.9x, 3x, 3.1x, 3.2x, 3.3x, 3.4x, 3.5x, 3.6x, 3.7x, 3.8x, 3.9x, 4x, 4.1x, 4.2x, 4.3x, 4.4x, 4.5x, 4.6x, 4.7x, 4.8x, or 4.9x of its unexpanded size. In some embodiments, the sample is isovolumetrically expanded to at least 2x and less than 20x of its unexpanded size.
[0366] (vii) Crosslinking and decrosslinking
[0367] In some embodiments, the biological sample is reversibly or irreversibly cross-linked before, during, or after the assay steps disclosed herein.
[0368] In some respects, the amplified product (for example, amplicon) of analyte, polynucleotide and / or analyte or the probe combined therewith can be anchored on the polymer matrix.For example, the polymer matrix can be a hydrogel.In some embodiments, the polymer matrix comprises a functional part.In some embodiments, one or more polynucleotide probes and / or its amplified product (for example, amplicon) can be modified to contain a functional group, which can be used as the anchoring point that polynucleotide probe and / or amplified product are connected to the polymer matrix.In some embodiments, the modified probe comprising few dT can be used for combining interested mRNA molecules, followed by the reversible crosslinking of mRNA molecules.
[0369] In some embodiments, the biological sample is fixed in the hydrogel by crosslinking of the polymer material forming the hydrogel. Crosslinking can be performed chemically and / or photochemically, or alternatively by any other suitable hydrogel formation method. The hydrogel can include a macromolecular polymer gel containing a network. In a network system, some polymer chains can be optionally crosslinked, but crosslinking does not always occur.
[0370] In some embodiments, the hydrogel can include hydrogel subunits such as, but not limited to, acrylamide, bisacrylamide, polyacrylamide and its derivatives, poly(ethylene glycol) and its derivatives (e.g., PEG-acrylate (PEG-DA), PEG-RGD), methacrylated gelatin (GelMA), methacrylated hyaluronic acid (MeHA), polyaliphatic polyurethanes, polyether polyurethanes, polyester polyurethanes, polyethylene copolymers, polyamides, polyvinyl alcohol, polypropylene glycol, polytetramethylene oxide, polyvinyl pyrrolidone, polyacrylamide, poly(hydroxyethyl acrylate) and poly(hydroxyethyl methacrylate), collagen, hyaluronic acid, chitosan, dextran, agarose, gelatin, alginate, protein polymers, methylcellulose, and the like, and combinations thereof.
[0371] In some embodiments, the hydrogel comprises a hybrid material, for example, the hydrogel material comprises elements of a synthetic polymer and a natural polymer. Examples of suitable hydrogels are described in, for example, U.S. Patent Nos. 6,391,937, 9,512,422, and 9,889,422 and U.S. Patent Application Publication Nos. 2017 / 0253918, 2018 / 0052081, and 2010 / 0055733, the entire contents of each document being incorporated herein by reference.
[0372] In some embodiments, the hydrogel can form a substrate. In some embodiments, the substrate includes a hydrogel and one or more second materials. In some embodiments, the hydrogel is placed on the top of the one or more second materials. For example, the hydrogel can be preformed and then placed on the top, bottom or any other configuration with the one or more second materials. In some embodiments, the hydrogel forms after contacting the one or more second materials during the formation of the substrate. The hydrogel formation can also occur in the structure (e.g., hole, ridge, protrusion and / or texture) located on the substrate.
[0373] In some embodiments, hydrogel formation on the substrate occurs before, simultaneously with, or after providing the probe to the sample. For example, hydrogel formation can be performed on a substrate that already contains the probe.
[0374] In some embodiments, hydrogel formation occurs within a biological sample. In some embodiments, a biological sample (e.g., a tissue section) is embedded in a hydrogel. In some embodiments, a hydrogel subunit is injected into a biological sample, and polymerization of the hydrogel is initiated by an external or internal stimulus.
[0375] In the embodiment of forming hydrogel in biological sample, functionalization chemistry can be used.In some embodiments, functionalization chemistry includes hydrogel-tissue chemistry (HTC).Any hydrogel-tissue skeleton (for example, synthetic or natural) suitable for HTC can be used for anchoring biomacromolecules and regulating functionalization.Non-limiting examples of methods using HTC skeleton variants include CLARITY, PACT, ExM, SWITCH and ePACT.In some embodiments, the hydrogel formation in biological sample is permanent.For example, biomacromolecules can be permanently adhered to hydrogel, allowing multiple rounds of inquiry.In some embodiments, the hydrogel formation in biological sample is reversible.
[0376] In some embodiments, additional reagents are added to the hydrogel subunits before, simultaneously and / or after polymerization. For example, additional reagents may include, but are not limited to, oligonucleotides (e.g., probes), endonucleases that fragment DNA, DNA fragmentation buffers, DNA polymerases, dNTPs for amplifying nucleic acids and connecting barcodes to amplified fragments. Other enzymes may be used, including but not limited to RNA polymerases, transposases, ligases, proteinase K, and DNAse. Additional reagents may also include reverse transcriptases, including enzymes with terminal transferase activity, primers, and switch oligonucleotides. In some embodiments, optical labels are added to the hydrogel subunits before, simultaneously and / or after polymerization.
[0377] In some embodiments, the HTC agent is added to the hydrogel before, simultaneously with, and / or after polymerization. In some embodiments, the cell labeling agent is added to the hydrogel before, simultaneously with, and / or after polymerization. In some embodiments, the cell permeation agent is added to the hydrogel before, simultaneously with, and / or after polymerization.
[0378] Any suitable method can be used to make the hydrogel embedded in the biological sample transparent. For example, the electrophoretic tissue clearing method can be used to remove biomacromolecules from the hydrogel-embedded sample. In some embodiments, the hydrogel-embedded sample is stored in a medium (e.g., a fixing medium, methylcellulose or other semi-solid medium) before or after the hydrogel is cleared.
[0379] In some embodiments, the methods disclosed herein include decrosslinking a reversibly crosslinked biological sample. Decrosslinking does not need to be complete. In some embodiments, only a portion of the crosslinked molecules in the reversibly crosslinked biological sample are decrosslinked and allowed to migrate.
[0380] (viii) Tissue permeabilization and processing
[0381] In some embodiments, biological samples can be permeabilized to facilitate transfer of analytes from the sample, and / or to facilitate transfer of species (such as probes) into the sample. In contrast, if the tissue sample is too permeable, the relative spatial relationships of the analytes within the tissue sample may be lost. Therefore, a balance between fully permeabilizing the tissue sample to obtain good signal intensity while still maintaining spatial resolution of the analyte distribution in the sample is desirable.
[0382] Typically, biological samples can be permeabilized by exposing the sample to one or more permeabilizing agents. Suitable agents for this purpose include, but are not limited to, organic solvents (e.g., acetone, ethanol, and methanol), cross-linking agents (e.g., paraformaldehyde), detergents (e.g., saponin, Triton X-100, TM or Tween-20 TM ) and enzymes (e.g., trypsin, proteases). In some embodiments, the biological sample can be incubated with a cell permeabilizing agent to promote permeabilization of the sample. Additional methods for sample permeabilization are described, for example, in Jamur et al., Method Mol. Biol. 588: 63-66, 2010, the entire contents of which are incorporated herein by reference. Any suitable sample permeabilization method can generally be used in conjunction with the samples described herein.
[0383] In some embodiments, the biological sample can be permeabilized by adding one or more lysing agents to the sample. Examples of suitable lysing agents include, but are not limited to, bioactive agents such as lysing enzymes for lysing different cell types (e.g., Gram-positive or negative bacteria, plants, yeasts, mammals), such as lysozymes, colorless peptidases, lysostaphin, labiase, kitalase, lysomycin, and various other commercially available lysing enzymes.
[0384] Other lysing agents can be added to the biological sample additionally or alternatively to promote permeabilization. For example, a lysing solution based on a surfactant can be used for lysing sample cells. The lysing solution can include an ionic surfactant, such as sodium lauryl sarcosinate and sodium lauryl sulfate (SDS). More generally, chemical lysing agents can include but are not limited to organic solvents, chelating agents, detergents, surfactants and chaotropic agents.
[0385] In some embodiments, the biological sample can be permeabilized by any suitable non-chemical permeabilization method. For example, the non-chemical permeabilization method that can be used includes, but is not limited to, physical lysis techniques such as electroporation, mechanical permeabilization methods (e.g., bead beating using a homogenizer and grinding balls to mechanically disrupt the sample tissue structure), acoustic permeabilization (e.g., ultrasonic treatment) and thermal lysis techniques (such as heating to induce thermal permeabilization of the sample).
[0386] Before analyzing the sample, other reagents can be added to the biological sample to perform various functions. In some embodiments, DNase and RNase inactivators or inhibitors such as protein enzyme K and / or chelating agents such as EDTA can be added to the sample. For example, the method disclosed herein can include a step for increasing the binding accessibility of nucleic acids, such as a denaturation step for probe hybridization of the DNA in the open cell. For example, protein enzyme K can be used to process and release the DNA bound to it.
[0387] (ix) Selective enrichment of RNA species
[0388] In some embodiments, when RNA is an analyte, one or more RNA analyte species of interest can be selectively enriched. For example, one or more RNA species of interest can be selected by adding one or more oligonucleotides to a sample. In some embodiments, additional oligonucleotides are sequences for initiating reactions by an enzyme (e.g., a polymerase). For example, one or more primer sequences having sequence complementarity with one or more RNAs of interest can be used to amplify one or more RNAs of interest, thereby selectively enriching these RNAs.
[0389] In some aspects, when analyzing two or more analytes, use the first and second probes that are specific (e.g., specifically hybridized with) to each RNA or cDNA analyte. For example, in some embodiments of the method provided herein, templated connection is used to detect gene expression in biological samples. The analyte of interest (such as protein) that can be targeted and combined by a labeling agent or a binding agent (e.g., an antibody or its epitope binding fragment) is used for analysis, wherein the binding agent is conjugated or otherwise associated with a reporter oligonucleotide containing a reporter sequence for identifying the binding agent. The probe can be hybridized with the reporter oligonucleotide and connected in a templated connection reaction to produce a product for analysis. In some embodiments, before connection, the gap between the probe oligonucleotides can be filled using, for example, Mu polymerase, DNA polymerase, RNA polymerase, reverse transcriptase, VENT polymerase, Taq polymerase and / or any combination thereof, derivatives and variants (e.g., engineered mutants). In some embodiments, the assay can also include the amplification (e.g., by multiplex PCR) of the templated connection product.
[0390] Alternatively, one or more RNA species can be down-selected (e.g., removed) using any of a variety of methods. For example, a probe can be applied to the sample that selectively hybridizes with ribosomal RNA (rRNA) to reduce the pool and concentration of rRNA in the sample. Additionally and alternatively, double-stranded specific nuclease (DSN) treatment can remove rRNA (see, e.g., Archer et al., Selective and flexible depletion of problematic sequences from RNA-seq libraries at the cDNA stage, BMC Genomics, 15401, (2014), the entire contents of which are incorporated herein by reference). In addition, hydroxyapatite chromatography can remove abundant species (e.g., rRNA) (see, e.g., Vandernoot, VA, cDNA normalization by hydroxyapatite chromatography to enrich transcriptome diversity in RNA-seq applications, Biotechniques, 53 (6) 373-80, (2012), the entire contents of which are incorporated herein by reference).
[0391] The biological sample may contain one or more analytes of interest. Methods are provided for performing multiplex assays to analyze two or more different analytes in a single biological sample.
[0392] B. Analyte
[0393] Methods and compositions disclosed herein can be used to detect and analyze a variety of different analytes. In some aspects, analyte can include any biological substance, structure, part or component to be analyzed. In some embodiments, any target nucleic acid molecule described herein can correspond to analyte. For example, target nucleic acid molecule can be endogenous nucleic acid analyte (for example, DNA or RNA), the product of endogenous nucleic acid analyte, the probe of endogenous nucleic acid analyte directly or indirectly combined, or the product of the probe of endogenous nucleic acid analyte directly or indirectly combined. In some aspects, analyte can include any biological substance, structure, part or component to be analyzed. In some embodiments, any target nucleic acid molecule described herein can correspond to analyte. For example, target nucleic acid molecule can be endogenous nucleic acid analyte (for example, DNA or RNA), the product of endogenous nucleic acid analyte, the probe of endogenous nucleic acid analyte directly or indirectly combined, or the product of the probe of endogenous nucleic acid analyte directly or indirectly combined. In some aspects, analyte can include any biological substance, structure, part or component to be analyzed. In some aspects, target disclosed herein can similarly include any analyte of interest. In some instances, target or analyte can be detected directly or indirectly.
[0394] The analyte can be derived from a particular type of cell and / or a particular subcellular region. For example, the analyte can be derived from the cytosol, from the nucleus, from the mitochondria, from the microsomes, and more generally, from any other compartment, organelle or part of the cell. Permeabilizing agents that specifically target certain cell compartments and organelles can be used to selectively release the analyte from the cell for analysis, and / or allow one or more reagents (e.g., probes for analyte detection) to approach the analyte in the cell or cell compartment or organelle.
[0395] Analyte can include any biomolecule or chemical compound, including protein or peptide, lipid or nucleic acid molecule, or small molecule (including organic molecule or inorganic molecule). Analyte can be cell or microorganism, including virus or its fragment or product. Analyte can be any substance or entity, can develop specific binding partner (such as affinity binding partner) for it. Such specific binding partner can be nucleic acid probe (for nucleic acid analyte) and can directly lead to the generation of RCA template. Alternatively, specific binding partner can be coupled to nucleic acid, and the nucleic acid can be detected using RCA strategy, such as in the determination of circular nucleic acid molecules that can be used as RCA template using or producing.
[0396] Analytes of particular interest may include nucleic acid molecules such as DNA (e.g., genomic DNA, mitochondrial DNA, plastid DNA, viral DNA, etc.) and RNA (e.g., mRNA, microRNA, rRNA, snRNA, viral RNA, etc.); and synthetic and / or modified nucleic acid molecules (e.g., including nucleic acid domains comprising synthetic or modified nucleotides such as LNA, PNA, morpholino, etc. or consisting of these substances); protein molecules such as peptides, polypeptides, proteins or prions, or any molecule comprising a protein or polypeptide component, etc., or a fragment thereof; or lipid or carbohydrate molecules or any molecule comprising a lipid or carbohydrate component. The analyte may be a single molecule or a complex containing two or more molecular subunits, for example, including but not limited to protein-DNA complexes, which may or may not be covalently bound to each other and which may be the same or different. Therefore, in addition to cells or microorganisms, such a complex analyte may also be a protein complex or a protein interactor. Therefore, such a complex or interaction may be a homopolymer or a heteropolymer. Aggregates of molecules (e.g., proteins) can also be target analytes, such as aggregates of the same protein or different proteins. Analytes can also be complexes between proteins or peptides and nucleic acid molecules (such as DNA or RNA), such as interactors between proteins and nucleic acids (e.g., regulatory factors (such as transcription factors) and DNA or RNA).
[0397] (i) Endogenous analytes or molecules of interest
[0398] In some embodiments, the target molecule herein corresponds to such an analyte, which is endogenous for a biological sample, and may include nucleic acid analytes and non-nucleic acid analytes. In some embodiments, the endogenous analyte described in detail herein may also be referred to as an analyte of interest or a molecule of interest. The methods and compositions disclosed herein may be used in any suitable combination for analyzing nucleic acid analytes (e.g., using nucleic acid probes or probe groups that are directly or indirectly hybridized with nucleic acid analytes) and / or non-nucleic acid analytes (e.g., using a labeling agent that comprises a reporter oligonucleotide and is directly or indirectly combined with a non-nucleic acid analyte).
[0399] Examples of non-nucleic acid analytes include, but are not limited to, lipids, carbohydrates, peptides, proteins, glycoproteins (N-connected or O-connected), lipoproteins, phosphoproteins, specific phosphorylation or acetylation variants of proteins, amidation variants of proteins, hydroxylation variants of proteins, methylation variants of proteins, ubiquitination variants of proteins, sulfated variants of proteins, viral capsid proteins, extracellular proteins and intracellular proteins, antibodies and antigen binding fragments. In some embodiments, the analyte is inside the cell or on the cell surface, such as a transmembrane analyte or an analyte attached to the cell membrane. In some embodiments, the analyte can be an organelle (e.g., a nucleus or mitochondria). In some embodiments, the analyte is an extracellular analyte, such as a secreted analyte. Exemplary analytes include, but are not limited to, receptors, antigens, surface proteins, transmembrane proteins, clusters of differentiation proteins, protein channels, protein pumps, carrier proteins, phospholipids, glycoproteins, glycolipids, cell-cell interaction protein complexes, antigen presentation complexes, major histocompatibility complexes, engineered T cell receptors, T cell receptors, B cell receptors, chimeric antigen receptors, extracellular matrix proteins, the post-translational modification (e.g., phosphorylation, glycosylation, ubiquitination, nitrosylation, methylation, acetylation, or lipidation) state of cell surface proteins, nick junctions, or adherens junctions.
[0400] Examples of nucleic acid analytes include DNA analytes, such as single-stranded DNA (ssDNA), double-stranded DNA (dsDNA), genomic DNA, methylated DNA, specific methylated DNA sequences, fragmented DNA, mitochondrial DNA, PCR products synthesized in situ, and RNA / DNA hybrids. A DNA analyte can be a transcript of another nucleic acid molecule (e.g., DNA or RNA (such as mRNA)) present in a tissue sample.
[0401] Examples of nucleic acid analytes also include RNA analytes, such as various types of coding and non-coding RNA. Examples of different types of RNA analytes include messenger RNA (mRNA), including nascent RNA, pre-mRNA, primary transcription RNA, and processed RNA (such as capped mRNA (e.g., with a 5'7-methylguanosine cap), polyadenylated mRNA (poly A tail at the 3' end), and spliced mRNA with one or more introns removed). Uncapped mRNA, unpolyadenylated mRNA, and unspliced mRNA are also included in the analytes disclosed herein. RNA analytes can be transcripts of another nucleic acid molecule (e.g., DNA or RNA (such as viral RNA)) present in a tissue sample. Examples of non-coding RNA (ncRNA) that are not translated into proteins include transfer RNA (tRNA) and ribosomal RNA (rRNA), as well as small non-coding RNAs such as microRNA (miRNA), small interfering RNA (siRNA), Piwi interacting RNA (piRNA), small nucleolar RNA (snoRNA), small nuclear RNA (snRNA), extracellular RNA (exRNA), small Cajal body specific RNA (scaRNA) and long ncRNA (such as Xist and HOTAIR). RNA can be small (e.g., less than 200 nucleic acid bases in length) or large (e.g., RNA greater than 200 nucleic acid bases in length). Examples of small RNA include 5.8S ribosomal RNA (rRNA), 5S rRNA, tRNA, miRNA, siRNA, snoRNA, piRNA, tRNA derived small RNA (tsRNA) and small rDNA derived RNA (srRNA). RNA can be double-stranded RNA or single-stranded RNA. RNA can be circular RNA. RNA can be bacterial rRNA (e.g., 16s rRNA or 23s rRNA).
[0402] In some embodiments described herein, the analyte can be a denatured nucleic acid, wherein the resulting denatured nucleic acid is single-stranded. The nucleic acid can be denatured, for example, optionally denatured using formamide, heat, or both formamide and heat. In some embodiments, the nucleic acid is not denatured and is used in the methods disclosed herein.
[0403] In certain embodiments, analytes can be extracted from living cells. Processing conditions can be adjusted to ensure that the biological sample remains alive during analysis and that analytes are extracted (or released) from living cells of the sample. Analytes derived from living cells can be obtained only once from a sample, or can be obtained at certain intervals from a sample that is continuously kept alive.
[0404] The methods and compositions disclosed herein can be used to analyze any number of analytes. For example, the number of analytes analyzed can be at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 20, at least about 25, at least about 30, at least about 40, at least about 50, at least about 100, at least about 1,000, at least about 10,000, at least about 100,000 or more different analytes present in one region of a sample or in a separate feature of a substrate.
[0405] In any of the embodiments described herein, the analyte comprises a target sequence. In some embodiments, the target sequence can be an endogenous sequence of the sample, a sequence produced in the sample, a sequence added to the sample, or a sequence associated with the analyte in the sample. In some embodiments, the target sequence is a single-stranded target sequence. In some embodiments, the analyte comprises one or more single-stranded target sequences. In one aspect, the first single-stranded target sequence is not identical to the second single-stranded target sequence. In another aspect, the first single-stranded target sequence is identical to one or more second single-stranded target sequences. In some embodiments, one or more second single-stranded target sequences are contained in an analyte (e.g., nucleic acid) identical to the first single-stranded target sequence. Alternatively, one or more second single-stranded target sequences are contained in an analyte (e.g., nucleic acid) different from the first single-stranded target sequence.
[0406] In some embodiments, the molecule of interest is a nucleic acid of interest or a protein of interest. In some embodiments, the molecule of interest is a nucleic acid of interest.
[0407] In some embodiments, the nucleic acid of interest is a cell or viral DNA or RNA or its product. In certain embodiments, the cell or viral DNA or RNA or its product is genomic DNA, coding RNA, non-coding RNA or cDNA. In certain other embodiments, the nucleic acid of interest is mRNA.
[0408] In some embodiments, the nucleic acid of interest is a nucleic acid probe that is directly or indirectly bound to a cell or viral DNA or RNA or its product. In certain embodiments, the cell or viral DNA or RNA or its product is genomic DNA, coding RNA, non-coding RNA or cDNA. In certain other embodiments, the coding RNA is mRNA. In some embodiments, the nucleic acid probe is linear, cyclizable, circular or branched. In certain embodiments, the nucleic acid probe comprises a 3' overhang and / or a 5' overhang when hybridizing with a cell or viral DNA or RNA or its product. In some embodiments, the nucleic acid probe comprises one or more barcode regions.
[0409] In other embodiments, the nucleic acid of interest is a probe product of one or more nucleic acid probes directly or indirectly bound to a cell or viral DNA or RNA or its product. In certain embodiments, the cell or viral DNA or RNA or its product is genomic DNA, coding RNA, non-coding RNA or cDNA. In certain other embodiments, coding RNA is mRNA. In some embodiments, the probe product is a rolling circle amplification (RCA) product, a hybridization chain reaction (HCR) product, a linear oligonucleotide hybridization chain reaction (LO-HCR) product, a primer exchange reaction (PER) product, an assembly of a branched structure, a plurality of fluorescently labeled probes or any combination thereof. In other embodiments, the probe product and / or one or more nucleic acid probes include one or more barcode regions.
[0410] In other embodiments, the nucleic acid of interest is a reporter oligonucleotide in a labeling agent comprising a binding moiety that binds directly or indirectly to a non-nucleic acid analyte, optionally wherein the reporter oligonucleotide comprises one or more barcode regions.
[0411] In other embodiments, the molecule of interest is a protein of interest.
[0412] (ii) Labeling agent
[0413] In some embodiments, provided herein are methods and compositions for analyzing endogenous analytes (e.g., RNA, ssDNA, and cell surface or intracellular proteins and / or metabolites) in a sample using one or more markers. In some embodiments, an analyte marker may include a reagent that interacts with an analyte (e.g., an endogenous analyte in a sample). In some embodiments, the marker may include a reporter oligonucleotide indicating an analyte or a portion thereof that interacts with the marker. For example, the reporter oligonucleotide may include a barcode sequence that allows identification of the marker. In some cases, the sample contacted by the marker may be further contacted with a probe (e.g., a single-stranded probe sequence), which is hybridized with the reporter oligonucleotide of the marker to identify the analyte associated with the marker. In some embodiments, the analyte marker includes an analyte binding moiety and a marker barcode domain, and the marker barcode domain includes one or more barcode sequences, such as a barcode sequence corresponding to an analyte binding moiety and / or an analyte. The analyte binding moiety barcode includes a barcode that associates with the analyte binding moiety or otherwise identifies the analyte binding moiety. In some embodiments, the analyte binding moiety is identified by identifying its associated analyte binding moiety barcode, and the analyte to which the analyte binding moiety binds can also be identified. The analyte binding moiety barcode can be a nucleic acid sequence of a given length and / or a sequence associated with the analyte binding moiety. The analyte binding moiety barcode can generally include any of the aspects of the barcode described herein.
[0414] In some embodiments, the methods include one or more post-fixation steps after contacting the sample with one or more labeling agents.
[0415] In the methods and systems described herein, one or more labeling agents that can be combined with or otherwise coupled to one or more features can be used to characterize analytes, cells and / or cell features. In some cases, cell features include cell surface features. Analytes can include but are not limited to proteins, receptors, antigens, surface proteins, transmembrane proteins, differentiation protein clusters, protein channels, protein pumps, carrier proteins, phospholipids, glycoproteins, glycolipids, cell-cell interaction protein complexes, antigen presentation complexes, major histocompatibility complexes, engineered T cell receptors, T cell receptors, B cell receptors, chimeric antigen receptors, gap connections, adhesion connections or any combination thereof. In some cases, cell features can include intracellular analytes, such as proteins, protein modifications (e.g., phosphorylation status or other post-translational modifications), nucleoproteins, nuclear membrane proteins or any combination thereof.
[0416] In some embodiments, the binding substance or analyte binding portion may include any molecule or part capable of binding to an analyte (e.g., a biological analyte, e.g., a macromolecular component). Labeling agents may include, but are not limited to, proteins, peptides, antibodies (or their epitope binding fragments), lipophilic moieties (such as cholesterol), cell surface receptor binding molecules, receptor ligands, small molecules, bispecific antibodies, bispecific T cell adapters, T cell receptor adapters, B cell receptor adapters, antibody prodrugs, aptamers, monoclonal antibodies, affimers, darpins, and protein scaffolds or any combination thereof. Labeling agents may include (e.g., connected to) a reporter oligonucleotide that indicates the cell surface features to which the binding group is combined. For example, a reporter oligonucleotide may include a barcode sequence that allows identification of a labeling agent. For example, a labeling agent specific to a type of cell feature (e.g., a first cell surface feature) may have a first reporter oligonucleotide coupled thereto, and a labeling agent specific to different cell features (e.g., a second cell surface feature) may have different reporter oligonucleotides coupled thereto. For a description of exemplary labeling agents, reporter oligonucleotides, and methods of use, see, e.g., U.S. Patent 10,550,429; U.S. Patent Publication 20190177800; and U.S. Patent Publication 20190367969, each of which is incorporated herein by reference in its entirety.
[0417] In some embodiments, the analyte binding portion includes one or more antibodies or antigen binding fragments thereof. The antibody or antigen binding fragment including the analyte binding portion can specifically bind to the target analyte. In some embodiments, the analyte is a protein (e.g., a protein on the surface of a biological sample (e.g., a cell) or an intracellular protein). In some embodiments, a plurality of analyte labeling agents comprising a plurality of analyte binding portions bind to a variety of analytes present in a biological sample. In some embodiments, a variety of analytes include a single species of analyte (e.g., a single species of polypeptide). In some embodiments in which a variety of analytes include a single species of analyte, the analyte binding portions of the plurality of analyte labeling agents are the same. In some embodiments in which a variety of analytes include a single species of analyte, the analyte binding portions of the plurality of analyte labeling agents are different (e.g., a member of a plurality of analyte labeling agents can have two or more species of analyte binding portions, wherein each species in the two or more species of analyte binding portions binds to a single species of analyte, such as in different binding sites). In some embodiments, a variety of analytes include a variety of different species of analytes (e.g., a variety of different species of polypeptides).
[0418] In other cases, for example to facilitate sample multiplexing, labeling agents specific for particular cellular features can have a first plurality of labeling agents (e.g., antibodies or lipophilic moieties) coupled to a first reporter oligonucleotide and a second plurality of labeling agents coupled to a second reporter oligonucleotide.
[0419] In some aspects, these reporter oligonucleotides can include certain nucleic acid barcode sequences that allow identification of the labeling agent to which the reporter oligonucleotide is coupled. Selecting an oligonucleotide as a reporter can provide the following advantages: it can generate significant diversity in sequence, while also being easily attached to most biomolecules (e.g., antibodies, etc.), and being easy to detect.
[0420] The reporter oligonucleotide can be linked (coupled) to the labeling agent by any of a variety of direct or indirect, covalent or non-covalent associations or linkages. For example, the oligonucleotide can be linked (coupled) using chemical conjugation techniques (e.g., Lightning-Tran available from Innova Biosciences). Antibody labeling kits) are covalently attached to a portion of a labeling agent (such as a protein, such as an antibody or antibody fragment), as well as attached using other non-covalent attachment mechanisms, such as using a biotinylated antibody and an oligonucleotide with an avidin or streptavidin linker (or beads comprising one or more biotinylated linkers coupled to an oligonucleotide). Antibody and oligonucleotide biotinylation techniques are available. See, for example, Fang et al., "Fluoride-Cleavable Biotinylation Phosphoramidite for 5′-end-Labelling and Affinity Purification of Synthetic Oligonucleotides," Nucleic Acids Res. 2003 Jan 15; 31(2):708-715, which is incorporated herein by reference in its entirety for all purposes. Similarly, protein and peptide biotinylation techniques have been developed and are readily available. See, for example, U.S. Pat. No. 6,265,552, which is incorporated herein by reference for all purposes. In addition, click reaction chemistry can be used to couple the reporter oligonucleotide to a labeling agent.Commercially available kits (such as those from Thunderlink and Abcam) and common techniques in the art can be used to couple the reporter oligonucleotide to a labeling agent when appropriate.In another example, the labeling agent is indirectly (e.g., via hybridization) coupled to the reporter oligonucleotide, and the reporter oligonucleotide includes a barcode sequence for identifying the labeling agent.For example, the labeling agent can be directly coupled (e.g., covalently bound) to a hybrid oligonucleotide, and the hybrid oligonucleotide includes a sequence hybridized with the sequence of the reporter oligonucleotide.The hybridization of the hybrid oligonucleotide and the reporter oligonucleotide couples the labeling agent to the reporter oligonucleotide.In some embodiments, such as when applying stimulation, the reporter oligonucleotide can be released from the labeling agent.For example, the reporter oligonucleotide can be connected to the labeling agent by an unstable bond (e.g., chemically unstable, light unstable, thermally unstable, etc.), as described herein elsewhere for releasing molecules from a support.In some cases, the reporter oligonucleotide described herein can include one or more functional sequences that can be used for subsequent processing.
[0421] In some cases, the labeling agent can include a reporter oligonucleotide and a label. The label can be a fluorophore, a radioisotope, a molecule capable of colorimetric reaction, a magnetic particle, or any other suitable molecule or compound capable of detection. The label can be directly or indirectly conjugated to a labeling agent (or reporter oligonucleotide) (for example, the label can be conjugated to a molecule that can be combined with a labeling agent or a reporter oligonucleotide). In some cases, the label is conjugated to a first oligonucleotide complementary to the sequence of the reporter oligonucleotide (for example, hybridization).
[0422] (iii) Products of endogenous analytes and / or labeling agents
[0423] In some embodiments, the molecule used for detection herein is the product of endogenous analyte and / or labeling agent in biological sample.In some embodiments, provided herein is the method and composition for analyzing one or more products of endogenous analyte and / or labeling agent in biological sample.In some embodiments, endogenous analyte (for example, virus or cell DNA or RNA) or product (for example, hybridization product, connection product, extension product (for example, by DNA or RNA polymerase), replication product, transcription / reverse transcription product and / or amplification product) or its derivative is analyzed.In some embodiments, the labeling agent (or the reporter oligonucleotide connected thereto) of analyte in biological sample directly or indirectly is analyzed.In some embodiments, the product (for example, hybridization product, connection product, extension product (for example, by DNA or RNA polymerase), replication product, transcription / reverse transcription product and / or amplification product) or derivative of the labeling agent of analyte in biological sample directly or indirectly is analyzed.
[0424] C. Target sequence and barcode
[0425] In some aspects, one or more of the target sequences comprises one or more barcodes, such as at least two, three, four, five, six, seven, eight, nine, ten or more barcodes. The barcodes can be attached to the analyte or another part or structure in a reversible or irreversible manner. The barcodes can allow identification and / or quantification of individual analytes (e.g., the barcodes can be or can include unique molecular identifiers or "UMIs"). In some aspects, the barcodes comprise about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more 30 nucleotides.
[0426] In some embodiments, a barcode includes two or more sub-barcodes that together act as a single barcode. For example, a polynucleotide barcode can include two or more polynucleotide sequences (e.g., sub-barcodes) separated by one or more non-barcode sequences. In some embodiments, one or more barcodes can also provide a platform for targeting functions, such as oligonucleotides, oligonucleotide-antibody conjugates, oligonucleotide-streptavidin conjugates, modified oligonucleotides, affinity purification, detectable moieties, enzymes, enzymes for detection assays or other functions, and / or enzymes for detection and identification of polynucleotides.
[0427] In some embodiments, the barcode sequence is detected to identify other molecules that contain nucleic acid molecules (DNA or RNA) that are longer than the barcode sequence itself, as opposed to directly sequencing longer nucleic acid molecules. In some embodiments, given a sequenced read of N bases, an N-mer barcode sequence contains 4 N The complexity of barcode sequencing is greatly increased, and molecular identification may require much shorter sequencing reads compared to non-barcode sequencing methods such as direct sequencing. For example, 1024 molecular species can be identified using a 5-nucleotide barcode sequence (4 5 =1024), and an 8-nucleotide barcode can be used to identify up to 65,536 molecular species, a number greater than the total number of different genes in the human genome. In some embodiments, the barcode sequence corresponding to the target molecule is detected instead of the endogenous sequence, which can be read out efficiently in terms of the amount of information per sequencing cycle. Because the barcode sequences are predetermined, they can also be designed to characterize error detection and correction mechanisms, see, for example, U.S. Patent Publication 20190055594 and U.S. Patent Publication 20210164039, all of which are hereby incorporated by reference in their entirety.
[0428] III. Polynucleotides and Hybridization Complexes
[0429] The probe can include any of a variety of entities that can be hybridized with nucleic acids, such as DNA, RNA, LNA, PNA, etc., usually by Watson-Crick base pairing, depending on the application. Nucleic acid probes generally include a hybridization region that can be combined with at least a portion of a target nucleic acid (in some embodiments, specifically combined). Nucleic acid probes may be able to be combined with specific target nucleic acids (e.g., mRNA or other nucleic acids as discussed herein). In some embodiments, nucleic acid probes can be detected using detectable labels and / or by using a secondary nucleic acid probe that can be combined with nucleic acid probes. In some embodiments, nucleic acid probes are compatible with one or more biological and / or chemical reactions. For example, nucleic acid probes disclosed herein can be used as templates or primers for polymerases, templates or substrates for ligases, substrates for click chemistry reactions, and / or substrates for nucleases (e.g., endonucleases for cutting).
[0430] In some aspects, the target nucleic acid disclosed herein includes any polynucleotide nucleic acid molecule (e.g., DNA molecule; RNA molecule, modified nucleic acid, etc.) for evaluating according to the provided embodiment, such as a polynucleotide present in a cell. In some embodiments, the target nucleic acid is a coding RNA (e.g., mRNA). In some embodiments, the target can be a single RNA molecule. In other embodiments, the target can be at least one RNA molecule, such as a group of 2, 3, 4, 5, 6 or more RNA molecules. These RNA molecules can be different in molecular type, and / or can be different in sequence. In some embodiments, the target nucleic acid is, for example, a non-coding RNA (e.g., tRNA, rRNA, microRNA (miRNA), mature miRNA or immature miRNA). In some embodiments, the target nucleic acid is a splice variant of an RNA molecule (e.g., mRNA, pre-mRNA, etc.) in a cell environment. Therefore, a suitable target nucleic acid can be an unspliced RNA (e.g., pre-mRNA, mRNA), a partially spliced RNA, or a completely spliced RNA, etc. The target nucleic acid of interest can be variably expressed in a cell population, for example, with different abundances, wherein the methods disclosed herein allow for profiling and comparison of expression levels of nucleic acids (including but not limited to RNA transcripts) in individual cells. The target nucleic acid can also be a DNA molecule, such as a denatured genome, virus, plasmid, etc. For example, the method can be used to detect copy number variants, such as in a cancer cell population, where the target nucleic acid is present in different abundances in the cell genome of the population; detecting virus-infected cells to determine viral load and kinetics, etc.
[0431] In some aspects, the method provided herein is used to analyze target nucleic acids, such as messenger RNA molecules. In some embodiments, the target nucleic acid is an endogenous nucleic acid present in a biological sample. In some embodiments, the target nucleic acid is present in cells in a tissue, such as in a tissue sample or a tissue section. In some embodiments, the tissue sample is a complete tissue sample or a non-homogenized tissue sample. In some embodiments, the tissue sample is a fresh tissue sample. In some embodiments, the tissue has previously been processed using any of the steps and / or schemes described in Section II, such as fixing, embedding, freezing or permeabilization. In some embodiments, the target nucleic acid is an exogenous nucleic acid contacted with a biological sample.
[0432] In some aspects, provided embodiments can be used for in situ detection of target nucleic acids in cells, e.g., in biological samples or samples derived from biological samples, such as tissue sections on solid supports, e.g., tissue sections on transparent slides.
[0433] In some aspects, there is provided herein an in situ determination using a microscope as a readout, for example, a detection or determination method related to an optical readout. In some aspects, the detection or determination of the sequence of one, two, three, four, five or more nucleotides of a target nucleic acid is carried out in situ in the cell of a complete tissue. In some aspects, detection or determination is related to the target nucleic acid or indicates the sequence of the target nucleic acid. In some aspects, detection or determination of the sequence is carried out to detect the location of the target nucleic acid (or the product or derivative thereof related to the target nucleic acid) in the original sample. In some embodiments, the determination includes the presence or absence of a detection amplification product or a part thereof (for example, an RCA product). In some embodiments, the disclosure provides a method for detecting and / or quantifying the nucleic acid in a large number of targets (such as transcripts and / or DNA loci) for in situ high-throughput spectroscopic analysis.
[0434] In some aspects, the methods disclosed herein include using one or more probes or probe groups hybridized with a target nucleic acid (such as an RNA molecule), wherein at least one probe is a circularizable probe or probe group (e.g., a padlock probe) comprising an asymmetric arm hybridized with a nucleic acid molecule. Exemplary probes can be based on circularizable probes or probe groups (e.g., padlock probes), gap circularizable probes or probe groups (e.g., gap padlock probes), SNAIL (splint nucleotide assisted intramolecular connection) probe groups, PLAYR (RNA proximity connection determination) probe groups, PLISH (proximity connection in situ hybridization) probe groups, and RNA templated connection probes. Specific probe or probe group design can vary. In some embodiments, a primary probe (e.g., a DNA probe directly binding to an RNA target) is amplified by rolling circle amplification. In some embodiments, a primary probe (such as a circularizable probe or probe group (e.g., a padlock probe) comprising a padlock probe) comprises one or more barcodes. In some embodiments, one or more barcodes indicate a sequence in a target nucleic acid, such as a single nucleotide of interest (e.g., SNP or point mutation), a dinucleotide sequence, or a short sequence of about 5 nucleotides in length.
[0435] In some embodiments, provided herein are methods for evaluating one or more target nucleic acids (such as multiple different mRNAs) in a biological sample (such as a cell or tissue sample (such as a tissue section)). In some embodiments, the target nucleic acid comprises DNA. In some embodiments, the target nucleic acid comprises RNA. In some embodiments, the probe comprises DNA. In some embodiments, the target nucleic acid is RNA and the probe comprises DNA.
[0436] In some respects, provided method is used for the in situ analysis of target nucleic acid, for example, for in situ detection or multiple analysis in the sample of intact tissue or retained cell or tissue structure. In some respects, provided method can be used for in situ detection or determine the identity or amount of interested mononucleotide in target nucleic acid, for example the SNP of interested gene.
[0437] In some aspects, the method provided relates to a step of contacting or hybridizing a cell or sample containing a target nucleic acid having a region of interest (e.g., a mononucleotide) with one or more polynucleotides (such as any probe described herein) to form a hybridization complex. In some aspects, the method provided includes one or more steps of connecting polynucleotides, such as connecting the end of a circularized probe or a probe group (e.g., a padlock probe) to form a circularized probe. In some aspects, the method provided includes one or more steps of connecting polynucleotides, such as connecting the end of a circularized probe or a probe group (e.g., a padlock probe) to form a circularized probe. In some aspects, the method provided relates to a step of amplifying one of the polynucleotides (e.g., a padlock probe or a circularized probe produced therefrom) to produce an amplified product. In some aspects, the method provided relates to a step of detecting and / or determining the sequence of all or a portion of an amplified product (e.g., one or more barcodes contained in the amplified product) and / or one or more amplified or unamplified polynucleotides (e.g., any barcode contained therein). In some aspects, the method provided relates to performing one or more steps described herein simultaneously and / or sequentially.
[0438] If present, the barcode sequence can be of any length. If more than one barcode sequence is used, the barcode sequences can independently be of the same or different lengths, such as at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 50 nucleotides in length. In some embodiments, the barcode sequence can be no more than 120, no more than 112, no more than 104, no more than 96, no more than 88, no more than 80, no more than 72, no more than 64, no more than 56, no more than 48, no more than 40, no more than 32, no more than 24, no more than 16, or no more than 8 nucleotides in length. Any combination of these is also possible, for example, the barcode sequence can be between 5 and 10 nucleotides, between 8 and 15 nucleotides, etc.
[0439] The barcode sequence can be arbitrary or random. In some cases, the barcode sequence is selected to reduce or minimize homology with other components in the sample, for example, so that the barcode sequence itself does not bind or hybridize with other nucleic acids suspected to be in the cell or other sample. In some embodiments, the homology between a specific barcode sequence and another sequence (e.g., a cell nucleic acid sequence in the sample or other barcode sequences in a probe added to the sample) may be less than 10%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2% or less than 1%. In some embodiments, the homology may be less than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3 or 2 bases, and in some embodiments, the bases are continuous bases.
[0440] In some embodiments, the number of different barcode sequences in a nucleic acid probe population is less than the number of different targets (e.g., nucleic acid analytes and / or protein analytes) of the nucleic acid probes, but different targets can still be uniquely identified from each other, for example, by encoding the probes with different combinations of barcode sequences. However, it is not necessary to use all possible combinations of a given set of barcode sequences. For example, each probe may contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, etc. or more barcode sequences. In some embodiments, nucleic acid probe populations may each contain the same number of barcode sequences, but in other cases, different numbers of barcode sequences may exist on different probes. In some embodiments, the barcode sequences in a nucleic acid probe population or any subset thereof may be detected and / or decoded independently and / or in combination.
[0441] IV. Ligation, Extension and Amplification
[0442] In some aspects, after forming a hybridization complex comprising the nucleic acid probe and / or probe set described in Section III and the target nucleic acid, the assay further comprises one or more steps, such as connection, extension and / or amplification of the probe or probe set hybridized to the target nucleic acid. In some embodiments, the methods of the present disclosure include a step of performing rolling circle amplification in the presence of a target nucleic acid of interest.
[0443] In some embodiments, the method includes using a circular or circularizable construct hybridized with a target nucleic acid comprising a region of interest to generate a product (e.g., a sequence comprising a region of interest or one or more barcode sequences associated with a target nucleic acid). In some aspects, RCA is used to generate a product. In any embodiment herein, the method may include connecting the end of a circularizable probe or probe set (e.g., a padlock probe) hybridized with a target RNA to form a circularized probe (e.g., a circularized padlock probe). In any embodiment herein, the method may also include a rolling circle amplification product that produces a circularized padlock probe. In some embodiments, RCA includes linear RCA. In some embodiments, RCA includes branched RCA. In some embodiments, RCA includes dendritic RCA. In some embodiments, RCA includes any combination of the foregoing. In any embodiment herein, the method may also include detecting a signal associated with a rolling circle amplification product in a biological sample. In some aspects, a connection product or a derivative thereof (e.g., an extension product) may be detected. In some cases, RCA is not performed.
[0444] In some embodiments, the circular construct is directly hybridized with the target nucleic acid. In some embodiments, the circular construct is formed by a circularizable probe or probe group (e.g., a padlock probe). In some embodiments, the circular construct is formed by a probe or probe group capable of DNA template connection. See, for example, U.S. Patent 8,551,710, the content of which is hereby incorporated by reference in its entirety. In some embodiments, the circular construct is formed by a probe or probe group capable of RNA template connection. Exemplary RNA template connection probes and methods are described in US2020 / 022424, which is hereby incorporated by reference in its entirety. In some embodiments, the circular construct is formed by a specific amplification of nucleic acid by intramolecular connection (e.g., SNAIL) probe groups. See, for example, U.S. Patent Publication 20190055594, the content of which is hereby incorporated by reference in its entirety. In some embodiments, the circular construct is formed by a probe capable of proximity connection (e.g., RNA proximity connection determination (e.g., PLAYR) probe group). See, e.g., U.S. Patent Publication 20160108458, the contents of which are hereby incorporated by reference in their entirety.
[0445] In some embodiments, the circular construct can hybridize indirectly to the target nucleic acid.In some embodiments, the circular construct is formed from a probe set capable of proximity ligation (eg, a proximity ligation in situ hybridization (PLISH) probe set).
[0446] In some embodiments, the cyclization step may include a connection selected from the group consisting of enzymatic ligation, chemical ligation, template-dependent ligation, and / or template-independent ligation. In any embodiments herein, the connection may include the use of a ligase having RNA-templated DNA ligase activity and / or RNA-templated RNA ligase activity. In any embodiments herein, the connection may include the use of a ligase selected from the group consisting of Chlorella virus DNA ligase (PBCV DNA ligase), T4 RNA ligase, T4 DNA ligase, and single-stranded DNA (ssDNA) ligase. In any embodiments herein, the connection may include the use of a PBCV-1 DNA ligase or a variant or derivative thereof and / or T4 RNA ligase 2 (T4 Rn12) or a variant or derivative thereof.
[0447] In the presence of suitable dNTP precursors and other cofactors, after adding DNA polymerase, extend the amplification primer (for example, to produce a concatemer of template) by duplicating multiple copies of the template. Secondary and higher-order probes and detection oligonucleotides such as described herein can be used to detect the amplification product. In some embodiments, for example, by using a detectably labeled probe and imaging to determine or otherwise analyze the sequence of amplicon or its part. The analysis of the amplification product can include sequencing while hybridizing, sequencing while connecting and / or fluorescence in situ detection, and / or wherein in situ hybridization includes sequential fluorescence in situ hybridization. In some cases, use secondary and higher-order probes and detection oligonucleotides such as described herein to carry out in situ detection.
[0448] In any embodiment herein, the method may also include the product of generating the circularized probe in situ in the biological sample. In any embodiment herein, rolling circle amplification (RCA) may be used to generate the product. In any embodiment herein, RCA may include linear RCA, branched RCA, dendritic RCA or any combination thereof. In any of the embodiments herein, the product can be produced using a polymerase selected from the group consisting of Phi29 DNA polymerase, Phi29-like DNA polymerase, M2 DNA polymerase, B103 DNA polymerase, GA-1 DNA polymerase, phi-PRD1 polymerase, Vent DNA polymerase, Deep Vent DNA polymerase, Vent (exo-) DNA polymerase, KlenTaq DNA polymerase, DNA polymerase I, Klenow fragment of DNA polymerase I, DNA polymerase III, T3 DNA polymerase, T4 DNA polymerase, T5 DNA polymerase, T7 DNA polymerase, Bst polymerase, rBST DNA polymerase, N29 DNA polymerase, TopoTaq DNA polymerase, T7 RNA polymerase, SP6 RNA polymerase, T3 RNA polymerase, and variants or derivatives thereof.
[0449] In any of the embodiments herein, the product may be immobilized in a biological sample. In any of the embodiments herein, the product may be cross-linked to one or more other molecules in a biological sample.
[0450] In some aspects, during the amplification step, modified nucleotides can be added to the reaction to incorporate the modified nucleotides into the amplification product (e.g., nanospheres). Examples of modified nucleotides include amine-modified nucleotides. In some aspects of the method, for example, for anchoring or cross-linking the generated amplification product (e.g., nanospheres) to a scaffold, a cell structure, and / or other amplification products (e.g., other nanospheres). In some aspects, the amplification product comprises modified nucleotides, such as amine-modified nucleotides. In some embodiments, the amine-modified nucleotides comprise acrylic acid N-hydroxysuccinimide moiety modification. Examples of other amine-modified nucleotides include, but are not limited to, 5-aminoallyl-dUTP moiety modification, 5-propargylamino-dCTP moiety modification, N 6 -6-aminohexyl-dATP partial modification or 7-deaza-7-propargylamino-dATP partial modification.
[0451] In some respects, polynucleotide and / or amplified product (e.g., amplicon) can be anchored to a polymer matrix. For example, the polymer matrix can be a hydrogel. In some embodiments, one or more polynucleotide probes can be modified to contain a functional group that can be used as an anchoring site for attaching polynucleotide probes and / or amplified product to the polymer matrix.
[0452] Exemplary modifications and polymer matrices that can be employed in accordance with the provided embodiments include, for example, those described in WO 2014 / 163886, WO 2014 / 025392, US 2017 / 0219465, US 2021 / 0215581, WO 2017 / 079406, US10138509, US2016 / 0024555, US2018 / 0251833, US2019 / 0276881, US2020 / 0071751, WO 2020 / 0076976, WO 2020 / 0076979, and WO 2020 / 0096687, all of which are incorporated herein by reference in their entirety. In some examples, the scaffold further comprises a modification or functional group capable of reacting with or incorporating a modification or functional group of the probe set or amplification product. In some examples, the scaffold may comprise an oligonucleotide, a polymer or a chemical group to provide a matrix and / or support structure.
[0453] V. Detection and Analysis
[0454] In some embodiments, the method disclosed herein includes using a plurality of primary probes to detect one or more target nucleic acids in a sample (e.g., genomic DNA, cellular RNA such as mRNA, cDNA, viral DNA or RNA, nucleic acid probes, reporter oligonucleotides attached to functional portions such as binding portions, or their products), wherein the primary probes are configured to hybridize with one or more target nucleic acids, wherein each primary probe comprises (i) a target hybridization region configured to hybridize with different target regions in the corresponding target nucleic acid, and (ii) a barcode region. In some embodiments, the sample is contacted with a plurality of detectable probes, wherein each detectable probe is configured to hybridize with a barcode sequence in the barcode region of (i) a plurality of primary probes, or (ii) a complementary sequence of the barcode sequence. In some embodiments, the method further includes detecting a signal or its absence associated with a plurality of detectable probes at one or more positions in the sample. In some embodiments, the sample is contacted with a plurality of subsequent detectable probes, wherein each of the subsequent multiple probes is configured to hybridize with a subsequent barcode sequence in the barcode region of (i) a plurality of primary probes, or (ii) a complementary sequence of the subsequent barcode sequence. In some embodiments, the method further comprises detecting a subsequent signal or its absence associated with a subsequent plurality of detectable probes at one or more positions in the sample. In some embodiments, the method further comprises generating a signal code sequence, the signal code sequence comprising a signal code corresponding to a signal or its absence at one or more positions and a subsequent signal or its absence, respectively, wherein the signal code sequence corresponds to one of the one or more target nucleic acids, thereby identifying the target nucleic acid at one or more positions in the sample.
[0455] In some embodiments, in situ detection of one or more target nucleic acids in a sample is performed using sequential hybridization of a detectable probe to a plurality of primary probes, and using signals associated with the sequentially hybridized detectable probes to decode signal code sequences, each of which is assigned to one of the one or more target nucleic acids in the sample. Each primary probe can be selected from a number of conductive groups: a probe comprising a 3' or 5' overhang (e.g., an L-shaped probe), optionally wherein the 3' or 5' overhang comprises one or more barcode sequences; a probe comprising a 3' overhang and a 5' overhang (e.g., a U-shaped probe), optionally wherein the 3' overhang and the 5' overhang each independently comprise one or more barcode sequences; a circularized probe; a circularizable probe or probe set; a probe or probe set comprising a segmented hybridization region configured to hybridize to a splint, optionally wherein the segmented hybridization region comprises one or more barcode sequences; and combinations thereof.
[0456] In some embodiments, the method includes generating a signal code sequence at one or more locations in the sample, the signal code sequence comprising a signal code corresponding to a signal (or the absence thereof) associated with a detectable probe for in situ hybridization sequentially applied to the sample, wherein the signal code sequence corresponds to an analyte in the sample, thereby detecting the analyte at one or more locations among a plurality of locations in the sample.
[0457] In some embodiments, the present disclosure relates to the use of probe hybridization cycles to detect nucleic acid sequences in situ and generate an amplified signal associated with the probe, wherein the background signal is reduced and the sensitivity is increased.
[0458] Exemplary in situ detection methods include targeted deposition of detectable reactive molecules around probe hybridization sites, targeted assembly of branched structures (e.g., bDNA or branched assays using locked nucleic acids (LNA)), programmed in situ growth of concatemers by enzymatic rolling circle amplification (RCA) (e.g., as described in US2019 / 0055594, which is incorporated herein by reference), hybridization chain reaction, assembly of topological concatenated DNA structures using consecutive rounds of chemical ligation (clampFISH), signal amplification by hairpin-mediated concatenation (e.g., as described in US2020 / 0362398, which is incorporated herein by reference), such as primer exchange reactions, such as signal amplification by exchange reactions (SABER) or SABER with DNA exchange (exchange-SABER). In some embodiments, non-enzymatic signal amplification methods can be used.
[0459] In some embodiments, the method disclosed herein includes generating a rolling circle amplification (RCA) product associated with one or more target nucleic acids in a sample. In some embodiments, the RCA product is detected in situ in the sample to detect one or more target nucleic acids. In some embodiments, each RCA product comprises a plurality of complementary copies of a barcode sequence, wherein the barcode sequence is associated with the target nucleic acid in the sample and is assigned a signal code sequence. In some embodiments, the method includes contacting the sample with a first detectable probe, the first detectable probe comprising (i) a recognition sequence complementary to a sequence in a complementary copy of the barcode sequence and (ii) a reporter. In some embodiments, the method includes detecting a first signal or a lack thereof of a reporter of a first detectable probe hybridized with a corresponding sequence of a complementary copy of a barcode sequence in an RCA product, wherein the first signal or a lack thereof corresponds to a first signal code in a signal code sequence. In some embodiments, the method includes contacting the sample with a subsequent detectable probe, the detectable probe comprising (i) a recognition sequence complementary to a sequence in a complementary copy of a barcode sequence and (ii) a reporter. In some embodiments, the method includes detecting a subsequent signal or lack thereof from a reporter of a subsequent detectable probe hybridized to a corresponding sequence of a complementary copy of the barcode sequence in the RCA product, wherein the subsequent signal or lack thereof corresponds to a subsequent signal code in the signal code sequence. In some embodiments, a signal code sequence comprising a first signal code and a subsequent signal code is determined at a position in the sample, thereby decoding the barcode sequence and identifying a target nucleic acid at the position in the sample.
[0460] In some embodiments, the barcode sequence comprises one or more barcode positions, each position comprising one or more barcode subunits. In some embodiments, the barcode position in the barcode sequence partially overlaps with the adjacent barcode position in the barcode sequence. In some embodiments, the first detectable probe and the subsequent detectable probe are in a group of detectable probes, and each probe comprises the same recognition sequence and reporter. In some embodiments, the reporter of each detectable probe in the group comprises a binding site for a reporter probe containing a detectable portion. In some embodiments, the reporter probe binding site of the first detectable probe and the reporter probe binding site of the subsequent detectable probe are the same. In some embodiments, the reporter probe binding site of the first detectable probe and the reporter probe binding site of the subsequent detectable probe are different. In some embodiments, the detectable portion is a fluorophore, and the signal code sequence is the only fluorophore sequence assigned to the target nucleic acid. In some embodiments, the detectable probes in the group are contacted with the sample in a predetermined order, and the predetermined order corresponds to the signal code sequence assigned to the barcode sequence. In some embodiments, the detectable probes in the set are contacted with the sample to determine the signal codes in the signal code sequence until sufficient signal codes have been determined to decode the barcode sequence, thereby identifying the target nucleic acid.
[0461] Detectable reactive molecules can include tyramide, such as for tyramide signal amplification (TSA) or multiple catalytic reporter deposition (CARD)-FISH. In some embodiments, detectable reactive molecules can be released and / or cut from detectable labels such as fluorophores. In some embodiments, methods disclosed herein include multiplex analysis of biological samples, including continuous cycles of probe hybridization, fluorescence imaging and signal removal, wherein the signal removal includes removing fluorophores from fluorophore-labeled reactive molecules (e.g., tyramide). Exemplary detectable reaction reagents and methods are described in US 6,828,109, US2019 / 0376956, WO 2019 / 236841, WO 2020 / 102094, WO 2020 / 163397 and WO 2021 / 067475, all of which are incorporated herein by reference in their entirety.
[0462] In some embodiments, hybridization chain reaction (HCR) can be used for in situ signal detection.HCR is an enzyme-free nucleic acid amplification based on the hybridization trigger chain of nucleic acid molecules, starting from HCR monomers, these monomers hybridize to form a nicked nucleic acid polymer.The polymer is the product of HCR reactions, which is ultimately detected to indicate the presence of a target analyte. HCR is described in detail in the following literature: Dirks and Pierce, 2004, PNAS, 101 (43), 15275-15278; and US 7,632,641 and US 7,721,721 (see also US 2006 / 00234261; Chemeris et al., 2008 Doklady Biochemistry and Biophysics, 419, 53-55; Niu et al., 2010, 46, 3089-3091; Choi et al., 2010, Nat. Biotechnol. 28 (11), 1208-1212; and Song et al., 2012, Analyst, 137, 1396-1401). HCR monomers typically contain hairpins or other metastable nucleic acid structures. In the simplest HCR form, when introducing " initiator " nucleic acid molecule, two different types of stable hairpin monomers (here referred to as the first and second HCR monomers) experience hybridization chain reaction events, forming a double-stranded DNA molecule with long nicks.HCR monomer has a hairpin structure, which comprises a double-stranded stem region, a loop region connecting two chains in the stem region and a single-stranded region at one end of the double-stranded stem region.When monomer is in a hairpin structure, the single-stranded region exposed (and therefore can be used for hybridization with another molecule such as initiator or other HCR monomers) can be referred to as "foothold region" (or "input domain").The first HCR monomer also includes a sequence complementary to the sequence in the foothold region exposed with the second HCR monomer.This complementary sequence in the first HCR monomer can be referred to as "interaction region" (or "output domain").Similarly, the second HCR monomer includes an interaction region (output domain) each, such as a sequence complementary to the foothold region (input domain) exposed with the first HCR monomer. In the absence of HCR initiators, these interaction regions are protected by secondary structures (e.g., they are not exposed), so hairpin monomers are stable or dynamically trapped (also referred to as "metastable"), and remain as monomers (e.g., to prevent rapid system equilibrium), because the first and second groups of HCR monomers cannot hybridize with each other. However, once an initiator is introduced, it is able to hybridize with the exposed foothold region of the first HCR monomer, and invade it, causing it to open. This will expose the interaction region of the first HCR monomer (e.g., a sequence complementary to the foothold region of the second HCR monomer), thereby allowing it to hybridize with the second HCR monomer at the foothold region and invade the second HCR monomer.This hybridization and invasion and then open the second HCR monomer, expose its interaction zone (it is complementary to the foothold zone of the first HCR monomer), and allow it to hybridize with another first HCR monomer and invade another first HCR monomer.Reaction continues in this way, until all HCR monomers are exhausted (for example, all HCR monomers are incorporated into polymer chain).Finally, this chain reaction causes the notched chain of the alternating unit forming the first and second monomer species.Therefore, it is necessary to have the presence of HCR initiator in order to trigger HCR reaction by hybridizing with the first HCR monomer and invading the first HCR monomer.The first and second HCR monomers are designed to hybridize each other and therefore can be defined as homologous to each other.They are also homologous to given HCR initiator sequence.The HCR monomer interacting with each other (hybridization) can be described as a group of HCR monomer or HCR monomer or hairpin system.
[0463] The HCR reaction can be carried out with more than two kinds or types of HCR monomers. For example, a system involving three HCR monomers can be used. In such a system, each first HCR monomer can include an interaction zone combined with the foothold area of the second HCR monomer; each second HCR can include an interaction zone combined with the foothold area of the third HCR monomer; and each third HCR monomer can include an interaction zone combined with the foothold area of the first HCR monomer. Then, the HCR polymerization reaction will be carried out as described above, except that the resulting product will be a polymer with a continuous repeating unit of the first, second and third monomers. It is easy to think of a corresponding system with a large amount of HCR monomer groups. Branched HCR systems have also been designed and described (see, for example, WO 2020 / 123742, incorporated herein by reference), and they can be used in the method herein.
[0464] In some embodiments, similar to the HCR reaction using hairpin monomers, linear oligo hybridization chain reaction (LO-HCR) can be used for in situ signal detection. In some embodiments, a method for detecting an analyte in a sample is provided herein, comprising: (i) performing a linear oligonucleotide hybridization chain reaction (LO-HCR), wherein an initiator is contacted with a plurality of LO-HCR monomers of at least the first and second species to generate a polymerized LO-HCR product hybridized with a target nucleic acid molecule, wherein the first species comprises a first hybridization region complementary to the initiator and a second hybridization region complementary to the second species, wherein the first species and the second species are linear single-stranded nucleic acid molecules; wherein the initiator is provided in one or more parts and is directly or indirectly hybridized with the target nucleic acid molecule or is contained in the target nucleic acid molecule; and (ii) detecting the polymer product, thereby detecting the analyte. In some embodiments, the first species and / or the second species may not contain a hairpin structure. In some embodiments, the plurality of LO-HCR monomers may not contain a metastable secondary structure. In some embodiments, the LO-HCR polymer may not contain a branched structure. In some embodiments, performing a linear oligonucleotide hybridization chain reaction comprises contacting the target nucleic acid molecule with an initiator to provide the initiator to hybridize to the target nucleic acid molecule.In any of the embodiments herein, the target nucleic acid molecule and / or the analyte may be an RCA product.
[0465] In some embodiments, the in situ detection of nucleic acid sequences includes generating components for branch signal amplification. In some embodiments, the component complex includes an amplification product that is directly or indirectly (via one or more oligonucleotides) hybridized with the sequence of the RCA product. In some embodiments, the component includes one or more amplification products, each of which includes amplification repeats. In some aspects, the one or more amplification products are labeled. This article describes a method for using the aforementioned components, which includes, for example, using the component in multiple error robust fluorescence in situ hybridization (MERFISH) applications, wherein branch DNA amplification is used for signal readout. In some embodiments, the amplification repeats are about 5-30 nucleotides and are repeated N times in the amplification product. In some embodiments, the amplification repeats are about 20 nucleotides and are repeated at least twice in the amplification product. In some aspects, the one or more amplification repeats are labeled. For exemplary branch signal amplification, see, for example, U.S. Patent Publication No. US20200399689A1 and Xia et al., Multiplexed Detection of RNA using MERFISHand branched DNA amplification.Scientific Reports (2019), each of which is fully incorporated herein by reference.
[0466] In some embodiments, the in situ detection of nucleic acid sequence includes primer exchange reaction (PER). In various embodiments, a primer with a domain at its 3' end is combined with a catalytic hairpin, and a new domain is extended by a strand displacement polymerase. For example, a primer with domain 1 at its 3' end is combined with a catalytic hairpin, and a new domain 1 is extended by a strand displacement polymerase, and a concatemer of a repeating domain 1 sequence is generated by repeated cycles. In various embodiments, the strand displacement polymerase is Bst. In various embodiments, the catalytic hairpin includes a stopper for releasing a strand displacement polymerase. In various embodiments, branch migration displaces the extended primer, which can then dissociate. In various embodiments, primers undergo repeated cycles to form concatemer primers. In various embodiments, a variety of concatemer primers are contacted with a sample comprising an RCA product produced using the method described herein. In various embodiments, RCA products can be contacted with multiple concatemer primers and multiple labeled probes. Regarding exemplary molecules and PER reaction components, see, for example, U.S. Patent Publication No. US20190106733, the contents of which are incorporated herein by reference.
[0467] In some embodiments, the sample is contacted with a detectable probe or probe group for in situ detection. In some embodiments, the detectable probe or probe group is circular or cyclizable, to generate a cyclized template. In some embodiments, the circular probe or cyclized template is used to generate an RCA product. In some embodiments, the detectable probe or probe group can include the region as the initiator of hybridization chain reaction (HCR) or the initiator hybridization with HCR. In some embodiments, the detectable probe or probe group can include the region as the initiator of linear oligonucleotide hybridization chain reaction (LO-HCR) or the initiator hybridization with LO-HCR. In some embodiments, the detectable probe or probe group can include the region as the primer of primer exchange reaction (PER) or the primer hybridization with PER. In some embodiments, the detectable probe or probe group can include the region as the preamplifier of branched DNA (bDNA) or the preamplifier hybridization with bDNA.
[0468] In some cases, the detectable probes disclosed herein may comprise one or more features and / or be modified based on the following features: a split FISH probe or probe set described in WO 2021 / 167526A1 or Goh et al., "Highly specific multiplexed RNA imaging in tissues with split-FISH," Nat Methods 17(7):689-693 (2020), all of which are incorporated herein by reference in their entirety; a Z-probe or probe set, such as a probe or probe set described in US 7,709,198 B2, US 8,604,182 B2, US 8,951,726 B2, US 8,658,361 B2 or Tripathi et al., "ZProbe, An Efficient Tool for Characterizing Long Non-Coding RNA in FFPET issues," Noncoding RNA 4(3):20 (2018), all of which are incorporated herein by reference in their entirety;HCR initiators or amplifiers, such as in US 7,632,641 B2, US2017 / 0009278 A1, US10,450,599 B2, Dirks and Pierce, "Triggered amplification by hybridization chain reaction," PNAS 101 (43): 15275-15278 (2004), Chemeris et al., "Real-time hybridization chain reaction," Dokl. Biochem 419: 53-55 (2008), Niu et al., "Fluorescence detection for DNA using hybridization chain reaction with enzyme-amplification," Chem Commun (Camb) 46 (18): 3089-91 (2010), Choi et al., "Programmable in situ amplification for multiplexed imaging of mRNA expression," Nat Biotechnol 28(11):1208-12(2010), Song et al., "Hybridization chain reaction-based aptameric system for the highly selective and sensitive detection of protein," Analyst 137(6):1396-401(2012), Choi et al., "Third-generation in situ hybridization chain reaction: multiplexed, quantitative, sensitive, versatile, robust," Development 145(12):dev165753(2018), or Tsuneoka and Funato, "Modified in situ Hybridization Chain Reaction Using Short Hairpin DNAs," Front Mol Neurosci 13:75(2020), all of which are incorporated herein by reference in their entirety;PLAYR probes or probe sets, such as those described in US2016 / 0108458 A1 or Frei et al., "Highly multiplexed simultaneous detection of RNAs and proteins in single cells," Nat Methods 13(3):269-75 (2016), all of which are incorporated herein by reference in their entirety; PLISH probes or probe sets, such as those described in US2020 / 0224243 A1 or Nagendran et al., "Automated cell-type classification in intact tissues by single-cell molecular profiling," eLife 7:e30510 (2018), all of which are incorporated herein by reference in their entirety; RollFISH probes or probe sets, such as those described in Wu et al., "RollFISH achieves robust quantification of single-molecule RNA biomarkers in paraffin-embedded tumor tissue samples," Commun Biol 1,209 (2018), the contents of which are incorporated herein by reference in their entirety; MERFISH probes or probe sets, such as those described in WO2020 / 123742 A1 (PCT / US2019 / 065857) or Chen et al., "Spatially resolved, highly multiplexed RNA profiling in single cells," Science 348(6233):aaa6090 (2015), all of which are incorporated herein by reference in their entirety; or primer exchange reaction (PER) probes or probe sets, such as those described in US2019 / 0106733 A1, the contents of which are incorporated herein by reference in their entirety. ;
[0469] In some embodiments, methods disclosed herein include detecting all or part of an amplified product, such as one or more barcode sequences present in an amplified product. In some embodiments, detection or determination include hybridization of a detectable probe (such as a detection oligonucleotide) labeled with a fluorophore, an isotope, a mass label, or a combination thereof with an amplified product. In some embodiments, detection or determination include imaging the amplified product. In some embodiments, the target nucleic acid is the mRNA in a tissue sample, and the target nucleic acid and / or the amplified product are detected or determined when they are located in situ in a tissue sample. In some embodiments, methods disclosed herein include detecting a polymer generated by a hybridization chain reaction (HCR) reaction, for exemplary probes and HCR reaction components, see, for example, US 2017 / 0009278, which is incorporated herein by reference.
[0470] In some embodiments, the in situ detection herein may include sequencing performed in situ by synthetic sequencing (SBS). In some embodiments, the sequencing primer is complementary to a sequence at or near one or more barcodes. In such embodiments, synthetic sequencing may include reverse transcription and / or amplification to generate a template sequence to which a primer sequence may bind. Exemplary SBS methods include, for example, but are not limited to, those described in US2007 / 0166705, US2006 / 0188901, US 7,057,026, US2006 / 0240439, US2006 / 0281109, WO 05 / 065814, US 2005 / 0100900, WO 06 / 064199, WO07 / 010,251, US2012 / 0270305, US2013 / 0260372, and US2013 / 0079232, all of which are incorporated herein by reference in their entirety.
[0471] In some embodiments, the in situ detection herein may include sequential hybridization, such as sequencing by hybridization and / or sequential in situ fluorescent hybridization.Sequential fluorescent hybridization may be related to the sequential hybridization of detectable probes comprising oligonucleotides and detectable labels.In some embodiments, the method disclosed herein includes the sequential hybridization of detectable probes disclosed herein, including detectably labeled probes (e.g., fluorophore conjugated oligonucleotides) and / or itself not detectably labeled but can be combined with detectably labeled probes (e.g., via nucleic acid hybridization) and detected by detectably labeled probes.Exemplary methods for sequential fluorescent hybridization comprising detectable probes are described in US 2019 / 0161796, US2020 / 0224244, US2022 / 0010358, US 2021 / 0340618, WO 2021 / 138676 and US2023 / 0039899, all of which are incorporated herein by reference.
[0472] In some embodiments, the in situ detection herein may include sequencing by connection. Such technology utilizes DNA ligase to incorporate oligonucleotides and identify the incorporation of such oligonucleotides. Oligonucleotides generally have different tags associated with the identity of specific nucleotides in the sequence to which the oligonucleotides hybridize. Aspects and features involved in sequencing while connecting are described in, for example, Shendure et al., Science (2005), 309: 1728-1732, and US 5,599,675; US 5,750,341; US 6,969,488; US 6,172,218; US 6,306,597, all of which are incorporated herein by reference in their entirety.
[0473] In some embodiments, the barcode of the detectable probe is targeted by a detectably labeled detection oligonucleotide (such as a fluorescently labeled oligonucleotide). In some embodiments, one or more decoding schemes are used to decode signals (such as fluorescence) for sequence determination. In any embodiment herein, any suitable method or technique can be used to analyze barcodes (e.g., primary and / or secondary barcode sequences), including those described herein, such as RNA target sequential detection (RNASPOT), sequential fluorescence in situ hybridization (seqFISH), single molecule fluorescence in situ hybridization (smFISH), multiple error robust fluorescence in situ hybridization (MERFISH), hybridization-based in situ sequencing (HybISS), in situ sequencing, targeted in situ sequencing, fluorescence in situ sequencing (FISSEQ) or spatial resolution transcript amplicon readout mapping (STARmap). In some embodiments, the method provided herein includes analyzing barcodes by sequential hybridization and detection with multiple labeled probes (e.g., detection oligonucleotides). Exemplary decoding schemes are described in Eng et al., "Transcriptome-scale Super-Resolved Imaging in Tissues by RNA SeqFISH+," Nature 568(7751):235-239(2019); Chen et al., "Spatially resolved, highly multiplexed RNA profiling in single cells," Science; 348(6233):aaa6090(2015); US 10,457,980B2; US2016 / 0369329 A1; WO 2018 / 026873 A1; US 2017 / 0220733A1; US2021 / 0017587, all of which are incorporated by reference in their entirety. In some embodiments, these assays enable simultaneous signal amplification, combined decoding, and error correction schemes.
[0474] In some embodiments, nucleic acid hybridization can be used for in situ detection. These methods utilize labeled nucleic acid decoder probes complementary to at least a portion of the barcode sequence. Multiplexed decoding can be performed with a pool of many different probes with distinguishable labels. Non-limiting examples of nucleic acid hybridization sequencing are described in, for example, US 8,460,865 and Gunderson et al., Genome Research 14:870-877 (2004), all of which are incorporated herein by reference in their entirety.
[0475] In some embodiments, real-time monitoring of DNA polymerase activity can be used during sequencing. For example, nucleotide incorporation can be detected by fluorescence resonance energy transfer (FRET), such as, for example, Levene et al., Science (2003), 299, 682-686, Lundquist et al., Opt. Lett. (2008), 33, 1026-1028 and Korlach et al., Proc. Natl. Acad. Sci. USA (2008), 105, 1176-1181, all of which are incorporated herein by reference in their entirety.
[0476] In some aspects, analysis and / or sequence determination can be performed at room temperature to best preserve tissue morphology with low background noise and reduced errors. In some embodiments, analysis and / or sequence determination includes eliminating error accumulation as sequencing proceeds.
[0477] In some embodiments, analysis and / or sequence determination involves washing to remove unbound polynucleotides, after which the fluorescent product is revealed for imaging.
[0478] In some aspects, detection (including imaging) is performed using any of a number of different types of microscopy, such as confocal microscopy, two-photon microscopy, light-field microscopy, intact tissue expansion microscopy, and / or CLARITY TM -Optimized light sheet microscopy (COLM).
[0479] In some embodiments, fluorescence microscopy is used to detect and image a detectable probe or probe group. In some aspects, a fluorescence microscope is an optical microscope that uses fluorescence and phosphorescence instead of or in addition to reflection and absorption to study the properties of organic or inorganic substances. In fluorescence microscopy, the sample is illuminated with light of a wavelength that excites fluorescence in the sample. The fluorescence is then imaged by a microscope objective, and the fluorescence wavelength is usually longer than the illumination wavelength. Two filters can be used in this technology; an illumination (or excitation) filter that ensures that the illumination is close to monochromatic and at the correct wavelength, and a second emission (or barrier) filter that ensures that no excitation light source reaches the detector. Alternatively, these functions can all be achieved by a single dichroic filter. "Fluorescence microscope" includes any microscope that uses fluorescence to generate images, whether it is a simpler device like an epifluorescence microscope, or a more complex design like a confocal microscope, which uses optical sectioning to obtain better resolution of fluorescent images.
[0480] In some embodiments, confocal microscopy is used for detection and imaging of detectable probes or probe groups. Confocal microscopy uses point illumination and a pinhole in an optically conjugate plane in front of the detector to eliminate out-of-focus signals. Since only light generated by fluorescence very close to the focal plane can be detected, the optical resolution of the image, especially in the sample depth direction, is much better than that of wide-field microscopy. However, since much of the light from the sample fluorescence is blocked at the pinhole, this increase in resolution comes at the expense of reduced signal intensity - so long exposure times are usually required. Since only one point in the sample is illuminated at a time, 2D or 3D imaging requires scanning in the specimen with a regular raster (e.g., a rectangular pattern of parallel scan lines). The achievable thickness of the focal plane is primarily limited by the wavelength of the light used divided by the numerical aperture of the objective, but is also limited by the optical properties of the specimen. Thin optical sections make these types of microscopes particularly good at 3D imaging and surface profile analysis of samples. CLARITY TM - Optimized Light Sheet Microscopy (COLM) provides an alternative microscopy technique for rapid 3D imaging of large clarified samples. COLM interrogates large immunostained tissues, allowing for increased acquisition speeds and producing higher quality generated data.
[0481] Other types of microscopy that may be employed include bright field microscopy, oblique illumination microscopy, dark field microscopy, phase contrast microscopy, differential interference contrast (DIC) microscopy, reflection interference microscopy (also known as reflected interference contrast or RIC), single plane illumination microscopy (SPIM), ultra-high resolution microscopy, laser microscopy, electron microscopy (EM), transmission electron microscopy (TEM), scanning electron microscopy (SEM), reflection electron microscopy (REM), scanning transmission electron microscopy (STEM), and low voltage electron microscopy. (LVEM), scanning probe microscopy (SPM), atomic force microscopy (ATM), ballistic electron emission microscopy (BEEM), chemical force microscopy (CFM), conductive atomic force microscopy (C-AFM), electrochemical scanning tunneling microscopy (ECSTM), electrostatic force microscopy (EFM), fluid force microscopy (FluidFM), force modulation microscopy (FMM), feature-oriented scanning probe microscopy (FOSPM), Kelvin probe force microscopy (KPFM), magnetic force microscopy (MFM ), magnetic resonance force microscopy (MRFM), near-field scanning optical microscopy (NSOM) (or SNOM, scanning near-field optical microscopy, SNOM, piezoelectric response force microscopy (PFM), PSTM, photon scanning tunneling microscopy (PSTM), PTMS, photothermal microspectroscopy / microscopy (PTMS), SCM, scanning capacitance microscopy (SCM), SECM, scanning electrochemical microscopy (SECM), SGM, scanning gate microscopy (SGM), SHPM, scanning Hall probe microscopy ( The invention relates to the present invention to a method for the treatment of tissue damage and tissue structure. The invention relates to a method for the treatment of tissue damage and tissue structure. The invention relates to a method for the treatment of tissue damage and tissue structure. The invention relates to a method for the treatment of tissue damage and tissue structure.
[0482] In some aspects, the method provided includes imaging one or more parts of an amplification product (e.g., an amplicon) and / or a polynucleotide, for example, via combining one or more detectable probes and detecting a detectable label directly or indirectly attached thereto. In some embodiments, the detectable probe comprises a detectable label that can be measured and quantitative. The terms "label" and "detectable label" comprise a direct or indirect detectable portion associated with (e.g., conjugated thereto) a molecule to be detected, such as a detectable probe, including but not limited to a fluorophore, a radioisotope, a fluorescent agent, a chemiluminescent agent, an enzyme, an enzyme substrate, an enzyme cofactor, an enzyme inhibitor, a chromophore, a dye, a metal ion, a metal sol, a ligand (e.g., biotin or a hapten), etc.
[0483] The term "fluorophore" includes a substance or a portion thereof that can exhibit fluorescence within a detectable range. Specific examples of labels that can be used according to the provided embodiments include, but are not limited to, phycoerythrin, Alexa dyes, fluorescein, YPet, CyPet, Cascade blue, allophycocyanin, Cy3, Cy5, Cy7, rhodamine, dansyl, umbelliferone, Texas red, luminol, acridinium esters, biotin, green fluorescent protein (GFP), enhanced green fluorescent protein (EGFP), yellow fluorescent protein (YFP), enhanced yellow fluorescent protein (EYFP), blue fluorescent protein (BFP), red fluorescent protein (RFP), firefly luciferase, Renilla luciferase, NADPH, β-galactosidase, horseradish peroxidase, glucose oxidase, alkaline phosphatase, chloramphenicol acetyltransferase, and urease.
[0484] In some embodiments, detectable probes containing detectable labels can be used to detect one or more polynucleotides and / or amplification products (e.g., amplicons) described herein. In some embodiments, the method involves incubating a detectable probe containing a detectable label with a sample, washing unbound detectable probes, and detecting the label, e.g., by imaging.
[0485] Examples of detectable labels include, but are not limited to, various radioactive moieties, enzymes, prosthetic groups, fluorescent labels, luminescent labels, bioluminescent labels, metal particles, protein-protein binding pairs, and protein-antibody binding pairs. Examples of fluorescent proteins include, but are not limited to, yellow fluorescent protein (YFP), green fluorescent protein (GFP), cyan fluorescent protein (CFP), umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride, and phycoerythrin.
[0486] Examples of bioluminescent markers include, but are not limited to, luciferase (e.g., bacteria, fireflies, and click beetles), luciferin, aequorin, and the like. Examples of enzyme systems with visually detectable signals include, but are not limited to, beta-galactosidase, glucuronidase, phosphatase, peroxidase, and cholinesterase. Identifiable markers also include radioactive compounds, such as 125 I. 35 S. 14 C or 3 H.
[0487] Examples of fluorescent labels and nucleotides and / or polynucleotides conjugated to such fluorescent labels include those described in, for example, Hoagland, Handbook of Fluorescent Probes and Research Chemicals, Ninth Edition (Molecular Probes, Inc., Eugene, 2002); Keller and Manak, DNA Probes, Second Edition (Stockton Press, New York, 1993); Eckstein, ed., Oligonucleotides and Analogues: A Practical Approach (IRL Press, Oxford, 1991); and Wetmur, Critical Reviews in Biochemistry and Molecular Biology, 26: 227-259 (1991). In some embodiments, exemplary techniques and methods suitable for use in the embodiments provided include, for example, those described in US 4,757,141, US 5,151,507, and US 5,091,519. In some embodiments, one or more fluorescent dyes are used as labels for labeled target sequences, for example, as described in the following documents: US 5,188,934 (4,7-dichlorofluorescein dye); US 5,366,860 (spectrally resolvable rhodamine dye); US 5,847,162 (4,7-dichlororhodamine dye); US 4,318,846 (ether-substituted fluorescein dye); US 5,800,996 (energy transfer dye); US 5,066,580 (xanthine dye); and US 5,688,648 (energy transfer dye). Quantum dots can also be used for labeling, as described in the following documents: US 6,322,901, US 6,576,291, US 6,423,551, US 6,251,303, US 6,319,426, US 6,426,513, US 6,444,143, US 5,990,479, US 6,207,392, US 2002 / 0045045 and US2003 / 0017264. In any embodiment herein, "fluorescent labeling" includes a signal transduction portion that conveys information through the fluorescence absorption and / or emission characteristics of one or more molecules. Exemplary fluorescence properties include fluorescence intensity, fluorescence lifetime, emission spectrum characteristics and energy transfer.
[0488] Examples of commercially available fluorescent nucleotide analogs that are readily incorporated into nucleotide and / or polynucleotide sequences include, but are not limited to, Cy3-dCTP, Cy3-dUTP, Cy5-dCTP, Cy5-dUTP (Amersham Biosciences, Piscataway, NJ), fluorescein-2-dUTP, tetramethylrhodamine-6-dUTP, Texas Red TM -5-dUTP, CASCADE BLUE TM -7-dUTP, BODIPY TMFL-14-dUTP, BODIPY TMR-14-dUTP, BODIPY TMTR-14-dUTP, RHOD AMINE GREEN TM -5-dUTP、OREGON GREENR TM 488-5-dUTP, Texas Red TM -l2-dUTP, BODIPY TM 630 / 650-14-dUTP, BODIPY TM 650 / 665-14-dUTP、ALEXA FLUOR TM 488-5-dUTP、ALEXAFLUOR TM 532-5-dUTP、ALEXA FLUOR TM 568-5-dUTP、ALEXA FLUOR TM 594-5-dUTP、ALEXAFLUOR TM 546-14-dUTP, fluorescein-12-UTP, tetramethylrhodamine-6-UTP, Texas Red TM -5-UTP, mCherry, CASCADE BLUE TM -7-UTP, BODIPY TM FL-14-UTP, BODIPY TMR-14-UTP, BODIPY TM TR-14-UTP、RHOD AMINE GREEN TM -5-UTP、ALEXA FLUOR TM 488-5-UTP and ALEXA FLUOR TM 546-14-UTP (Molecular Probes, Inc. Eugene, Ore.).
[0489] Other fluorophores available for post-synthetic attachment include, but are not limited to, ALEXA FLUOR TM 350、ALEXAFLUORTM 532. ALEXA FLUOR TM 546. ALEXA FLUOR TM 568. ALEXA FLUOR TM 594、ALEXA FLUOR TM 647, BODIPY 493 / 503, BODIPY FL, BODIPY R6G, BODIPY 530 / 550, BODIPY TMR, BODIPY 558 / 568, BODIPY 558 / 568, BODIPY 564 / 570, BODIPY 576 / 589, BODIPY 581 / 591, BODIPY 630 / 650, BODIPY 650 / 665, Cascade Blue, Cascade Yellow, Dansyl, Lissamine Rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, Rhodamine 6G, Rhodamine Green, Rhodamine Red, Tetramethylrhodamine, Texas Red (available from Molecular Biology, Inc. Probes, Inc., Eugene, Oreg.), Cy2, Cy3.5, Cy5.5, and Cy7 (Amersham Biosciences, Piscataway, NJ). FRET tandem fluorophores can also be used, including but not limited to PerCP-Cy5.5, PE-Cy5, PE-Cy5.5, PE-Cy7, PE-Texas Red, APC-Cy7, PE-Alexa dyes (610, 647, 680), and APC-Alexa dyes.
[0490] In some cases, metallic silver or gold particles can be used to enhance the signal from fluorescently labeled nucleotide and / or polynucleotide sequences (Lakowicz et al. (2003) Bio Techniques 34:62).
[0491] Biotin or its derivatives can also be used as labels on nucleotides and / or polynucleotide sequences, and are subsequently bound by detectably labeled avidin / streptavidin derivatives (e.g., phycoerythrin-conjugated streptavidin) or detectably labeled anti-biotin antibodies. Digoxigenin can be incorporated as a label, and is subsequently bound by detectably labeled anti-digoxigenin antibodies (e.g., fluoresceinized anti-digoxigenin). Aminoallyl-dUTP residues can be incorporated into polynucleotide sequences, and subsequently coupled to fluorescent dyes derived from N-hydroxysuccinimide (NHS). In general, any member of the conjugate pair can be incorporated into the detection polynucleotide as long as the detectably labeled conjugated partner can be combined to allow detection. In any embodiment herein, the antibody comprises any class of antibody molecules or any subfragment thereof, such as Fab.
[0492] Other suitable labels for polynucleotide sequences can include fluorescein (FAM), digoxigenin, dinitrophenol (DNP), dansyl, biotin, bromodeoxyuridine (BrdU), hexahistidine (6xHis) and phosphor-amino acids (e.g., P-tyr, P-ser, P-thr). In some embodiments, the following hapten / antibody pairs are used for detection, wherein each antibody is derivatized with a detectable label: biotin / a-biotin, digoxigenin / a-digoxigenin, dinitrophenol (DNP) / a-DNP, 5-carboxyfluorescein (FAM) / a-FAM.
[0493] VI. Compositions and Kits
[0494] Also provided herein is a kit, for example, comprising one or more quenchers, such as described in Section I (B), comprising one or more detectable probes, such as described in Section I (D) or Section V, comprising one or more polynucleotides, such as any polynucleotide described in Section III, and reagents for performing the methods provided herein, such as reagents required for one or more steps of hybridization, connection, amplification, detection, sequencing and / or sample preparation described herein. In some embodiments, the kit also comprises a target nucleic acid, such as any target nucleic acid described in Section II. In some embodiments, any or all of the polynucleotides are DNA molecules. In some embodiments, the target nucleic acid is a messenger RNA molecule. In some embodiments, the kit also comprises one or more ligases, such as for forming a circular probe. In some embodiments, the kit also comprises a polymerase, such as a polymerase for amplifying the probe using any method described in Section IV. In some embodiments, the kit also comprises a primer for amplification. In some embodiments, the kit also comprises one or more detection reagents, such as those disclosed in Section V.
[0495] In some embodiments, disclosed herein is a kit for reducing autofluorescence in a biological sample, the kit comprising a quencher, wherein the quencher comprises a targeting moiety capable of reacting or binding to an endogenous biological moiety in the biological sample. In other embodiments, disclosed herein is a kit for reducing autofluorescence in a tissue sample, the kit comprising a quencher, wherein the quencher comprises a targeting moiety capable of reacting or binding to an endogenous biological moiety in the tissue sample.
[0496] In other embodiments, disclosed herein is a kit for analyzing a biological sample, the kit comprising a quencher, wherein the quencher comprises a targeting portion capable of reacting or binding to an endogenous biological moiety in the biological sample. In other embodiments, disclosed herein is a kit for analyzing a tissue sample, the kit comprising a quencher, wherein the quencher comprises a targeting portion capable of reacting or binding to an endogenous biological moiety in the tissue sample.
[0497] In some embodiments of any of the preceding embodiments, the kit can further comprise one or more detectable probes, optionally wherein the detectable probes are fluorescently labeled, optionally wherein the detectable probes are nucleic acid probes.
[0498] The various components of the kit may be present in separate containers, or certain compatible components may be pre-combined into a single container. In some embodiments, the kit also contains instructions for using the kit components to perform the provided methods.
[0499] In some embodiments, the test kit may contain reagents and / or consumables required for one or more steps of the method provided. In some embodiments, the test kit contains reagents for fixing, embedding and / or permeabilizing biological samples. In some embodiments, the test kit contains reagents, such as enzymes and buffers for connection and / or amplification, such as ligases and / or polymerases. In some respects, the test kit may also include any reagent as described herein, such as washing buffer and connection buffer. In some embodiments, the test kit contains reagents for detection and / or sequencing, such as detectable probes or detectable labels with bar codes. In some embodiments, the test kit optionally contains other components, such as nucleic acid primers, enzymes and reagents, buffers, nucleotides, modified nucleotides, reagents for other determinations.
[0500] VII. Application
[0501] Fluorescence detection in tissue samples is often hampered by the presence of strong background fluorescence. "Autofluorescence" is a general term used to distinguish background fluorescence (which can be caused by a variety of sources (including aldehyde fixation, extracellular matrix components, erythrocytes, lipofuscin, etc.) from the desired immunofluorescence of fluorescently labeled antibodies or probes. Tissue autofluorescence may make it difficult to distinguish signals caused by fluorescent antibodies or probes from general background. As described in detail herein, the present disclosure provides a method for reducing the autofluorescence of biological samples including tissue samples, thereby enabling the biological samples to be analyzed by fluorescence detection. The method of the present disclosure achieves this reduction of background autofluorescence by contacting the biological sample with a quencher having a targeting portion that can react or bind to one or more autofluorescent endogenous biological parts present in the biological sample. The interaction between the targeting portion and the autofluorescence source can be covalent in nature (e.g., forming a chemical bond), or can be driven by strong intermolecular forces (e.g., lipophilic attraction). Due to the targeted binding of the quencher to the autofluorescent endogenous biological part, the background fluorescence is significantly reduced and remains reduced in multiple imaging cycles. In some embodiments, the methods disclosed herein may include contacting a...
Claims
1. A method for reducing autofluorescence, comprising: (a) contacting a tissue sample with a quencher comprising a quencher dye and a targeting moiety, wherein the targeting moiety binds to and / or reacts with an endogenous biological moiety in the tissue sample, thereby targeting the quencher to the endogenous biological moiety; as well as (b) detecting a signal associated with a detectable probe that binds directly or indirectly to a molecule of interest in the tissue sample, wherein the quencher reduces autofluorescence in the tissue sample.
2. The method of claim 1, wherein the autofluorescence of the tissue sample is reduced compared to an unquenched tissue sample.
3. The method of claim 1 or 2, wherein the autofluorescence is reduced by at least about 50%, at least about 60%, at least about 70%, or at least about 80% compared to an unquenched tissue sample.
4. The method of any one of claims 1 to 3, wherein the signal associated with the detectable probe is detected at a location in the tissue sample, and the detected signal has an increased signal-to-noise ratio compared to an unquenched tissue sample.
5. The method of any one of claims 1 to 4, wherein the signal-to-noise ratio is increased by at least about 10%, at least about 20%, or at least about 25% compared to an unquenched tissue sample.
6. The method of any one of claims 1 to 5, wherein the detectable object count density associated with the tissue sample is increased compared to an unquenched tissue sample.
7. The method of any one of claims 1 to 6, wherein the detectable object count density is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, or at least about 5-fold compared to an unquenched tissue sample.
8. The method of any one of claims 1 to 7, wherein the tissue sample is contacted with the detectable probe in the detection step (b) before being contacted with the quencher in the contacting step (a).
9. The method of any one of claims 1 to 7, wherein the tissue sample is contacted with the detectable probe in the detecting step (b) after being contacted with the quencher in the contacting step (a).
10. The method of any one of claims 1 to 7, wherein the tissue sample is contacted with the detectable probe in the detecting step (b) and simultaneously contacted with the quencher in the contacting step (a).
11. The method of any one of claims 1 to 10, further comprising bleaching the tissue sample using a chemical reagent, an enzyme, light, heat, or any combination thereof before, simultaneously with, or after contacting in step (a).
12. The method of any one of claims 1 to 11, further comprising removing the detectable probe or a portion thereof from the tissue sample, wherein the quencher remains in the tissue sample.
13. The method of claim 12, wherein removing the detectable probe or a portion thereof comprises treating the tissue sample with a denaturing agent comprising dimethyl sulfoxide (DMSO), formamide, and / or an alkaline solution.
14. The method of any one of claims 1 to 13, further comprising contacting the tissue sample with one or more additional detectable probes, wherein each additional detectable probe directly or indirectly binds to additional molecules of interest in the tissue sample, and the additional molecules of interest are the same or different from the molecules of interest in the detection step (b).
15. The method of claim 14, further comprising detecting the one or more signals associated with the one or more additional detectable probes in the tissue sample, wherein the autofluorescence of the tissue sample remains reduced compared to an unquenched tissue sample.
16. The method of claim 14 or 15, wherein the one or more additional detectable probes are contacted with the tissue sample and the one or more signals associated with the one or more additional detectable probes are detected in one or more cycles.
17. The method of claim 16, wherein: After a given cycle, the quencher remains in the tissue sample and the autofluorescence of the tissue sample remains reduced compared to an unquenched tissue sample.
18. The method of claim 16 or 17, wherein the autofluorescence remains reduced by at least about 50%, at least about 60%, at least about 70%, or at least about 80% for a given cycle compared to an unquenched tissue sample.
19. The method of any one of claims 16 to 18, wherein the autofluorescence increases by less than about 5%, less than about 10%, or less than about 15% for a given cycle compared to a previous cycle.
20. The method of any one of claims 16 to 19, wherein: After a given cycle, the signal-to-noise ratio remains increased compared to the unquenched tissue sample.
21. The method of any one of claims 16 to 20, wherein for a given cycle, the signal-to-noise ratio remains increased by at least about 10%, at least about 20%, or at least about 25% compared to an unquenched tissue sample.
22. The method of any one of claims 16 to 21, wherein the signal-to-noise ratio decreases by less than about 5%, less than about 10%, or less than about 15% for a given cycle compared to the previous cycle.
23. The method of any one of claims 16 to 22, wherein for a given cycle, the detectable object count density remains increased compared to an unquenched tissue sample.
24. The method of any one of claims 16 to 23, wherein for a given cycle, the detectable object count density remains increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, or at least about 5-fold compared to an unquenched tissue sample.
25. The method of any one of claims 16 to 24, wherein the detectable object count density decreases by less than about 5%, less than about 10%, or less than about 15% for a given cycle compared to the previous cycle.
26. The method of any one of claims 16 to 25, comprising at least two, three, four, five, six or more cycles of contacting the tissue sample with the one or more additional detectable probes.
27. The method of any one of claims 1 to 26, further comprising staining the tissue sample.
28. The method of any one of claims 1 to 27, further comprising fixing the tissue sample.
29. The method of any one of claims 1 to 28, wherein the method further comprises decrosslinking the tissue sample.
30. A method for analyzing a biological sample, comprising: (a) contacting the biological sample with a quencher comprising a quencher dye and a targeting moiety, wherein the targeting moiety directly or indirectly binds to and / or reacts with an endogenous biological moiety of the biological sample, thereby targeting the quencher to the biological moiety; (b) contacting the biological sample with a detectable probe that directly or indirectly binds to a molecule of interest in the biological sample; as well as (c) detecting a signal associated with the detectable probe bound to the molecule of interest in the biological sample, wherein the quencher dye reduces autofluorescence of the biological sample, Thereby, the molecule of interest in the biological sample is detected.
31. The method of claim 30, wherein the quencher reduces the autofluorescence of the biological sample without substantially reducing the signal associated with the detectable probe.
32. The method of claim 30 or claim 31, wherein the autofluorescence of the biological sample is reduced compared to an unquenched biological sample.
33. The method of any one of claims 30 to 32, wherein the autofluorescence is reduced by at least about 50%, at least about 60%, at least about 70%, or at least about 80% compared to an unquenched biological sample.
34. The method of any one of claims 30 to 33, wherein the signal associated with the detectable probe is detected at a location in the biological sample, and the detected signal has an increased signal-to-noise ratio compared to an unquenched biological sample.
35. The method of any one of claims 30 to 34, wherein the signal-to-noise ratio is increased by at least about 10%, at least about 20%, or at least about 25% compared to an unquenched biological sample.
36. The method of any one of claims 30 to 35, wherein the detectable object count density associated with the biological sample is increased compared to an unquenched biological sample.
37. The method of any one of claims 30 to 36, wherein the detectable object count density is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, or at least about 5-fold compared to an unquenched biological sample.
38. The method of any one of claims 30 to 37, wherein the biological sample is contacted with the detectable probe in contacting step (b) prior to contacting with the quencher in contacting step (a).
39. The method of any one of claims 30 to 37, wherein the biological sample is contacted with the detectable probe in the contacting step (b) after being contacted with the quencher in the contacting step (a).
40. The method of any one of claims 30 to 37, wherein the biological sample is contacted with the detectable probe in the contacting step (b) and simultaneously contacted with the quencher in the contacting step (a).
41. The method of any one of claims 30 to 40, further comprising bleaching the biological sample with a chemical reagent, an enzyme, light, heat, or any combination thereof, before, simultaneously with, or after contacting in step (a).
42. The method of any one of claims 30 to 41, wherein: Prior to the contacting step (b), the method comprises contacting the biological sample with a nucleic acid probe that directly or indirectly binds to the molecule of interest in the biological sample, and wherein, in the contacting step (b), the detectable probe directly or indirectly binds to the nucleic acid probe.
43. The method of any one of claims 30 to 42, further comprising removing the detectable probe or a portion thereof from the biological sample, wherein the quencher remains in the biological sample.
44. The method of claim 43, wherein the removing step comprises treating the biological sample with a denaturing agent comprising dimethyl sulfoxide (DMSO), formamide and / or an alkaline solution.
45. The method of claims 30 to 44, further comprising contacting the biological sample with one or more additional detectable probes, wherein each additional detectable probe directly or indirectly binds to an additional molecule of interest in the biological sample, and the additional molecule of interest is the same or different from the molecule of interest in the contacting step (b).
46. The method of any of claim 45, further comprising detecting the one or more signals associated with the one or more additional detectable probes in the biological sample, wherein the autofluorescence of the biological sample remains reduced compared to an unquenched biological sample.
47. The method of claim 45 or 46, wherein the one or more additional detectable probes are contacted with the biological sample and the one or more signals associated with the one or more additional detectable probes are detected in one or more cycles.
48. The method of claim 47, wherein: After a given cycle, the quencher remains in the biological sample and the autofluorescence of the biological sample remains reduced compared to an unquenched biological sample.
49. The method of claim 47 or 48, wherein the autofluorescence remains reduced by at least about 50%, at least about 60%, at least about 70%, or at least about 80% for a given cycle compared to an unquenched biological sample.
50. The method of any one of claims 47 to 49, wherein the autofluorescence increases by less than about 5%, less than about 10%, or less than about 15% for a given cycle compared to a previous cycle.
51. The method of any one of claims 47 to 50, wherein: After a given cycle, the signal-to-noise ratio remains increased compared to the unquenched biological sample.
52. The method of any one of claims 47 to 51, wherein for a given cycle, the signal-to-noise ratio remains increased by at least about 10%, at least about 20%, or at least about 25% compared to an unquenched biological sample.
53. The method of any one of claims 47 to 52, wherein the signal-to-noise ratio decreases by less than about 5%, less than about 10%, or less than about 15% for a given cycle compared to the previous cycle.
54. The method of any one of claims 47 to 53, wherein for a given cycle, the detectable object count density remains increased compared to an unquenched biological sample.
55. The method of any one of claims 47 to 54, wherein for a given cycle, the detectable object count density remains increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, or at least about 5-fold compared to an unquenched biological sample.
56. The method of any one of claims 47 to 55, wherein the detectable object count density decreases by less than about 5%, less than about 10%, or less than about 15% for a given cycle compared to the previous cycle.
57. The method of any one of claims 47 to 56, comprising at least two, three, four, five, six or more cycles of contacting the biological sample with the one or more additional detectable probes.
58. The method of any one of claims 47 to 57, further comprising staining the biological sample.
59. The method of any one of claims 30 to 58, further comprising fixing the biological sample.
60. The method of any one of claims 30 to 59, further comprising decrosslinking the biological sample.
61. The method of any one of claims 30 to 60, wherein the biological sample is a tissue sample.
62. The method of any one of claims 1 to 61, wherein each detectable probe is capable of being independently detectably labeled or hybridizing to a detectably labeled probe.
63. The method of any one of claims 1 to 62, wherein the quencher further comprises a linker moiety linking the quencher dye and the targeting moiety.
64. The method of claim 63, wherein the linker moiety is an alkylene moiety, an aminoalkylene moiety, an amino(alkyl)alkylene moiety, a polyethylene glycol moiety, a disulfide moiety, or a carbamate moiety.
65. The method of any one of claims 1 to 64, wherein the quencher dye comprises: (a) at least three aromatic residues, wherein each aromatic residue is independently unsubstituted aryl, substituted aryl, unsubstituted heteroaryl or substituted heteroaryl, wherein at least one aromatic residue is covalently linked to two other aromatic residues via two exocyclic azo bonds; or (b) at least two aromatic residues, wherein each aromatic residue is independently unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, or substituted heteroaryl, wherein at least two of the aromatic residues are covalently linked via an exocyclic azo bond, wherein at least one of the aromatic residues is unsubstituted polycyclic aryl, substituted polycyclic aryl, unsubstituted polycyclic heteroaryl, or substituted polycyclic heteroaryl.
66. The method of any one of claims 1 to 65, wherein the quencher dye comprises an optionally substituted 1,4-bis((E)-phenyldiazenyl)benzene Partially or optionally substituted (E)-5-phenyl-3-(phenyldiazenyl)phenazin-5-ium moiety or a salt thereof.
67. The method of any one of claims 1 to 66, wherein the quencher has a UV-visible absorption spectrum as shown in Figure 1.
68. The method of any one of claims 1 to 66, wherein the quencher has a UV-visible absorption curve having at least one absorption peak having a maximum absorption of about 400 nm to 700 nm and a full width at half maximum of at least about 100 nm.
69. The method of any one of claims 1 to 68, wherein the quencher has a UV-visible absorption curve having at least one absorption peak having a maximum absorption of about 500 nm to about 600 nm and a full width at half maximum of at least about 100 nm.
70. The method of any one of claims 1 to 65 and 67 to 69, wherein the quencher is a compound of formula (I) or a salt thereof, wherein Each are independently selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; X a is H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 , -NO2, -SO3H, -SO3-, -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO or -L-(R 靶 ) w , where w is any integer such as 1 or 2; X c is H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO or -L-(R 靶 ) w , where w is any integer such as 1 or 2; Where R 1 and R 2 are independently H, C1-C6 alkyl or substituted C1-C6 alkyl; and Each R a and R c are independently H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2, -NO2, -SO3H, -SO3-, -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN or -NCO; Each R b are independently H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3-、-OSO2-C1-C6 alkyl、-OSO2-C1-C6 haloalkyl、-CN、-SCN、-NCO、R b1 or -L-(R 靶 ) w , where w is any integer such as 1 or 2; R b1 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; L is a bond or linker moiety; R 靶 is the targeting portion; m is an integer from 0 to 6; n is an integer from 0 to 6; and Each of x, y and z is independently an integer from 0 to 5; The condition is that at least one of m and n is non-zero; and the condition is that X a , X c or R b At least one of them is -L-(R 靶 ) w , where w is any integer such as 1 or 2.
71. A method for analyzing a tissue sample, comprising: (a) contacting the tissue sample with a nucleic acid probe that directly or indirectly binds to a molecule of interest in the tissue sample; (b) contacting the tissue sample with a quencher comprising a quencher dye and a targeting moiety, wherein the targeting moiety directly or indirectly binds to and / or reacts with an endogenous biological moiety in the tissue sample, thereby targeting the quencher to the biological moiety, wherein the quencher is a compound of formula (I) (I), or a salt thereof, wherein Each are independently selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; X a is H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 , -NO2, -SO3H, -SO3-, -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO or -L-(R 靶 ) w , where w is any integer such as 1 or 2; X c is H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO or -L-(R 靶 ) w , where w is any integer such as 1 or 2; Where R 1 and R 2 are independently H, C1-C6 alkyl or substituted C1-C6 alkyl; and Each R a and R c are independently H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN or -NCO; Each R b are independently H, halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy-C1-C6 alkylene, -NR 1 R 2 、-NO2、-SO3H、-SO3 - , -OSO2-C1-C6 alkyl, -OSO2-C1-C6 haloalkyl, -CN, -SCN, -NCO, R b1 or -L-(R 靶 ) w , where w is any integer such as 1 or 2; R b1 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; L is a bond or linker moiety; R 靶 is the targeting portion; m is an integer from 0 to 6; n is an integer from 0 to 6; and Each of x, y and z is independently an integer from 0 to 5; The condition is that at least one of m and n is non-zero; and the condition is that X a , X c or R b At least one of them is -L-(R 靶 ) w , where w is any integer such as 1 or 2; (c) contacting the tissue sample with a fluorescently labeled detectable probe, which directly or indirectly binds to the nucleic acid probe or an amplification product of the nucleic acid probe; as well as (d) detecting a signal associated with the fluorescently labeled detectable probe in the tissue sample, wherein the quencher dye reduces autofluorescence in the tissue sample, Thereby, the molecule of interest is detected in the tissue sample.
72. The method of claim 71, wherein the autofluorescence of the tissue sample is reduced compared to an unquenched tissue sample.
73. The method of claim 71 or 72, wherein the autofluorescence is reduced by at least about 50%, at least about 60%, at least about 70%, or at least about 80% compared to an unquenched tissue sample.
74. The method of any one of claims 71 to 73, wherein a signal associated with the detectable probe is detected at a location in the tissue sample, and the detected signal has an increased signal-to-noise ratio compared to an unquenched tissue sample.
75. The method of any one of claims 71 to 74, wherein the signal-to-noise ratio is increased by at least about 10%, at least about 20%, or at least about 25% compared to an unquenched tissue sample.
76. The method of any one of claims 71 to 75, wherein the detectable object count density associated with the quenched tissue sample is increased compared to the unquenched tissue sample.
77. The method of any one of claims 71 to 76, wherein the detectable object count density is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, or at least about 5-fold compared to an unquenched tissue sample.
78. The method of any one of claims 71 to 77, wherein the tissue sample is contacted with the detectable probe in contacting step (b) prior to contacting with the quencher in contacting step (a).
79. The method of any one of claims 71 to 77, wherein the tissue sample is contacted with the detectable probe in the contacting step (b) after being contacted with the quencher in the contacting step (a).
80. The method of any one of claims 71 to 77, wherein the tissue sample is contacted with the detectable probe in the contacting step (b) and simultaneously contacted with the quencher in the contacting step (a).
81. The method of any one of claims 71 to 80, further comprising bleaching the tissue sample with a chemical reagent, an enzyme, light, heat, or any combination thereof, before, simultaneously with, or after contacting in step (b).
82. The method of any one of claims 71 to 81, further comprising removing the detectable probe or a portion thereof from the tissue sample, wherein the quencher remains in the tissue sample.
83. The method of claim 82, wherein removing the detectable probe comprises treating the tissue sample with a denaturing agent comprising dimethyl sulfoxide (DMSO), formamide, and / or an alkaline solution.
84. The method of any one of claims 82 to 83, further comprising contacting the tissue sample with one or more additional detectable probes, wherein each additional detectable probe directly or indirectly binds to additional molecules of interest in the tissue sample, and the additional molecules of interest are the same or different from the molecules of interest in the contacting step (b).
85. The method of claim 84, further comprising detecting the one or more signals associated with the one or more additional detectable probes in the tissue sample, wherein the autofluorescence of the tissue sample remains reduced compared to an unquenched tissue sample.
86. The method of claim 84 or 85, wherein the one or more additional detectable probes are contacted with the tissue sample and the one or more signals associated with the one or more additional detectable probes are detected in one or more cycles.
87. The method of claim 86, wherein: After a given cycle, the quencher remains in the tissue sample and the autofluorescence of the tissue sample remains reduced compared to an unquenched tissue sample.
88. The method of claim 86 or 87, wherein the autofluorescence remains reduced by at least about 50%, at least about 60%, at least about 70%, or at least about 80% for a given cycle compared to an unquenched tissue sample.
89. The method of any one of claims 86 to 88, wherein for a given cycle, the autofluorescence increases by less than about 5%, less than about 10%, or less than about 15% compared to a previous cycle.
90. The method of any one of claims 86 to 89, wherein: After a given cycle, the signal-to-noise ratio remains increased compared to the unquenched tissue sample.
91. The method of any one of claims 86 to 90, wherein for a given cycle, the signal-to-noise ratio remains increased by at least about 10%, at least about 20%, or at least about 25% compared to an unquenched tissue sample.
92. The method of any one of claims 86 to 91, wherein the signal-to-noise ratio decreases by less than about 5%, less than about 10%, or less than about 15% for a given cycle compared to the previous cycle.
93. The method of any one of claims 86 to 92, wherein for a given cycle, the detectable object count density remains increased compared to an unquenched tissue sample.
94. The method of any one of claims 86 to 93, wherein for a given cycle, the detectable object count density remains increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, or at least about 5-fold compared to an unquenched tissue sample.
95. The method of any one of claims 86 to 94, wherein for a given cycle, the detectable object count density decreases by less than about 5%, less than about 10%, or less than about 15% compared to the previous cycle.
96. The method of any one of claims 86 to 95, comprising at least two, three, four, five, six or more cycles of contacting the tissue sample with the one or more additional detectable probes.
97. The method of any one of claims 71 to 96, further comprising staining the tissue sample.
98. The method of any one of claims 71 to 97, further comprising fixing the tissue sample.
99. The method of any one of claims 71 to 98, wherein the method further comprises decrosslinking the tissue sample.
100. The method of any one of claims 70 to 99, wherein m is an integer from 1 to 6 and n is an integer from 1 to 6.
101. The method of any one of claims 70 to 100, wherein At least one, at least two, or at least three examples of are substituted phenyl or unsubstituted phenyl.
102. The method of any one of claims 70 to 101, wherein the quencher has the structure: or a salt thereof, The condition is X a and X c At least one of them is -L-(R 靶 ) w , wherein w is any integer, such as 1 or 2, and wherein L is a bond or linker moiety; and R 靶 It is the targeting part.
103. The method of any one of claims 70 to 101, wherein yes: Where R b1 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group.
104. The method of claim 103, wherein yes Where R d is H, C1-C6 alkyl or halo; and s is an integer from 0 to 5.
105. The method of any one of claims 70 to 101 and 103 to 104, wherein the quencher has the following structure: or a salt thereof.
106. The method of any one of claims 1 to 105, wherein the molecule of interest is a nucleic acid of interest or a protein of interest.
107. The method of claim 106, wherein the detectable probe hybridizes to the nucleic acid of interest.
108. The method of claim 106, wherein the detectable probe hybridizes to one or more intermediate probes that bind directly or indirectly to the nucleic acid of interest.
109. The method of claim 108, wherein the detectable probe hybridizes to one or more intermediate probes, which in turn hybridize to the nucleic acid of interest.
110. The method of claim 108 or 109, further comprising adding a primary probe prior to adding the detectable probe and one or more intermediate probes, wherein the intermediate probes bind to the primary probe or a product thereof.
111. The method of any one of claims 106 to 110, wherein the nucleic acid of interest is cellular or viral DNA or RNA or a product thereof.
112. The method of claim 111, wherein the cellular or viral DNA or RNA or its product is genomic DNA, coding RNA, non-coding RNA or cDNA.
113. The method of claim 112, wherein the nucleic acid of interest is mRNA.
114. The method of any one of claims 106 to 110, wherein the nucleic acid of interest is a nucleic acid probe that binds directly or indirectly to cellular or viral DNA or RNA or a product thereof.
115. The method of claim 114, wherein the cellular or viral DNA or RNA or its product is genomic DNA, coding RNA, non-coding RNA or cDNA.
116. The method of claim 115, wherein the coding RNA is mRNA.
117. The method of any one of claims 115 to 116, wherein the nucleic acid probe is linear, circularizable, circular or branched.
118. The method of claim 117, wherein the nucleic acid probe comprises a 3' overhang and / or a 5' overhang when hybridizing to the cellular or viral DNA or RNA or a product thereof.
119. The method of any one of claims 114 to 118, wherein the nucleic acid probe comprises one or more barcode regions.
120. The method of any one of claims 106 to 110, wherein the nucleic acid of interest is a probe product of one or more nucleic acid probes that bind directly or indirectly to cellular or viral DNA or RNA or its products.
121. The method of claim 120, wherein the cellular or viral DNA or RNA or its product is genomic DNA, coding RNA, non-coding RNA or cDNA.
122. The method of claim 121, wherein the coding RNA is mRNA.
123. The method of any one of claims 120 to 122, wherein the probe product is a rolling circle amplification (RCA) product, a hybridization chain reaction (HCR) product, a linear oligonucleotide hybridization chain reaction (LO-HCR) product, a primer exchange reaction (PER) product, an assembly of a branched structure, a hybridization complex of multiple fluorescently labeled probes, or any combination thereof.
124. The method of any one of claims 120 to 123, wherein the probe product and / or one or more nucleic acid probes comprise one or more barcode regions.
125. The method of any one of claims 106 to 110, wherein the nucleic acid of interest is a reporter oligonucleotide in a labeling agent comprising a binding moiety that binds directly or indirectly to a non-nucleic acid analyte.
126. The method of any one of claims 1 to 125, wherein the detectable probe is linear, circularizable, annular or branched.
127. The method of any one of claims 1 to 29 and 61 to 126, wherein the tissue sample is a formalin-fixed tissue sample or a formalin-fixed paraffin-embedded (FFPE) sample.
128. The method of any one of claims 1 to 127, wherein the autofluorescence is fixative-induced autofluorescence.
129. The method of any one of claims 1 to 29 and 61 to 128, wherein the tissue sample is melanoma tissue, brain tissue, lung tissue, tonsil tissue, intestinal tissue, kidney tissue, spleen tissue, liver tissue, breast tissue, or liver tissue.
130. The method of any one of claims 1 to 129, wherein the endogenous biological moiety is autofluorescent.
131. The method of any one of claims 1 to 130, wherein the endogenous biological moiety is selected from the group consisting of lipofuscin, collagen, elastin, erythrocytes, flavin, nicotinamide adenine dinucleotide (NADH), and extracellular matrix.
132. The method of claim 131, wherein the targeting moiety comprises a hydrophobic portion for lipophilic insertion into the endogenous biological moiety.
133. The method of claim 132, wherein the hydrophobic moiety for lipophilic insertion into the endogenous biological moiety is C6-C 14 Alkyl part, C6-C 14 an alkenyl moiety, a terpenoid moiety, a sterol moiety or a wax moiety.
134. The method of any one of claims 1 to 131, wherein the targeting moiety comprises a first functional group and the endogenous biological moiety comprises a second functional group capable of reacting with the first functional group to form a covalent bond.
135. The method of claim 134, wherein the first functional group is a carboxylic acid moiety or a derivative thereof, an aldehyde or ketone moiety, a sulfonyl halide moiety, a hydroxyl moiety, a thiol moiety, an amino moiety, an alkenyl or dienyl moiety, an epoxide moiety, or a haloalkyl moiety.
136. The method of claim 134 or claim 135, wherein the first functional group is a maleimido moiety, an azido moiety, an alkynyl moiety, an N-hydroxysuccinimidyl ester moiety, or a carbonyl imidazolyl moiety.
137. The method of claim 136, wherein the first functional group is a maleimido moiety.
138. The method of any one of claims 1 to 99, 106 to 131, and 133 to 136, wherein the quencher is selected from the group consisting of: and any salts thereof.
139. The method of any one of claims 1 to 96, 103 to 128, and 130 to 135, wherein the quencher is a compound selected from the group consisting of: and any salts thereof.
140. The method of any one of claims 134 to 139, further comprising the step of treating the biological or tissue sample to enrich, generate and / or introduce the second functional group in the endogenous biological portion.
141. The method of claim 140, wherein the second functional group is a thiol and the biological or tissue sample is treated with a reducing agent to convert the disulfide group to a thiol group.
142. A method as described in claim 140, wherein the endogenous biological part comprises a third functional group different from the second functional group, and wherein the biological sample or tissue sample is treated with a heterobifunctional cross-linking agent, which comprises the second functional group and a fourth functional group capable of reacting with the third functional group to form a covalent bond, thereby introducing the second functional group into the endogenous biological part.
143. The method of any one of claims 1 to 142, wherein the step of detecting a signal associated with the detectable probe bound to the molecule of interest comprises imaging at one or more wavelengths of about 400 nm to about 700 nm.
144. The method of claim 143, wherein the one or more wavelengths are selected from the group consisting of 488 nm, 532 nm, 561 nm, 590 nm, 640 nm, and 647 nm.
145. The method of any one of claims 1 to 144, wherein the quencher is provided in a DMSO solution at a concentration of about 0.01 mM to about 0.8 mM.
